

# The spectrum of neuromyelitis optica

Lancet Neurology, The  
6, 805-815

DOI: [10.1016/s1474-4422\(07\)70216-8](https://doi.org/10.1016/s1474-4422(07)70216-8)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Neuromyelitis optica. Current Treatment Options in Neurology, 2008, 10, 55-66.	0.7	129
2	Isolated, relapsing and progressive demyelinating diseases of the central nervous system. Journal of Neurology, 2008, 255, 69-76.	1.8	12
3	Neuromyelitis Optica and Asian Phenotype of Multiple Sclerosis. Annals of the New York Academy of Sciences, 2008, 1142, 58-71.	1.8	60
5	Neuromyelitis optica/Devic's disease: Gene expression profiling of brain lesions. Neuropathology, 2008, 28, 561-576.	0.7	21
6	Getting specific: monoclonal antibodies in multiple sclerosis. Lancet Neurology, The, 2008, 7, 538-547.	4.9	78
7	Chapter 4 B Cells and Autoantibodies in the Pathogenesis of Multiple Sclerosis and Related Inflammatory Demyelinating Diseases. Advances in Immunology, 2008, 98, 121-149.	1.1	75
8	New onset neuromyelitis optica in a young Nigerian woman with possible antiphospholipid syndrome: a case report. Journal of Medical Case Reports, 2008, 2, 348.	0.4	19
9	Differential diagnosis of suspected multiple sclerosis: a consensus approach. Multiple Sclerosis Journal, 2008, 14, 1157-1174.	1.4	560
10	Variants of Multiple Sclerosis. Neuroimaging Clinics of North America, 2008, 18, 703-716.	0.5	33
11	Neuromyelitis Optica in a Young Child With Positive Serum Autoantibody. Pediatric Neurology, 2008, 39, 209-212.	1.0	8
12	Optic neuritis and recurrent myelitis in a woman with systemic lupus erythematosus. Nature Clinical Practice Rheumatology, 2008, 4, 381-386.	3.2	61
13	Disseminated encephalomyelitis in adults. Clinical Neurology and Neurosurgery, 2008, 110, 913-918.	0.6	15
14	Current concepts in the diagnosis of transverse myelopathies. Clinical Neurology and Neurosurgery, 2008, 110, 919-927.	0.6	25
15	Neuromy�lite optique et NMO-IgG. Revue Francophone Des Laboratoires, 2008, 2008, 21-23.	0.0	0
16	Intractable hiccup and nausea in neuromyelitis optica with anti-aquaporin-4 antibody: a herald of acute exacerbations. Journal of Neurology, Neurosurgery and Psychiatry, 2008, 79, 1075-1078.	0.9	130
17	Optic Neuritis: An Update Typical and Atypical Optic Neuritis. Neuro-Ophthalmology, 2008, 32, 237-248.	0.4	25
18	Spectrum of Pediatric Neuromyelitis Optica. Pediatrics, 2008, 122, e1039-e1047.	1.0	160
19	CNS aquaporin-4 autoimmunity in children. Neurology, 2008, 71, 93-100.	1.5	299

#	ARTICLE	IF	CITATIONS
20	Aquaporin-4 Autoantibodies in a Paraneoplastic Context. Archives of Neurology, 2008, 65, 629-32.	4.9	177
21	Review: Treatment of neuromyelitis optica: Current debate. Therapeutic Advances in Neurological Disorders, 2008, 1, 43-52.	1.5	21
22	Aquaporin-4 Antibodies in Neuromyelitis Optica and Longitudinally Extensive Transverse Myelitis. Archives of Neurology, 2008, 65, 913-9.	4.9	259
23	Neuromyelitis Optica and Autoimmune Diseasesâ€”Reply. Archives of Neurology, 2008, 65, 992.	4.9	4
24	Aquaporin-4â€”binding autoantibodies in patients with neuromyelitis optica impair glutamate transport by down-regulating EAAT2. Journal of Experimental Medicine, 2008, 205, 2473-2481.	4.2	330
25	IL-12â€” and IL-23â€”modulated T cells induce distinct types of EAE based on histology, CNS chemokine profile, and response to cytokine inhibition. Journal of Experimental Medicine, 2008, 205, 1535-1541.	4.2	528
26	Neuromyelitis optica immunoglobulins as a marker of disease activity and response to therapy in patients with neuromyelitis optica. Multiple Sclerosis Journal, 2008, 14, 1061-1067.	1.4	35
27	Functional Consequences of Neuromyelitis Optica-IgG Astrocyte Interactions on Blood-Brain Barrier Permeability and Granulocyte Recruitment. Journal of Immunology, 2008, 181, 5730-5737.	0.4	233
28	A devilishly interesting case. Practical Neurology, 2008, 8, 186-190.	0.5	0
29	Antibody to aquaporin-4 in the long-term course of neuromyelitis optica. Brain, 2008, 131, 3072-3080.	3.7	397
30	NMO Antibodyâ€”Positive Recurrent Optic Neuritis Without Clear Evidence of Transverse Myelitis. JAMA Ophthalmology, 2008, 126, 566.	2.6	12
31	NEUROLOGIC COMPLICATIONS OF SJÅ–GREN SYNDROME AND RHEUMATOID ARTHRITIS. CONTINUUM Lifelong Learning in Neurology, 2008, 14, 120-144.	0.4	2
32	PATIENT MANAGEMENT PROBLEM. CONTINUUM Lifelong Learning in Neurology, 2008, 14, 200-208.	0.4	0
33	INFECTIOUS AND INFLAMMATORY MYELOPATHIES. CONTINUUM Lifelong Learning in Neurology, 2008, 14, 36-57.	0.4	3
34	Optic neuritis and multiple sclerosis. Current Opinion in Neurology, 2008, 21, 16-21.	1.8	49
35	Retinal Peripapillary Nerve Fiber Layer Thickness in Neuromyelitis Optica. , 2008, 49, 4412.		97
36	Live Cell Analysis of Aquaporin-4 M1/M23 Interactions and Regulated Orthogonal Array Assembly in Glial Cells. Journal of Biological Chemistry, 2009, 284, 35850-35860.	1.6	77
37	NMO-IgG DETECTED IN CSF IN SERONEGATIVE NEUROMYELITIS OPTICA. Neurology, 2009, 72, 1101-1103.	1.5	75

#	ARTICLE	IF	CITATIONS
38	Effector Functions of Antiaquaporin-4 Autoantibodies in Neuromyelitis Optica. <i>Annals of the New York Academy of Sciences</i> , 2009, 1173, 478-486.	1.8	23
39	Diagnosis of Neuromyelitis Spectrum Disorders. <i>Archives of Neurology</i> , 2009, 66, 1134-8.	4.9	87
40	Relapsing neuromyelitis optica: long term history and clinical predictors of death. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2009, 80, 1162-1164.	0.9	79
41	Initiation and Progression of Axonopathy in Experimental Autoimmune Encephalomyelitis. <i>Journal of Neuroscience</i> , 2009, 29, 14965-14979.	1.7	130
42	Early highly aggressive MS successfully treated by hematopoietic stem cell transplantation. <i>Multiple Sclerosis Journal</i> , 2009, 15, 229-237.	1.4	77
43	Neuromyelitis Optica IgG Serostatus in Fulminant Central Nervous System Inflammatory Demyelinating Disease. <i>Archives of Neurology</i> , 2009, 66, 964-6.	4.9	29
44	Pathologic and immunologic profiles of a limited form of neuromyelitis optica with myelitis. <i>Neurology</i> , 2009, 73, 1628-1637.	1.5	88
45	Commentary: Patient's view. <i>BMJ: British Medical Journal</i> , 2009, 339, b5178-b5178.	2.4	0
46	AQP4-IgG Immunoprecipitation Assay Optimization. <i>Clinical Chemistry</i> , 2009, 55, 592-594.	1.5	10
47	Transverse myelitis spectrum disorders. <i>Neurology India</i> , 2009, 57, 126.	0.2	30
48	A case of NMO seropositive for aquaporin-4 antibody more than 10 years before onset. <i>Neurology</i> , 2009, 72, 1960-1961.	1.5	139
49	Antiaquaporin 4 antibodies detection by different techniques in neuromyelitis optica patients. <i>Multiple Sclerosis Journal</i> , 2009, 15, 1153-1163.	1.4	63
50	Prediction of Neuromyelitis Optica Attack Severity by Quantitation of Complement-Mediated Injury to Aquaporin-4-Expressing Cells. <i>Archives of Neurology</i> , 2009, 66, 1164-7.	4.9	106
51	Greatly attenuated experimental autoimmune encephalomyelitis in aquaporin-4 knockout mice. <i>BMC Neuroscience</i> , 2009, 10, 94.	0.8	55
52	Patient with neuromyelitis optica and inflammatory demyelinating lesions comprising whole spinal cord from C2 level till conus: case report. <i>BMC Neurology</i> , 2009, 9, 56.	0.8	11
53	Anti-aquaporin-4 auto-antibodies orchestrate the pathogenesis in neuromyelitis optica. <i>Autoimmunity Reviews</i> , 2009, 9, 132-135.	2.5	53
54	Intrathecal pathogenic anti-aquaporin-4 antibodies in early neuromyelitis optica. <i>Annals of Neurology</i> , 2009, 66, 617-629.	2.8	516
55	Neuromyelitis optica: Pathogenicity of patient immunoglobulin in vivo. <i>Annals of Neurology</i> , 2009, 66, 630-643.	2.8	504

#	ARTICLE	IF	CITATIONS
56	Aquaporin-4 orthogonal arrays of particles are the target for neuromyelitis optica autoantibodies. <i>Glia</i> , 2009, 57, 1363-1373.	2.5	143
57	Levosulpiride-induced resting orolingual tremor. <i>Movement Disorders</i> , 2009, 24, 1700-1701.	2.2	7
58	Pallidal deep brain stimulation in belly dancer's dyskinesia. <i>Movement Disorders</i> , 2009, 24, 1698-1700.	2.2	8
59	The treatment of persistent vascular hemidystonia/hemiballismus with unilateral GPi deep brain stimulation. <i>Movement Disorders</i> , 2009, 24, 1697-1698.	2.2	27
60	Normal diffusion-weighted MR imaging predicts a good prognosis in extrapontine myelinolysis-induced parkinsonism. <i>Movement Disorders</i> , 2009, 24, 1701-1703.	2.2	12
61	Axial myoclonus in devic neuromyelitis optica. <i>Movement Disorders</i> , 2009, 24, 1708-1709.	2.2	6
62	Early and marked benefit with GPi DBS for Lubag syndrome presenting with rapidly progressive life-threatening dystonia. <i>Movement Disorders</i> , 2009, 24, 1710-1712.	2.2	48
63	Lingual dystonia as a manifestation of thalamic infarction. <i>Movement Disorders</i> , 2009, 24, 1703-1704.	2.2	14
64	Acquired hepatocerebral degeneration in a patient heterozygote carrier for a novel mutation in <i>ATP7B</i> gene. <i>Movement Disorders</i> , 2009, 24, 1706-1708.	2.2	6
65	Linburg's syndrome, can it cause focal dystonia?. <i>Movement Disorders</i> , 2009, 24, 1704-1706.	2.2	9
66	A possible paraneoplastic neuromyelitis optica associated with lung cancer. <i>Neurological Sciences</i> , 2009, 30, 397-400.	0.9	40
67	Devic's neuromyelitis optica and pregnancy: distinction from multiple sclerosis is essential. <i>Archives of Gynecology and Obstetrics</i> , 2009, 280, 475-477.	0.8	31
68	Prevalence of neuromyelitis optica spectrum disorder and phenotype distribution. <i>Journal of Neurology</i> , 2009, 256, 1891-1898.	1.8	112
69	Efficacy of tacrolimus in Sjögren's syndrome-associated CNS disease with aquaporin-4 autoantibodies. <i>Journal of Neurology</i> , 2009, 256, 1762-1764.	1.8	3
72	The pathological spectrum of CNS inflammatory demyelinating diseases. <i>Seminars in Immunopathology</i> , 2009, 31, 439-453.	2.8	123
73	MicroRNA miR-326 regulates TH-17 differentiation and is associated with the pathogenesis of multiple sclerosis. <i>Nature Immunology</i> , 2009, 10, 1252-1259.	7.0	726
74	Therapeutic apheresis: history, clinical application, and lingering uncertainties. <i>Transfusion</i> , 2010, 50, 1413-1426.	0.8	41
75	Neuromyelitis optica IgG in idiopathic inflammatory demyelinating disorders amongst Hong Kong Chinese. <i>European Journal of Neurology</i> , 2009, 16, 310-316.	1.7	35

#	ARTICLE	IF	CITATIONS
76	Neuromyelitis optica and the evolving spectrum of water channel autoimmunity: a new direction. <i>European Journal of Neurology</i> , 2009, 16, 433-435.	1.7	4
77	Spinal cord lesions in patients with neuromyelitis optica: a retrospective long-term MRI follow-up study. <i>European Radiology</i> , 2009, 19, 2535-2543.	2.3	92
78	Symptomatic, radiological and pathological involvement of the hypothalamus in neuromyelitis optica. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2009, 80, 679-682.	0.9	52
79	Disorders of Salt and Fluid Balance: Diabetes Insipidus, Cerebral Salt-Wasting Syndrome, and Syndrome of Inappropriate Antidiuresis. , 2009, , 3235-3267.		2
80	Prediction of conversion from clinically isolated syndrome to clinically definite multiple sclerosis according to baseline MRI findings: comparison of revised McDonald criteria and Swanton modified criteria. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2009, 80, 1107-1109.	0.9	14
81	Crystal structure of human aquaporin 4 at 1.8 Å, and its mechanism of conductance. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 7437-7442.	3.3	297
82	Clustering and commonalities among autoimmune diseases. <i>Journal of Autoimmunity</i> , 2009, 33, 170-177.	3.0	90
83	Occurrence of acute large and edematous callosal lesions in neuromyelitis optica. <i>Multiple Sclerosis Journal</i> , 2009, 15, 695-700.	1.4	93
84	The intrathecal, polyspecific antiviral immune response: Specific for MS or a general marker of CNS autoimmunity?. <i>Journal of the Neurological Sciences</i> , 2009, 280, 98-100.	0.3	72
85	Aquaporin-4 antibody positive longitudinally extensive transverse myelitis following varicella zoster infection. <i>Journal of the Neurological Sciences</i> , 2009, 276, 184-186.	0.3	49
86	Frequency and clinical patterns of multiple sclerosis in Arab countries: A systematic review. <i>Journal of the Neurological Sciences</i> , 2009, 278, 1-4.	0.3	64
87	Neuromyelitis optica: Effect of gender. <i>Journal of the Neurological Sciences</i> , 2009, 286, 18-23.	0.3	98
88	MRI of the spinal cord in neuromyelitis optica and recurrent longitudinal extensive myelitis. <i>Journal of Neuroradiology</i> , 2009, 36, 199-205.	0.6	49
89	Aquaporins: translating bench research to human disease. <i>Journal of Experimental Biology</i> , 2009, 212, 1707-1715.	0.8	141
90	Roles of B lymphocytes in multiple sclerosis: diversifying beyond the antibody response. <i>Immunotherapy</i> , 2009, 1, 181-185.	1.0	3
91	Brain abnormalities in Sjogren syndrome with recurrent CNS manifestations: association with neuromyelitis optica. <i>Multiple Sclerosis Journal</i> , 2009, 15, 1069-1076.	1.4	59
92	Transverse myelitis and vaccines: a multi-analysis. <i>Lupus</i> , 2009, 18, 1198-1204.	0.8	122
95	Neuromyelitis optica: current concepts and prospects for future management. <i>Current Opinion in Ophthalmology</i> , 2009, 20, 434-439.	1.3	11

#	ARTICLE	IF	CITATIONS
99	Neuromyelitis Optica with HTLV-1 Infection: Different from Acute Progressive HAM?. Internal Medicine, 2009, 48, 1157-1159.	0.3	14
100	Differential Diagnosis of White Matter Lesions with High-field MR. Neuroradiology Journal, 2009, 22, 71-73.	0.6	0
101	Clinical and Pharmacological Aspects of Inflammatory Demyelinating Diseases in Childhood: An Update. Current Neuropharmacology, 2010, 8, 135-148.	1.4	7
102	Diagnosing central nervous system vasculitis in children. Current Opinion in Pediatrics, 2010, 22, 731-738.	1.0	29
103	Central nervous system vasculitis in children. Current Opinion in Rheumatology, 2010, 22, 590-597.	2.0	64
104	NEUROMYELITIS OPTICA SPECTRUM DISORDERS. CONTINUUM Lifelong Learning in Neurology, 2010, 16, 105-121.	0.4	28
105	PATIENT MANAGEMENT PROBLEM. CONTINUUM Lifelong Learning in Neurology, 2010, 16, 226-233.	0.4	0
106	A 32-year-old Man with Neuromyelitis Optica Presenting Peculiar Itching.. The Journal of the Japanese Society of Internal Medicine, 2010, 99, 1650-1652.	0.0	0
108	Human T-lymphotropic virus type I or II (HTLV-I/II) associated with recurrent longitudinally extensive transverse myelitis (LETM): two case reports. Journal of NeuroVirology, 2010, 16, 249-253.	1.0	9
110	Aquaporin-4 water channel expression by thymoma of patients with and without myasthenia gravis. Journal of Neuroimmunology, 2010, 227, 178-184.	1.1	31
111	Neuromyelitis optica, psychiatric symptoms and primary polydipsia: a case report. General Hospital Psychiatry, 2010, 32, 648.e5-648.e8.	1.2	953
112	Espectro cl�nico asociado a anticuerpos contra acuaporina 4 (IgG-NMO). Neurolog�a, 2010, 25, 5-12.	0.3	9
113	Increased frontoparietal integration after stroke and cognitive recovery. Annals of Neurology, 2010, 68, 753-756.	2.8	60
114	Intractable vomiting as the initial presentation of neuromyelitis optica. Annals of Neurology, 2010, 68, 757-761.	2.8	168
115	Heightened neurologic complications in children with pandemic H1N1 influenza. Annals of Neurology, 2010, 68, 762-766.	2.8	83
116	Deletion of aquaporin�4 renders retinal glial cells more susceptible to osmotic stress. Journal of Neuroscience Research, 2010, 88, 2877-2888.	1.3	59
117	Different responses to interferon beta�1b treatment in patients with neuromyelitis optica and multiple sclerosis. European Journal of Neurology, 2010, 17, 672-676.	1.7	89
118	Relapsing Neuromyelitis Optica: demographic and clinical features in Iranian patients. European Journal of Neurology, 2010, 17, 794-799.	1.7	38

#	ARTICLE	IF	CITATIONS
119	EFNS guidelines on diagnosis and management of neuromyelitis optica. <i>European Journal of Neurology</i> , 2010, 17, 1019-1032.	1.7	376
121	Neuromyélite optique de Devic: une forme particulière de SEP ou une entité isolée?. <i>Neurologie Com</i> , 2010, 2, 34-36.	0.0	1
122	Eye disorders in patients with multiple sclerosis: natural history and management. <i>Clinical Ophthalmology</i> , 2010, 4, 1409.	0.9	51
123	New developments in the treatment of optic neuritis. <i>Eye and Brain</i> , 2010, 2, 83.	3.8	6
124	Neuromyelitis Optica. <i>Blue Books of Neurology</i> , 2010, 35, 258-275.	0.1	4
125	Modifications to the McDonald MRI dissemination in space criteria for use in Asians with classic multiple sclerosis: the Taiwanese experience. <i>Multiple Sclerosis Journal</i> , 2010, 16, 1213-1219.	1.4	7
126	Anti-aquaporin-4 antibodies in Devic's neuromyelitis optica: therapeutic implications. <i>Therapeutic Advances in Neurological Disorders</i> , 2010, 3, 311-321.	1.5	28
127	Brain MRI lesions characteristic of neuromyelitis optica and positive anti-aquaporin 4-antibody may predict longitudinal extensive myelitis and optic neuritis in Sjögren's syndrome. <i>Multiple Sclerosis Journal</i> , 2010, 16, 762-764.	1.4	7
128	Compressive Myelopathy Mimicking Transverse Myelitis. <i>Neurologist</i> , 2010, 16, 120-122.	0.4	32
129	CD8 <sup>+</sup> CD11a <sup>+</sup> high Cells Decreased in Multiple Sclerosis but Not in Neuromyelitis Optica. <i>European Neurology</i> , 2010, 63, 159-163.	0.6	1
130	The Onset of Multiple Sclerosis in Greece: A Single-Center Study of 1,034 Consecutive Patients. <i>European Neurology</i> , 2010, 63, 350-356.	0.6	10
131	IFN $\beta$ -1b may severely exacerbate Japanese optic-spinal MS in neuromyelitis optica spectrum. <i>Neurology</i> , 2010, 75, 1423-1427.	1.5	183
133	Anti-AQP4-Antikörper als Biomarker zur Früherkennung von Neuromyelitis Optica-Spektrum-Erkrankungen / AQP4-IgG antibodies as biomarkers for early diagnosis of neuromyelitis optica spectrum disorders. <i>Laboratoriums Medizin</i> , 2010, 34, 337-342.	0.1	0
134	Neuromyelitis optica: a demyelinating disease characterized by acute destruction and regeneration of perivascular astrocytes. <i>Multiple Sclerosis Journal</i> , 2010, 16, 1156-1172.	1.4	114
135	A case of chronic progressive myelopathy. <i>Multiple Sclerosis Journal</i> , 2010, 16, 1255-1257.	1.4	9
136	Astrocytic damage is far more severe than demyelination in NMO. <i>Neurology</i> , 2010, 75, 208-216.	1.5	209
137	Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice. <i>Brain</i> , 2010, 133, 349-361.	3.7	480
138	B-CELL ACTIVATING FACTOR OF THE TNF FAMILY IS UPREGULATED IN NEUROMYELITIS OPTICA. <i>Neurology</i> , 2010, 74, 177-178.	1.5	42



#	ARTICLE	IF	CITATIONS
139	Neuromyelitis optica and NMO-IgG in European pediatric patients. <i>Neurology</i> , 2010, 75, 1740-1744.	1.5	56
140	Oligodendrocytes are damaged by neuromyelitis optica immunoglobulin G via astrocyte injury. <i>Brain</i> , 2010, 133, 2578-2591.	3.7	180
141	Familial neuromyelitis optica. <i>Neurology</i> , 2010, 75, 310-315.	1.5	114
142	Pearls: Myelopathy. <i>Seminars in Neurology</i> , 2010, 30, 038-043.	0.5	16
143	Diffuse White Matter Damage Is Absent in Neuromyelitis Optica. <i>American Journal of Neuroradiology</i> , 2010, 31, 76-79.	1.2	50
144	ASYMPTOMATIC SPINAL CORD INVOLVEMENT IN POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME. <i>Neurology</i> , 2010, 74, 1478-1479.	1.5	10
145	Quantification and Functional Characterization of Antibodies to Native Aquaporin 4 in Neuromyelitis Optica. <i>Archives of Neurology</i> , 2010, 67, 1201-8.	4.9	82
146	Approaches to neuroprotective strategies in multiple sclerosis. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 2869-2878.	0.9	11
148	Transverse Myelitis. <i>New England Journal of Medicine</i> , 2010, 363, 564-572.	13.9	158
149	Standardized method for the detection of antibodies to aquaporin-4 based on a highly sensitive immunofluorescence assay employing recombinant target antigen. <i>Journal of the Neurological Sciences</i> , 2010, 291, 52-56.	0.3	189
150	Frequency and prognostic impact of antibodies to aquaporin-4 in patients with optic neuritis. <i>Journal of the Neurological Sciences</i> , 2010, 298, 158-162.	0.3	169
151	Differential Diagnosis and Diagnostic Criteria for Multiple Sclerosis. <i>Blue Books of Neurology</i> , 2010, 35, 19-42.	0.1	1
152	Visual field defects of optic neuritis in neuromyelitis optica compared with multiple sclerosis. <i>BMC Neurology</i> , 2010, 10, 45.	0.8	59
153	Aquaporin-4 autoantibodies in neuromyelitis optica spectrum disorders: comparison between tissue-based and cell-based indirect immunofluorescence assays. <i>Journal of Neuroinflammation</i> , 2010, 7, 50.	3.1	52
154	Clinical spectrum associated with aquaporin-4 antibodies (NMO-IgG). <i>Neurologia (English Edition)</i> , 2010, 25, 5-12.	0.2	1
155	Treatments for Neuro-Ophthalmologic Conditions. <i>Neurologic Clinics</i> , 2010, 28, 1005-1035.	0.8	4
156	N-methyl-d-aspartate antibody encephalitis: temporal progression of clinical and paraclinical observations in a predominantly non-paraneoplastic disorder of both sexes. <i>Brain</i> , 2010, 133, 1655-1667.	3.7	900
157	Characteristic brain magnetic resonance imaging abnormalities in central nervous system aquaporin-4 autoimmunity. <i>Multiple Sclerosis Journal</i> , 2010, 16, 1229-1236.	1.4	171

#	ARTICLE	IF	CITATIONS
158	Chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS). <i>Brain</i> , 2010, 133, 2626-2634.	3.7	316
159	Regulation of brain aquaporins. <i>Neurochemistry International</i> , 2010, 57, 468-488.	1.9	118
160	Aquaporin 4 antibody positive central nervous system autoimmunity and multiple sclerosis are characterized by a distinct profile of antibodies to herpes viruses. <i>Neurochemistry International</i> , 2010, 57, 662-667.	1.9	15
162	The clinical spectrum and immunobiology of parainfectious neuromyelitis optica (Devic) syndromes. <i>Journal of Autoimmunity</i> , 2010, 34, 371-379.	3.0	121
163	Aquaporin-4 in brain and spinal cord oedema. <i>Neuroscience</i> , 2010, 168, 1036-1046.	1.1	165
164	Neurological autoimmunity targeting aquaporin-4. <i>Neuroscience</i> , 2010, 168, 1009-1018.	1.1	77
165	Molecular disruptions of the panglial syncytium block potassium siphoning and axonal saltatory conduction: pertinence to neuromyelitis optica and other demyelinating diseases of the central nervous system. <i>Neuroscience</i> , 2010, 168, 982-1008.	1.1	143
167	Identifying targets for autoantibodies in CNS inflammation: Strategies and achievements. <i>Clinical and Experimental Neuroimmunology</i> , 2010, 1, 47-60.	0.5	11
168	Pathogenesis, diagnosis and treatment of neuromyelitis optica: Changing concept of an old disease. <i>Clinical and Experimental Neuroimmunology</i> , 2010, 1, 103-123.	0.5	4
169	A case of cerebral aquaporinopathy. <i>Multiple Sclerosis Journal</i> , 2010, 16, 1252-1254.	1.4	6
170	Cytokine and chemokine profiles in neuromyelitis optica: significance of interleukin-6. <i>Multiple Sclerosis Journal</i> , 2010, 16, 1443-1452.	1.4	285
172	Multi-system neurological disease is common in patients with OPA1 mutations. <i>Brain</i> , 2010, 133, 771-786.	3.7	385
173	The optic nerve head in acquired optic neuropathies. <i>Nature Reviews Neurology</i> , 2010, 6, 221-236.	4.9	14
174	Aquaporin-4: orthogonal array assembly, CNS functions, and role in neuromyelitis optica. <i>Acta Pharmacologica Sinica</i> , 2011, 32, 702-710.	2.8	79
175	Genetic analysis of aquaporin-4 in neuromyelitis optica. <i>Neurology</i> , 2011, 77, 1149-1155.	1.5	48
176	Relapsing demyelinating CNS disease in a Korean pediatric population: Multiple sclerosis versus neuromyelitis optica. <i>Multiple Sclerosis Journal</i> , 2011, 17, 67-73.	1.4	25
177	Serum and CSF N-acetyl aspartate levels differ in multiple sclerosis and neuromyelitis optica. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2011, 82, 1355-1359.	0.9	29
178	Lupus Related Longitudinal Myelitis. <i>Journal of Rheumatology</i> , 2011, 38, 1520-1520.	1.0	5

#	ARTICLE	IF	CITATIONS
179	Optimizing rituximab therapy for neuromyelitis optica. <i>Nature Reviews Neurology</i> , 2011, 7, 664-665.	4.9	10
180	Neuroimaging in Acute Transverse Myelitis. <i>Neuroimaging Clinics of North America</i> , 2011, 21, 951-973.	0.5	24
181	Clinical features of neuromyelitis optica in a large Japanese cohort: comparison between phenotypes. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2011, 82, 1360-1364.	0.9	113
182	Historia de la enfermedad de Devic. <i>Revista Colombiana De ReumatologÃa</i> , 2011, 18, 271-284.	0.0	0
183	What makes a prognostic biomarker in CNS diseases: strategies for targeted biomarker discovery? Part 2: chronic progressive and relapsing disease. <i>Expert Opinion on Medical Diagnostics</i> , 2011, 5, 393-410.	1.6	5
184	Neuromyelitis optica and opticospinal multiple sclerosis: Mechanisms and pathogenesis. <i>Pathophysiology</i> , 2011, 18, 69-79.	1.0	72
185	Intravascular lymphoma presenting as a longitudinally-extensive myelitis: Diagnostic challenges and etiologic clues. <i>Journal of the Neurological Sciences</i> , 2011, 303, 146-149.	0.3	21
186	Systemic sclerosis in aquaporin-4 antibody-positive longitudinally extensive transverse myelitis. <i>Journal of the Neurological Sciences</i> , 2011, 303, 139-141.	0.3	21
187	Neuromyelitis optica and astrocytic damage in its pathogenesis. <i>Journal of the Neurological Sciences</i> , 2011, 306, 183-187.	0.3	62
188	Magnetic Resonance Imaging in Multiple Sclerosis: The Role of Conventional Imaging. <i>Neurologic Clinics</i> , 2011, 29, 343-356.	0.8	14
189	Clinical isolated syndrome: A 3-year follow-up study in China. <i>Clinical Neurology and Neurosurgery</i> , 2011, 113, 658-660.	0.6	16
190	Regional homogeneity changes in patients with neuromyelitis optica revealed by resting-state functional MRI. <i>Clinical Neurophysiology</i> , 2011, 122, 121-127.	0.7	42
191	Abnormal baseline brain activity in patients with neuromyelitis optica: A resting-state fMRI study. <i>European Journal of Radiology</i> , 2011, 80, 407-411.	1.2	56
192	Inflammation, demyelination, and degeneration â€” Recent insights from MS pathology. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2011, 1812, 275-282.	1.8	207
193	Fine specificity of antibodies against AQP4: Epitope mapping reveals intracellular epitopes. <i>Journal of Autoimmunity</i> , 2011, 36, 221-227.	3.0	36
194	Usefulness of serum S100B as a marker for the acute phase of aquaporin-4 autoimmune syndrome. <i>Neuroscience Letters</i> , 2011, 494, 86-88.	1.0	15
195	Interleukin-17-secreting T cells in neuromyelitis optica and multiple sclerosis during relapse. <i>Journal of Clinical Neuroscience</i> , 2011, 18, 1313-1317.	0.8	141
196	The limited demyelinating diseases: the voyage of optic neuritis and transverse myelitis to multiple sclerosis and neuromyelitis. <i>Expert Review of Neurotherapeutics</i> , 2011, 11, 451-462.	1.4	3

#	ARTICLE	IF	CITATIONS
197	Neuromyelitis optica: An update. Journal of the Neurological Sciences, 2011, 303, 13-21.	0.3	31
198	Autoimmunity in neuromyelitis optica and opticospinal multiple sclerosis: Astrocytopathy as a common denominator in demyelinating disorders. Journal of the Neurological Sciences, 2011, 311, 69-77.	0.3	49
199	Atypical presentations of neuromyelitis optica. Arquivos De Neuro-Psiquiatria, 2011, 69, 824-828.	0.3	29
201	Plasma exchange treatment for CNS inflammatory demyelinating disease. , 0, , 454-464.		0
202	Diagnosis, pathogenesis, and treatment of neuromyelitis optica (NMO) spectrum disorders. , 0, , 614-631.		0
203	Neuromyelitis Optica. , 2011, , 237-251.		0
204	NMO-DBr: the Brazilian Neuromyelitis Optica Database System. Arquivos De Neuro-Psiquiatria, 2011, 69, 687-692.	0.3	8
206	NMO in pediatric patients: brain involvement and clinical expression. Arquivos De Neuro-Psiquiatria, 2011, 69, 34-38.	0.3	21

207

#	ARTICLE	IF	CITATIONS
217	Repeated Non-enhancing Tumefactive Lesions in a Patient with a Neuromyelitis Optica Spectrum Disorder. <i>Internal Medicine</i> , 2011, 50, 1061-1064.	0.3	24
219	A review of orbital and intracranial magnetic resonance imaging in 79 canine and 13 feline patients (2004-2010). <i>Veterinary Ophthalmology</i> , 2011, 14, 215-226.	0.6	49
220	Cerebrospinal fluid B-cell expansion in longitudinally extensive transverse myelitis associated with neuromyelitis optica immunoglobulin G. <i>Developmental Medicine and Child Neurology</i> , 2011, 53, 856-860.	1.1	9
221	Neuromyelitis optica (NMO) - an autoimmune disease of the central nervous system (CNS). <i>Acta Neurologica Scandinavica</i> , 2011, 123, 369-384.	1.0	31
222	Reappraisal of Aquaporin-4 Astrocytopathy in Asian Neuromyelitis Optica and Multiple Sclerosis Patients. <i>Brain Pathology</i> , 2011, 21, 516-532.	2.1	41
223	Neuromyelitis optica: Concepts in evolution. <i>Journal of Neuroimmunology</i> , 2011, 231, 100-104.	1.1	18
224	HLA-DPB1*0501 is associated with susceptibility to anti-aquaporin-4 antibodies positive neuromyelitis optica in Southern Han Chinese. <i>Journal of Neuroimmunology</i> , 2011, 233, 181-184.	1.1	105
225	T cell deficiency does not reduce lesions in mice produced by intracerebral injection of NMO-IgG and complement. <i>Journal of Neuroimmunology</i> , 2011, 235, 27-32.	1.1	31
226	Increased serum matrix metalloproteinase-9 in neuromyelitis optica: Implication of disruption of blood-brain barrier. <i>Journal of Neuroimmunology</i> , 2011, 236, 81-86.	1.1	42
227	Orthogonal array formation by human aquaporin-4: Examination of neuromyelitis optica-associated aquaporin-4 polymorphisms. <i>Journal of Neuroimmunology</i> , 2011, 236, 93-98.	1.1	19
228	Role of glial cells in innate immunity and their role in CNS demyelination. <i>Journal of Neuroimmunology</i> , 2011, 239, 13-20.	1.1	44
229	Neuromyelitis Optica Spectrum Disorder as an Initial Presentation of Primary Sjögren's Syndrome. <i>Seminars in Arthritis and Rheumatism</i> , 2011, 40, 343-348.	1.6	64
230	Purinergic signaling involved in Müller cell function in the mammalian retina. <i>Progress in Retinal and Eye Research</i> , 2011, 30, 324-342.	7.3	71
231	Strategy for anti-aquaporin-4 auto-antibody identification and quantification using a new cell-based assay. <i>Clinical Immunology</i> , 2011, 138, 239-246.	1.4	24
232	Aquaporin-4 seropositivity in a patient with coeliac disease but normal neurological examination and imaging. <i>Journal of Neurology</i> , 2011, 258, 702-703.	1.8	9
233	Acute transverse myelitis in demyelinating diseases among the Chinese. <i>Journal of Neurology</i> , 2011, 258, 2206-2213.	1.8	19
234	Clinical manifestations of neurological involvement in primary Sjögren's syndrome. <i>Clinical Rheumatology</i> , 2011, 30, 485-490.	1.0	96
236	Aquaporin Membrane Channels: Biophysics, Classification, Functions, and Possible Biotechnological Applications. <i>Food Biophysics</i> , 2011, 6, 241-249.	1.4	30

#	ARTICLE	IF	CITATIONS
237	NMDA Receptor Antibody Encephalitis. <i>Current Neurology and Neuroscience Reports</i> , 2011, 11, 298-304.	2.0	96
238	Neuromyelitis Optica-AQP4: An Update. <i>Current Rheumatology Reports</i> , 2011, 13, 496-505.	2.1	8
239	Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria. <i>Annals of Neurology</i> , 2011, 69, 292-302.	2.8	8,001
240	The blood-spinal cord barrier: Morphology and Clinical Implications. <i>Annals of Neurology</i> , 2011, 70, 194-206.	2.8	341
241	Ex vivo spinal cord slice model of neuromyelitis optica reveals novel immunopathogenic mechanisms. <i>Annals of Neurology</i> , 2011, 70, 943-954.	2.8	142
242	Neuromyelitis optica spectrum disorder in patients with connective tissue disease and myelitis. <i>Arthritis Care and Research</i> , 2011, 63, 1203-1208.	1.5	24
243	Conventional apheresis therapies: A review. <i>Journal of Clinical Apheresis</i> , 2011, 26, 230-238.	0.7	110
244	The pathology of multiple sclerosis and related disorders. <i>Diagnostic Histopathology</i> , 2011, 17, 225-231.	0.2	3
245	A paraneoplastic neuromyelitis optica spectrum disorder associated with a mature B-cell neoplasm. <i>Leukemia Research</i> , 2011, 35, e111-e113.	0.4	15
246	Aquaporins at a glance. <i>Journal of Cell Science</i> , 2011, 124, 2107-2112.	1.2	199
247	Neuromyelitis optica and pulmonary tuberculosis: a case-control study. <i>International Journal of Tuberculosis and Lung Disease</i> , 2011, 15, 1675-1680.	0.6	39
248	Beneficial Plasma Exchange Response in Central Nervous System Inflammatory Demyelination. <i>Archives of Neurology</i> , 2011, 68, 870.	4.9	173
249	Increased T-cell immunity against aquaporin-4 and proteolipid protein in neuromyelitis optica. <i>International Immunology</i> , 2011, 23, 565-573.	1.8	51
250	Ocular Oscillations in the Neuromyelitis Optica Spectrum. <i>Journal of Neuro-Ophthalmology</i> , 2011, 31, 255-259.	0.4	25
251	Cognitive Function, Depression, Fatigue, and Activities of Daily Living in Patients With Neuromyelitis Optica After Acute Relapse. <i>International Journal of Neuroscience</i> , 2011, 121, 677-683.	0.8	36
252	Antibodies against aquaporin-4 in neuromyelitis optica: distinction between recurrent and monophasic patients. <i>Multiple Sclerosis Journal</i> , 2011, 17, 1527-1530.	1.4	39
253	Pearls & Oysters: Clues for spinal dural arteriovenous fistulae. <i>Neurology</i> , 2011, 76, e10-2.	1.5	20
254	Repeated Treatment With Rituximab Based on the Assessment of Peripheral Circulating Memory B Cells in Patients With Relapsing Neuromyelitis Optica Over 2 Years. <i>Archives of Neurology</i> , 2011, 68, 1412.	4.9	267

#	ARTICLE	IF	CITATIONS
255	Mycobacteria Infection in Incomplete Transverse Myelitis Is Refractory to Steroids: A Pilot Study. <i>Clinical and Developmental Immunology</i> , 2011, 2011, 1-8.	3.3	5
256	AQP4 antibodyâ€“positive Thai cases. <i>Neurology</i> , 2011, 77, 827-834.	1.5	68
257	Insights into the Changing Perspectives of Multiple Sclerosis in India. <i>Autoimmune Diseases</i> , 2011, 2011, 1-5.	2.7	8
258	Efficacy and Safety of Mitoxantrone in Patients With Highly Relapsing Neuromyelitis Optica. <i>Archives of Neurology</i> , 2011, 68, 473.	4.9	100
259	Failure of Autologous Hematopoietic Stem Cell Transplantation to Prevent Relapse of Neuromyelitis Optica. <i>Archives of Neurology</i> , 2011, 68, 953.	4.9	35
260	Neuromyelitis Optica Spectrum Disorders. , 2011, , 219-232.		33
261	Anti-Aquaporin-4 Antibody-Positive Neuromyelitis Optica Presenting with Syndrome of Inappropriate Antidiuretic Hormone Secretion as an Initial Manifestation. <i>Case Reports in Neurology</i> , 2011, 3, 263-267.	0.3	35
262	Evidence against Cellular Internalization in Vivo of NMO-IgG, Aquaporin-4, and Excitatory Amino Acid Transporter 2 in Neuromyelitis Optica. <i>Journal of Biological Chemistry</i> , 2011, 286, 45156-45164.	1.6	60
263	Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 3701-3706.	3.3	383
264	Brain abnormalities as an initial manifestation of neuromyelitis optica spectrum disorder. <i>Multiple Sclerosis Journal</i> , 2011, 17, 1107-1112.	1.4	99
265	A population-based study of neuromyelitis optica in Caucasians. <i>Neurology</i> , 2011, 76, 1589-1595.	1.5	240
266	Brain Involvement in Neuromyelitis Optica Spectrum Disorders. <i>Archives of Neurology</i> , 2011, 68, 1432.	4.9	97
267	Wall-eyed bilateral internuclear ophthalmoplegia (WEBINO) syndrome in a patient with neuromyelitis optica spectrum disorder and anti-aquaporin-4 antibody. <i>Multiple Sclerosis Journal</i> , 2011, 17, 885-887.	1.4	27
268	Neuromyelitis optica unique area postrema lesions. <i>Neurology</i> , 2011, 76, 1229-1237.	1.5	262
269	Does detection of anti-AQP4 antibodies trump clinical criteria for neuromyelitis optica?. <i>Neurology</i> , 2011, 77, 812-813.	1.5	5
270	First attack of Devicâ€™s neuromyelitis optica following endovascular treatment and rupture of brain arteriovenous malformation. <i>Multiple Sclerosis Journal</i> , 2011, 17, 895-896.	1.4	3
271	Neuromyelitis Optica Spectrum Disease with Positive Autoimmune Indices: A Case Report and Review of the Literature. <i>Case Reports in Medicine</i> , 2011, 2011, 1-4.	0.3	7
272	Syndrome of inappropriate antidiuresis may herald or accompany neuromyelitis optica. <i>Neurology</i> , 2011, 77, 1644-1646.	1.5	49

#	ARTICLE	IF	CITATIONS
273	Clinical approach to optic neuritis: pitfalls, red flags and differential diagnosis. <i>Therapeutic Advances in Neurological Disorders</i> , 2011, 4, 123-134.	1.5	69
274	Sjögren Sendromunda Ortaya Çıkan Nöromiyelitis Optika Spektrum Bozukluğu. <i>Noropsikiyatri Arsivi</i> , 2011, 48, 1-1.	0.7	0
275	Painful Tonic Spasm in Neuromyelitis Optica. <i>Archives of Neurology</i> , 2012, 69, 1026-31.	4.9	95
276	Molecular Pathogenesis of Neuromyelitis Optica. <i>International Journal of Molecular Sciences</i> , 2012, 13, 12970-12993.	1.8	54
277	Neuromyelitis Optica: An Antibody-Mediated Disorder of the Central Nervous System. <i>Neurology Research International</i> , 2012, 2012, 1-13.	0.5	64
278	Genetic variations within the OPA1 gene are not associated with neuromyelitis optica. <i>Multiple Sclerosis Journal</i> , 2012, 18, 240-243.	1.4	1
279	Optic neuritis: Experience from a south Indian demyelinating disease registry. <i>Neurology India</i> , 2012, 60, 470.	0.2	29
280	Comment: Human papillomavirus vaccination, induced autoimmunity, and neuromyelitis optica. <i>Neurology</i> , 2012, 79, 287-287.	1.5	3
281	Optic neuritis: A blurry issue. <i>Neurology India</i> , 2012, 60, 459.	0.2	1
282	Interferon- $\beta$ Increases Th2 Response in Neuromyelitis Optica. <i>International Journal of Molecular Sciences</i> , 2012, 13, 12213-12223.	1.8	5
283	Membrane Transport. , 2012, , 40-62.		3
284	Acute Transverse Myelitis: Demyelinating, Inflammatory, and Infectious Myelopathies. <i>Seminars in Neurology</i> , 2012, 32, 097-113.	0.5	91
285	<sup>11</sup> C-PiB PET does not detect PrP-amyloid in prion disease patients including variant Creutzfeldt-Jakob disease: Figure 1. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2012, 83, 340-341.	0.9	8
286	CSF interleukin-6 level predicts recovery from neuromyelitis optica relapse. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2012, 83, 339-340.	0.9	41
287	Pediatric Optic Neuritis. <i>International Ophthalmology Clinics</i> , 2012, 52, 29-49.	0.3	26
288	Anti-aquaporin-4 Antibody-positive Definite Neuromyelitis Optica in a Patient With Thymectomy for Myasthenia Gravis. <i>Neurologist</i> , 2012, 18, 76-79.	0.4	15
289	Neuromyelitis Optica. <i>Journal of Neuro-Ophthalmology</i> , 2012, 32, 154-166.	0.4	55
291	Aquaporin 4 Antibodies in the Cerebrospinal Fluid Are Helpful in Diagnosing Chinese Patients with Neuromyelitis Optica. <i>NeuroImmunoModulation</i> , 2012, 19, 96-102.	0.9	28



#	ARTICLE	IF	CITATIONS
292	Distinct lesion morphology at 7-T MRI differentiates neuromyelitis optica from multiple sclerosis. <i>Neurology</i> , 2012, 79, 708-714.	1.5	190
293	Recurrent hyperCKemia with normal muscle biopsy in a pediatric patient with neuromyelitis optica. <i>Neurology</i> , 2012, 79, 1182-1184.	1.5	27
294	Neuromyelitis optica following human papillomavirus vaccination. <i>Neurology</i> , 2012, 79, 285-287.	1.5	47
295	A tract-based diffusion study of cerebral white matter in neuromyelitis optica reveals widespread pathological alterations. <i>Multiple Sclerosis Journal</i> , 2012, 18, 1013-1021.	1.4	63
296	Complement-dependent Cytotoxicity in Neuromyelitis Optica Requires Aquaporin-4 Protein Assembly in Orthogonal Arrays. <i>Journal of Biological Chemistry</i> , 2012, 287, 13829-13839.	1.6	124
297	Cortical oscillopsia without nystagmus, an isolated symptom of neuromyelitis optica spectrum disorder with anti-aquaporin 4 antibody. <i>Multiple Sclerosis Journal</i> , 2012, 18, 244-247.	1.4	11
298	HLA, PTPN22 and PD-1 associations as markers of autoimmunity in neuromyelitis optica. <i>Multiple Sclerosis Journal</i> , 2012, 18, 23-30.	1.4	50
299	Pediatric idiopathic transverse myelitis presenting as an anterior cord syndrome: A case report. <i>Journal of Pediatric Rehabilitation Medicine</i> , 2012, 5, 1-6.	0.3	2
300	Treatment of Optic Neuritis by Plasma Exchange (Add-On) in Neuromyelitis Optica. <i>JAMA Ophthalmology</i> , 2012, 130, 858.	2.6	140
301	Cutting-edge Questions About CLIPPERS (Chronic Lymphocytic Inflammation With Pontine Perivascular) Tj ETQq1 1 0.784314 rgBT /Ov 4.9 13	1.0	13
302	The Diagnostic and Prognostic Value of Neurofilament Heavy Chain Levels in Immune-Mediated Optic Neuropathies. <i>Multiple Sclerosis International</i> , 2012, 2012, 1-5.	0.4	16
303	Brain Abnormalities in Neuromyelitis Optica Spectrum Disorder. <i>Multiple Sclerosis International</i> , 2012, 2012, 1-10.	0.4	70
304	Plasma Exchange in Severe Attacks of Neuromyelitis Optica. <i>Multiple Sclerosis International</i> , 2012, 2012, 1-9.	0.4	75
305	Where Do AQP4 Antibodies Fit in the Pathogenesis of NMO?. <i>Multiple Sclerosis International</i> , 2012, 2012, 1-6.	0.4	9
306	Should Optical Coherence Tomography Be Used to Manage Patients With Multiple Sclerosis?. <i>Journal of Neuro-Ophthalmology</i> , 2012, 32, 363-371.	0.4	6
307	Does interferon beta treatment exacerbate neuromyelitis optica spectrum disorder?. <i>Multiple Sclerosis Journal</i> , 2012, 18, 1480-1483.	1.4	149
308	Effects of Age and Sex on Aquaporin-4 Autoimmunity. <i>Archives of Neurology</i> , 2012, 69, 1039-43.	4.9	91
309	Anti-AQP4 antibody in idiopathic acute transverse myelitis with recurrent clinical course: frequency of positivity and influence in prognosis. <i>Journal of Spinal Cord Medicine</i> , 2012, 35, 251-255.	0.7	6

#	ARTICLE	IF	CITATIONS
310	Role of NMO-IgG in Distinguishing the Type of Optic Neuritis. <i>Optometry and Vision Science</i> , 2012, 89, 234-237.	0.6	0
312	Association of Neuromyelitis Optica With Severe and Intractable Pain. <i>Archives of Neurology</i> , 2012, 69, 1482.	4.9	80
313	Recurrent Brainstem Lesions Mimicking Infarctions in an Elderly Patient with Neuromyelitis Optica Spectrum Disorder. <i>Internal Medicine</i> , 2012, 51, 809-812.	0.3	8
314	T-cell reactivity against AQP4 in neuromyelitis optica. <i>Neurology</i> , 2012, 79, 945-946.	1.5	29
315	Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan. <i>Brain</i> , 2012, 135, 1834-1849.	3.7	361
316	Cross-Immunoreactivity between Bacterial Aquaporin-Z and Human Aquaporin-4: Potential Relevance to Neuromyelitis Optica. <i>Journal of Immunology</i> , 2012, 189, 4602-4611.	0.4	33
317	Diagnostic Dilemmas. , 2012, , 253-281.		0
318	Influence of pregnancy on neuromyelitis optica spectrum disorder. <i>Neurology</i> , 2012, 78, 1264-1267.	1.5	105
319	No MRI evidence of cortical lesions in neuromyelitis optica. <i>Neurology</i> , 2012, 79, 1671-1676.	1.5	107
320	Comparison of clinical, immunological and neuroimaging features between anti-aquaporin-4 antibody-positive and antibody-negative Sjögren's syndrome patients with central nervous system manifestations. <i>Multiple Sclerosis Journal</i> , 2012, 18, 807-816.	1.4	33
321	Quantitative assays for anti-aquaporin-4 antibody with subclass analysis in neuromyelitis optica. <i>Multiple Sclerosis Journal</i> , 2012, 18, 1541-1551.	1.4	36
322	Intérêt des anticorps anti-aquaporine-4 dans le diagnostic et le suivi de la neuromyélite optique. <i>Revue Francophone Des Laboratoires</i> , 2012, 2012, 32-34.	0.0	0
323	Neuromyelitis Optica Spectrum Disorder-Related Optic Neuritis Mimicking Idiopathic Orbital Inflammation. <i>Neuro-Ophthalmology</i> , 2012, 36, 153-157.	0.4	0
324	The unfolding tale of an unusual brain stem syndrome. <i>Practical Neurology</i> , 2012, 12, 55-59.	0.5	0
325	Reversible Leukoencephalopathy—A Differential Diagnosis Beyond Posterior Reversible Encephalopathy Syndrome. <i>Neuro-Ophthalmology</i> , 2012, 36, 158-164.	0.4	0
326	The Spectrum of Neuromyelitis Optica (NMO) in Childhood. <i>Journal of Child Neurology</i> , 2012, 27, 1437-1447.	0.7	38
327	Evidence-Based Review of Therapeutic Plasma Exchange in Neurological Disorders. <i>Seminars in Dialysis</i> , 2012, 25, 132-139.	0.7	9
328	Serologic diagnosis of NMO. <i>Neurology</i> , 2012, 78, 665-671.	1.5	454

#	ARTICLE	IF	CITATIONS
329	Cerebrospinal fluid $\alpha$ -synuclein levels are elevated in multiple sclerosis and neuromyelitis optica patients during relapse. <i>Journal of Neurochemistry</i> , 2012, 122, 19-23.	2.1	29
330	The emerging relationship between neuromyelitis optica and systemic rheumatologic autoimmune disease. <i>Multiple Sclerosis Journal</i> , 2012, 18, 5-10.	1.4	192
331	Hypothermia, Hypotension, Hypersomnia, and Obesity Associated With Hypothalamic Lesions in a Patient Positive for the Anti-aquaporin 4 Antibody. <i>Archives of Neurology</i> , 2012, 69, 1355-9.	4.9	66
333	Neuromyelitis optica: Aquaporin-4 based pathogenesis mechanisms and new therapies. <i>International Journal of Biochemistry and Cell Biology</i> , 2012, 44, 1519-1530.	1.2	91
334	Anti-aquaporin-4 antibody in Chinese patients with central nervous system inflammatory demyelinating disorders. <i>Clinical Neurology and Neurosurgery</i> , 2012, 114, 1131-1134.	0.6	10
335	Subacute encephalopathy associated with aquaporin-4 autoantibodies: A report of 2 adult cases. <i>Clinical Neurology and Neurosurgery</i> , 2012, 114, 1110-1113.	0.6	3
336	Comparison of grey matter atrophy between patients with neuromyelitis optica and multiple sclerosis: A voxel-based morphometry study. <i>European Journal of Radiology</i> , 2012, 81, e110-e114.	1.2	73
337	Innate immunity in the central nervous system. <i>Journal of Clinical Investigation</i> , 2012, 122, 1164-1171.	3.9	805
338	Anti-aquaporin 4 antibody binding character in clinical subtypes of neuromyelitis optica. <i>Clinical and Experimental Neuroimmunology</i> , 2012, 3, 109-115.	0.5	2
339	Small molecule inhibitors of NMO-IgG binding to aquaporin-4 reduce astrocyte cytotoxicity in neuromyelitis optica. <i>FASEB Journal</i> , 2012, 26, 2197-2208.	0.2	76
340	Feasibility of grey matter and white matter segmentation of the upper cervical cord in vivo: A pilot study with application to magnetisation transfer measurements. <i>NeuroImage</i> , 2012, 63, 1054-1059.	2.1	72
341	Acute transverse myelitis in Buenos Aires, Argentina. A retrospective cohort study of 8 years follow-up. <i>Neurología (English Edition)</i> , 2012, 27, 348-353.	0.2	1
342	Optic neuritis in an ethnically diverse population: Higher risk of atypical cases in patients of African or African-Caribbean heritage. <i>Journal of the Neurological Sciences</i> , 2012, 312, 21-25.	0.3	31
343	Serum GFAP levels in optic neuropathies. <i>Journal of the Neurological Sciences</i> , 2012, 317, 117-122.	0.3	26
344	Testing for antibodies to human aquaporin-4 by ELISA: Sensitivity, specificity, and direct comparison with immunohistochemistry. <i>Journal of the Neurological Sciences</i> , 2012, 320, 32-37.	0.3	60
345	Diagnostic utility of NMO/AQP4-IgG in evaluating CNS inflammatory disease in Thai patients. <i>Journal of the Neurological Sciences</i> , 2012, 320, 118-120.	0.3	23
346	Presentation of neuromyelitis optica spectrum disorder after more than twenty years of systemic sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2012, 1, 202-203.	0.9	5
347	Sera from neuromyelitis optica patients disrupt the blood-brain barrier. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2012, 83, 288-297.	0.9	87

#	ARTICLE	IF	CITATIONS
348	Aquaporin-4 Antibodies Are Not Related to HTLV-1 Associated Myelopathy. PLoS ONE, 2012, 7, e39372.	1.1	13
350	The expanded spectrum of neuromyelitis optica: evidences for a new definition. Arquivos De Neuro-Psiquiatria, 2012, 70, 807-813.	0.3	29
351	Multiple Sclerosis and Celiac Disease. , 0, , .		0
352	Clinical Usefulness of Cell-based Indirect Immunofluorescence Assay for the Detection of Aquaporin-4 Antibodies in Neuromyelitis Optica Spectrum Disorder. Annals of Laboratory Medicine, 2012, 32, 331-338.	1.2	33
353	Neuroimaging in Multiple Sclerosis. , 2012, , .		4
354	Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients. Journal of Neuroinflammation, 2012, 9, 14.	3.1	593
355	Detection of Anti-Aquaporin-4 Antibodies in Neuromyelitis Optica: Comparison of Tissue-Based and Cell-Based Indirect Immunofluorescence Assays and ELISA. Journal of Clinical Laboratory Analysis, 2012, 26, 184-189.	0.9	16
356	Myasthenia gravis and neuromyelitis optica spectrum disorder. Neurology, 2012, 78, 1601-1607.	1.5	177
357	Proteomic pattern analysis discriminates among multiple sclerosis-related disorders. Annals of Neurology, 2012, 71, 614-623.	2.8	23
358	Anti-Aquaporin-4 monoclonal antibody blocker therapy for neuromyelitis optica. Annals of Neurology, 2012, 71, 314-322.	2.8	232
359	Neutrophil protease inhibition reduces neuromyelitis optica-immunoglobulin G-induced damage in mouse brain. Annals of Neurology, 2012, 71, 323-333.	2.8	153
360	Clinical spectrum of CNS aquaporin-4 autoimmunity. Neurology, 2012, 78, 1179-1185.	1.5	83
361	Aquaporins in Clinical Medicine. Annual Review of Medicine, 2012, 63, 303-316.	5.0	306
362	Diagnostic approach of patients with longitudinally extensive transverse myelitis. Acta Neurologica Belgica, 2012, 112, 39-43.	0.5	7
363	Neuromyelitis optica IgG and natural killer cells produce NMO lesions in mice without myelin loss. Acta Neuropathologica, 2012, 123, 861-872.	3.9	97
364	A differential diagnosis of central nervous system demyelination: beyond multiple sclerosis. Journal of Neurology, 2012, 259, 801-816.	1.8	49
365	Seroconversion of anti-aquaporin-4 antibody in NMO spectrum disorder: a case report. Journal of Neurology, 2012, 259, 980-981.	1.8	6
366	Anti-Aquaporin-4 antibodies in the context of assorted immune-mediated diseases. European Journal of Neurology, 2012, 19, 248-252.	1.7	18

#	ARTICLE	IF	CITATIONS
367	Aquaporin-4 autoantibody: a neurogenic cause of anorexia and weight loss. <i>Developmental Medicine and Child Neurology</i> , 2012, 54, 45-47.	1.1	11
368	Transverse myelitis. <i>Autoimmunity Reviews</i> , 2012, 11, 231-248.	2.5	90
369	Clinically isolated syndromes. <i>Lancet Neurology</i> , The, 2012, 11, 157-169.	4.9	398
370	Aquaporin 4 and neuromyelitis optica. <i>Lancet Neurology</i> , The, 2012, 11, 535-544.	4.9	460
371	Neuromyelitis optica should be classified as an astrocytopathic disease rather than a demyelinating disease. <i>Clinical and Experimental Neuroimmunology</i> , 2012, 3, 58-73.	0.5	79
372	Aquaporin-4 autoantibodies cause asymptomatic aquaporin-4 loss and activate astrocytes in mouse. <i>Journal of Neuroimmunology</i> , 2012, 245, 32-38.	1.1	25
373	Autoantibodies against aquaporin-4 and myelin oligodendrocyte glycoprotein in paediatric CNS demyelination: Recent developments and future directions. <i>Multiple Sclerosis and Related Disorders</i> , 2012, 1, 116-122.	0.9	3
375	The prevalence of neuromyelitis optica in South East Wales. <i>European Journal of Neurology</i> , 2012, 19, 655-659.	1.7	86
376	Acute reversible periependymal ventricular enhancement in neuromyelitis optica. <i>European Journal of Neurology</i> , 2012, 19, e57-8.	1.7	6
377	Phagocytized corpora amylacea as a histological hallmark of astrocytic injury in neuromyelitis optica. <i>Neuropathology</i> , 2012, 32, 587-594.	0.7	14
378	Treatment of Pediatric Optic Neuritis. <i>Current Treatment Options in Neurology</i> , 2012, 14, 93-102.	0.7	22
379	Immune Mediated Diseases and Immune Modulation in the Neurocritical Care Unit. <i>Neurotherapeutics</i> , 2012, 9, 99-123.	2.1	14
380	The history of neuromyelitis optica. <i>Journal of Neuroinflammation</i> , 2013, 10, 8.	3.1	188
381	The Ex Vivo Production of IL-6 and IL-21 by CD4+ T Cells is Directly Associated with Neurological Disability in Neuromyelitis Optica Patients. <i>Journal of Clinical Immunology</i> , 2013, 33, 179-189.	2.0	64
382	Successful trabeculectomy in a patient with corticosteroid-induced glaucoma with anti-aquaporin 4 antibody-positive neuromyelitis optica: a case report. <i>Journal of Medical Case Reports</i> , 2013, 7, 101.	0.4	2
383	Progressive Multiple Sclerosis. , 2013, , .		0
384	Distinctive clinical and neuroimaging characteristics of longitudinally extensive transverse myelitis associated with aquaporin-4 autoantibodies. <i>Journal of Neurology</i> , 2013, 260, 2396-2402.	1.8	44
385	Modifications of longitudinally extensive transverse myelitis and brainstem lesions in the course of neuromyelitis optica (NMO): a population-based, descriptive study. <i>BMC Neurology</i> , 2013, 13, 33.	0.8	84

#	ARTICLE	IF	CITATIONS
386	Individualized Rituximab Treatment for Neuromyelitis Optica Spectrum Disorders. <i>JAMA Neurology</i> , 2013, 70, 1102.	4.5	9
387	Combination of cyclosporine A with corticosteroids is effective for the treatment of neuromyelitis optica. <i>Journal of Neurology</i> , 2013, 260, 627-634.	1.8	50
388	Aquaporin 4 Expression and Tissue Susceptibility to Neuromyelitis Optica. <i>JAMA Neurology</i> , 2013, 70, 1118.	4.5	70
389	C1q-targeted monoclonal antibody prevents complement-dependent cytotoxicity and neuropathology in in vitro and mouse models of neuromyelitis optica. <i>Acta Neuropathologica</i> , 2013, 125, 829-840.	3.9	57
390	Recent insights into the pathology of multiple sclerosis and neuromyelitis optica. <i>Clinical Neurology and Neurosurgery</i> , 2013, 115, S38-S41.	0.6	16
391	Myasthenia gravis and neuromyelitis optica: A causal link. <i>Multiple Sclerosis and Related Disorders</i> , 2013, 2, 233-237.	0.9	16
392	Association of serum vitamin D levels in Japanese patients with multiple sclerosis. <i>Clinical and Experimental Neuroimmunology</i> , 2013, 4, 193-200.	0.5	11
393	Neurologic diseases of the central nervous system with pathophysiologically relevant autoantibodies – Perspectives for immunoadsorption. <i>Atherosclerosis Supplements</i> , 2013, 14, 161-165.	1.2	22
394	Aquaporin-4 Antibodies (NMO-IgG) as a Serological Marker of Neuromyelitis Optica: A Critical Review of the Literature. <i>Brain Pathology</i> , 2013, 23, 661-683.	2.1	214
395	Serum anticardiolipin antibodies in patients with neuromyelitis optica spectrum disorder. <i>Journal of Neurology</i> , 2013, 260, 3150-3157.	1.8	17
396	Putative association of GPC5 polymorphism with the risk of inflammatory demyelinating diseases. <i>Journal of the Neurological Sciences</i> , 2013, 335, 82-88.	0.3	17
397	Updates on Clinically Isolated Syndrome and Diagnostic Criteria for Multiple Sclerosis. <i>Neurohospitalist, The</i> , 2013, 3, 65-80.	0.3	35
398	Fulminant Demyelinating Diseases. <i>Neurohospitalist, The</i> , 2013, 3, 81-91.	0.3	51
399	Clinical Spectrum and Treatment of Neuromyelitis Optica Spectrum Disorders: Evolution and Current Status. <i>Brain Pathology</i> , 2013, 23, 647-660.	2.1	36
400	The effect of intravenous immunoglobulin on neuromyelitis optica. <i>Neurologia (English Edition)</i> , 2013, 28, 65-72.	0.2	15
401	Blind and Confused. <i>JAMA Neurology</i> , 2013, 70, 932.	4.5	0
402	Development, maintenance and disruption of the blood-brain barrier. <i>Nature Medicine</i> , 2013, 19, 1584-1596.	15.2	1,750
403	Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study. <i>Lancet Neurology, The</i> , 2013, 12, 554-562.	4.9	335

#	ARTICLE	IF	CITATIONS
404	Reduced antibody formation after influenza vaccination in patients with neuromyelitis optica spectrum disorder treated with rituximab. <i>European Journal of Neurology</i> , 2013, 20, 975-980.	1.7	53
405	Involvement of antibody-dependent cell-mediated cytotoxicity in inflammatory demyelination in a mouse model of neuromyelitis optica. <i>Acta Neuropathologica</i> , 2013, 126, 699-709.	3.9	95
406	Idiopathic acute transverse myelitis: outcome and conversion to multiple sclerosis in a large series. <i>BMC Neurology</i> , 2013, 13, 135.	0.8	38
409	Optic neuritis in neuromyelitis optica. <i>Progress in Retinal and Eye Research</i> , 2013, 36, 159-171.	7.3	76
410	Monitoring neuromyelitis optica activity. <i>Expert Review of Neurotherapeutics</i> , 2013, 13, 989-999.	1.4	1
411	Analyses of haptoglobin level in the cerebrospinal fluid and serum of patients with neuromyelitis optica and multiple sclerosis. <i>Clinica Chimica Acta</i> , 2013, 417, 26-30.	0.5	31
412	Longitudinally extensive spinal cord lesion after initiation, and multiple extensive brain lesions after cessation of fingolimod treatment in a patient with recurrent myelitis and anti-aquaporin 4 antibodies. <i>Clinical and Experimental Neuroimmunology</i> , 2013, 4, 239-240.	0.5	8
413	An approach to optic neuritis: the initial presentation. <i>Expert Review of Ophthalmology</i> , 2013, 8, 539-551.	0.3	4
414	Aquaporins, anti-aquaporin-4 autoantibodies and neuromyelitis optica. <i>Clinica Chimica Acta</i> , 2013, 415, 350-360.	0.5	8
415	Associations of <i>CD6</i> , <i>TNFRSF1A</i> and <i>IRF8</i> polymorphisms with risk of inflammatory demyelinating diseases. <i>Neuropathology and Applied Neurobiology</i> , 2013, 39, 519-530.	1.8	28
416	Current concept of neuromyelitis optica (NMO) and NMO spectrum disorders. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013, 84, 922-930.	0.9	149
417	Therapeutic Benefits from Nanoparticles: The Potential Significance of Nanoscience in Diseases with Compromise to the Blood Brain Barrier. <i>Chemical Reviews</i> , 2013, 113, 1877-1903.	23.0	187
418	Disease Amelioration With Tocilizumab in a Treatment-Resistant Patient With Neuromyelitis Optica. <i>JAMA Neurology</i> , 2013, 70, 390.	4.5	112
419	The astrocyte in multiple sclerosis revisited. <i>Glia</i> , 2013, 61, 453-465.	2.5	213
421	Post-acute serum eosinophil and neutrophil-associated cytokine/chemokine profile can distinguish between patients with neuromyelitis optica and multiple sclerosis; and identifies potential pathophysiological mechanisms – A pilot study. <i>Cytokine</i> , 2013, 64, 90-96.	1.4	45
422	Partial recovery of the damaged rat blood-brain barrier is mediated by adherens junction complexes, extracellular matrix remodeling and macrophage infiltration following focal astrocyte loss. <i>Neuroscience</i> , 2013, 250, 773-785.	1.1	40
423	The role of aquaporin-1 in idiopathic and drug-induced intracranial hypertension. <i>Medical Hypotheses</i> , 2013, 81, 1059-1062.	0.8	19
424	Central nervous system inflammatory demyelinating disorders among Hong Kong Chinese. <i>Journal of Neuroimmunology</i> , 2013, 262, 100-105.	1.1	20

#	ARTICLE	IF	CITATIONS
425	Intractable Nausea and Vomiting From Autoantibodies Against a Brain Water Channel. <i>Clinical Gastroenterology and Hepatology</i> , 2013, 11, 240-245.	2.4	49
426	High in vitro immune reactivity to <i>Escherichia coli</i> in neuromyelitis optica patients is correlated with both neurological disabilities and elevated plasma lipopolysaccharide levels. <i>Human Immunology</i> , 2013, 74, 1080-1087.	1.2	23
427	Estudio del efecto del tratamiento con inmunoglobulinas por vía intravenosa en la neuromielitis Óptica. <i>Neurología</i> , 2013, 28, 65-72.	0.3	58
428	Myelin oligodendrocyte glycoprotein induces aquaporin-4 autoantibodies in mouse experimental autoimmune encephalomyelitis. <i>Journal of Neuroimmunology</i> , 2013, 261, 1-6.	1.1	5
429	Seropositive Neuromyelitis Optica: A Pediatric Case Report and 6-Year Follow-Up. <i>Pediatric Neurology</i> , 2013, 49, 198-202.	1.0	2
430	Complement-dependent pathogenicity of brain-specific antibodies in cerebrospinal fluid. <i>Journal of Neuroimmunology</i> , 2013, 254, 76-82.	1.1	38
431	NMO sera down-regulate AQP4 in human astrocyte and induce cytotoxicity independent of complement. <i>Journal of the Neurological Sciences</i> , 2013, 331, 136-144.	0.3	39
432	Neuromielitis Óptica: actualización clínica y terapéutica. <i>Neurología Argentina</i> , 2013, 5, 259-269.	0.1	3
434	Neuromyelitis Optica: Potential Roles for Intravenous Immunoglobulin. <i>Journal of Clinical Immunology</i> , 2013, 33, 33-37.	2.0	35
435	Aquaporin water channels in the nervous system. <i>Nature Reviews Neuroscience</i> , 2013, 14, 265-277.	4.9	600
436	Transverse Myelitis. <i>Neurologic Clinics</i> , 2013, 31, 79-138.	0.8	172
437	A guide to facilitate the early treatment of patients with idiopathic demyelinating disease (multiple) Tj ETQq1 1 0.784314 rgBT /Overl	1.4	7
438	Distinct Serum Cytokine Profiles in Neuromyelitis Optica and Multiple Sclerosis. <i>Journal of Interferon and Cytokine Research</i> , 2013, 33, 58-64.	0.5	33
439	Clinical Relevance of Serum Aquaporin-4 Antibody Levels in Neuromyelitis Optica. <i>Neurochemical Research</i> , 2013, 38, 997-1001.	1.6	11
440	Low Myo-inositol indicating astrocytic damage in a case series of neuromyelitis optica. <i>Annals of Neurology</i> , 2013, 74, 301-305.	2.8	44
441	Idiopathic Inflammatory Demyelinating Diseases of the Brainstem. <i>Seminars in Ultrasound, CT and MRI</i> , 2013, 34, 123-130.	0.7	8
442	Brain-Reactive Antibodies and Disease. <i>Annual Review of Immunology</i> , 2013, 31, 345-385.	9.5	115
443	Hope for a rare disease: eculizumab in neuromyelitis optica. <i>Lancet Neurology</i> , The, 2013, 12, 529-531.	4.9	13



#	ARTICLE	IF	CITATIONS
444	The role of aquaporin-4 antibodies in Chinese patients with neuromyelitis optica. <i>Journal of Clinical Neuroscience</i> , 2013, 20, 94-98.	0.8	30
445	Plasma Exchange for Steroid-Refractory Relapses in Multiple Sclerosis: An Observational, MRI Pilot Study. <i>Clinical Therapeutics</i> , 2013, 35, 474-485.	1.1	26
447	A case of simultaneous neuromyelitis optica spectrum disorder and subacute combined degeneration. <i>Neurological Sciences</i> , 2013, 34, 1819-1821.	0.9	5
448	In vivo identification of morphologic retinal abnormalities in neuromyelitis optica. <i>Neurology</i> , 2013, 80, 1406-1414.	1.5	138
449	Aquaporin-4 antibody-negative neuromyelitis optica. <i>Neurology</i> , 2013, 80, 2194-2200.	1.5	157
450	Neuropsychiatric systemic lupus erythematosus: pathophysiology and the future of treatment. <i>International Journal of Clinical Rheumatology</i> , 2013, 8, 585-595.	0.3	0
451	Seronegative NMO. <i>Neurology</i> , 2013, 80, 2176-2177.	1.5	13
452	AQP4 antibody serostatus. <i>Neurology</i> , 2013, 81, 1186-1188.	1.5	12
453	Meningoencephalitis as an initial manifestation of neuromyelitis optica spectrum disorder. <i>Multiple Sclerosis Journal</i> , 2013, 19, 639-643.	1.4	15
454	Optimizing the management of neuromyelitis optica and spectrum disorders in resource poor settings: Experience from the Mangalore demyelinating disease registry. <i>Annals of Indian Academy of Neurology</i> , 2013, 16, 572.	0.2	21
455	Aquaporin-4 antibody-positive cases beyond current diagnostic criteria for NMO spectrum disorders. <i>Neurology</i> , 2013, 80, 2210-2216.	1.5	98
456	Simultaneous PML-IRIS and myelitis in a patient with neuromyelitis optica spectrum disorder. <i>Neurology: Clinical Practice</i> , 2013, 3, 448-451.	0.8	10
457	Recurrent longitudinally extensive transversal myelitis in a patient with Sjögren's syndrome. <i>Vojnosanitetski Pregled</i> , 2013, 70, 1056-1058.	0.1	2
458	Immunotherapy of Neuromyelitis Optica. <i>Autoimmune Diseases</i> , 2013, 2013, 1-7.	2.7	8
459	Efficacy and safety of beta-interferon in Thai patients with demyelinating diseases. <i>Multiple Sclerosis Journal</i> , 2013, 19, 585-592.	1.4	11
460	Abnormal Nerve Conduction Study Findings Indicating the Existence of Peripheral Neuropathy in Multiple Sclerosis and Neuromyelitis Optica. <i>BioMed Research International</i> , 2013, 2013, 1-6.	0.9	22
461	Spinal cord tract diffusion tensor imaging reveals disability substrate in demyelinating disease. <i>Neurology</i> , 2013, 80, 2201-2209.	1.5	63
462	Factors associated with the effectiveness of plasma exchange for the treatment of NMO-IgG-positive neuromyelitis optica spectrum disorders. <i>Multiple Sclerosis Journal</i> , 2013, 19, 1216-1218.	1.4	49

#	ARTICLE	IF	CITATIONS
463	Intractable hiccup caused by spinal cord lesions in demyelination disease. <i>Journal of Spinal Cord Medicine</i> , 2013, 36, 711-714.	0.7	10
464	Updated estimate of AQP4-IgG serostatus and disability outcome in neuromyelitis optica. <i>Neurology</i> , 2013, 81, 1197-1204.	1.5	206
465	Diagnosis and Differential Diagnosis of Multiple Sclerosis. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2013, 19, 922-943.	0.4	24
466	Therapeutic Cleavage of Anti-Aquaporin-4 Autoantibody in Neuromyelitis Optica by an IgG-Selective Proteinase. <i>Molecular Pharmacology</i> , 2013, 83, 1268-1275.	1.0	58
467	Spectral-Domain Optical Coherence Tomography of Retinal Nerve Fiber Layer Thickness in NMO Patients. <i>Journal of Neuro-Ophthalmology</i> , 2013, 33, 213-219.	0.4	45
468	Distinguishing Optic Neuritis in Neuromyelitis Optica Spectrum Disease From Multiple Sclerosis. <i>Journal of Neuro-Ophthalmology</i> , 2013, 33, 123-127.	0.4	96
469	Inflammatory, vascular, and infectious myelopathies in children. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2013, 112, 999-1017.	1.0	11
470	Neuromyelitis optica and pregnancy during therapeutic B cell depletion: infant exposure to anti-AQP4 antibody and prevention of rebound relapses with low-dose rituximab postpartum. <i>Multiple Sclerosis Journal</i> , 2013, 19, 1544-1547.	1.4	44
471	Intractable Vomiting as an Initial Presentation of Lupus-Related Neuromyelitis Optica. <i>Journal of Clinical Rheumatology</i> , 2013, 19, 154-155.	0.5	5
472	Distinct features between longitudinally extensive transverse myelitis presenting with and without anti-Aquaporin 4 antibodies. <i>Multiple Sclerosis Journal</i> , 2013, 19, 299-307.	1.4	41
473	Role of Autoantibodies in Acquired Inflammatory Demyelinating Diseases of the Central Nervous System in Children. <i>Neuropediatrics</i> , 2013, 44, 297-301.	0.3	22
474	A 5-Year Follow-up of Rituximab Treatment in Patients With Neuromyelitis Optica Spectrum Disorder. <i>JAMA Neurology</i> , 2013, 70, 1110.	4.5	279
475	Utility of aquaporin-4 antibody assay in patients with neuromyelitis optica spectrum disorders. <i>Multiple Sclerosis Journal</i> , 2013, 19, 1060-1067.	1.4	24
476	Longitudinally Extensive Transverse Myelitis With and Without Aquaporin 4 Antibodies. <i>JAMA Neurology</i> , 2013, 70, 1375.	4.5	100
477	Acute Disseminated Encephalomyelitis, Transverse Myelitis, and Neuromyelitis Optica. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2013, 19, 944-967.	0.4	27
478	Anti-Aquaporin-4 Antibody Positivity in Neuromyelitis Optica Is Associated with Lesion Activity. <i>European Neurology</i> , 2013, 70, 113-116.	0.6	1
479	The Retinal Nerve Fiber Layer of Patients With Neuromyelitis Optica and Chronic Relapsing Optic Neuritis is More Severely Damaged than Patients With Multiple Sclerosis. <i>Journal of Neuro-Ophthalmology</i> , 2013, 33, 220-224.	0.4	33
480	Multiple Sclerosis in Malaysia: Demographics, Clinical Features, and Neuroimaging Characteristics. <i>Multiple Sclerosis International</i> , 2013, 2013, 1-10.	0.4	11

#	ARTICLE	IF	CITATIONS
481	Olfactory Dysfunction in Patients with Neuromyelitis Optica. <i>Multiple Sclerosis International</i> , 2013, 2013, 1-4.	0.4	19
482	Bloodâ€œneural barrier: Overview and latest progress. <i>Clinical and Experimental Neuroimmunology</i> , 2013, 4, 220-227.	0.5	4
483	Immunology of neuromyelitis optica: a T cellâ€œB cell collaboration. <i>Annals of the New York Academy of Sciences</i> , 2013, 1283, 57-66.	1.8	64
484	Tissueâ€œand columnâ€œspecific measurements from multiâ€œparameter mapping of the human cervical spinal cord at 3 T. <i>NMR in Biomedicine</i> , 2013, 26, 1823-1830.	1.6	19
485	Enzymatic deglycosylation converts pathogenic neuromyelitis optica antiâ€œaquaporinâ€œ4 immunoglobulin G into therapeutic antibody. <i>Annals of Neurology</i> , 2013, 73, 77-85.	2.8	83
486	Clinical characteristics and outcome of multiple sclerosis in Korea: does multiple sclerosis in Korea really differ from that in the Caucasian populations?. <i>Multiple Sclerosis Journal</i> , 2013, 19, 1493-1498.	1.4	24
487	Distinct genetic and infectious profiles in Japanese neuromyelitis optica patients according to anti-aquaporin 4 antibody status. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013, 84, 29-34.	0.9	118
488	Efficacy of Intravenous Cyclophosphamide Therapy for Neuromyelitis Optica Spectrum Disorder. <i>Internal Medicine</i> , 2013, 52, 969-972.	0.3	53
489	Neuromyelitis Optica: An Often Forgotten Cause of Intractable Nausea and Vomiting. <i>Case Reports in Gastroenterology</i> , 2013, 7, 281-286.	0.3	7
490	Radiolabeled anti-aquaporin-4 protein antibody imaging. <i>Nuclear Medicine Communications</i> , 2013, 34, 413-416.	0.5	1
493	Neuromyelitis Optica Preceded by HyperCKemia and a Possible Association with Coxsackie Virus Group A10 Infection. <i>Internal Medicine</i> , 2013, 52, 2665-2668.	0.3	21
494	Anorexia Heraldng the Onset of Neuromyelitis Optica. <i>Internal Medicine</i> , 2013, 52, 489-491.	0.3	4
495	Anti-Aquaporin-4 Antibody-Seronegative NMO Spectrum Disorder with BalÃ³'s Concentric Lesions. <i>Internal Medicine</i> , 2013, 52, 1517-1521.	0.3	22
497	Visual field characteristics in neuromyelitis optica in absence of and after one episode of optic neuritis. <i>Clinical Ophthalmology</i> , 2013, 7, 1145.	0.9	33
498	European Ancestry Predominates in Neuromyelitis Optica and Multiple Sclerosis Patients from Brazil. <i>PLoS ONE</i> , 2013, 8, e58925.	1.1	14
499	Optic Neuritis Is Associated with Inner Nuclear Layer Thickening and Microcystic Macular Edema Independently of Multiple Sclerosis. <i>PLoS ONE</i> , 2013, 8, e71145.	1.1	102
500	Anti-Aquaporin-1 Autoantibodies in Patients with Neuromyelitis Optica Spectrum Disorders. <i>PLoS ONE</i> , 2013, 8, e74773.	1.1	49
501	An Optimized Immunohistochemistry Technique Improves NMO-IgG Detection: Study Comparison with Cell-Based Assays. <i>PLoS ONE</i> , 2013, 8, e79083.	1.1	39

#	ARTICLE	IF	CITATIONS
502	Plasmablasts as Migratory IgG-Producing Cells in the Pathogenesis of Neuromyelitis Optica. PLoS ONE, 2013, 8, e83036.	1.1	62
503	Optical Coherence Tomography Reveals Distinct Patterns of Retinal Damage in Neuromyelitis Optica and Multiple Sclerosis. PLoS ONE, 2013, 8, e66151.	1.1	162
504	Evaluation of Clinical Interest of Anti-Aquaporin-4 Autoantibody Followup in Neuromyelitis Optica. Clinical and Developmental Immunology, 2013, 2013, 1-7.	3.3	22
505	Computer-based diagnosis of illness in historical persons. Journal of the Royal College of Physicians of Edinburgh, The, 2013, 43, 161-168.	0.2	4
506	Clinical Efficacy of Plasmapheresis in Patients with Neuromyelitis Optica Spectrum Disorder and		

#	ARTICLE	IF	CITATIONS
520	Crescentic glomerulonephritis in a patient with neuromyelitis optica (Devic's syndrome). Case Reports in Internal Medicine, 2014, 2, .	0.0	0
521	Ocular Manifestations of Systemic Lupus Erythematosus. Journal of Clinical & Cellular Immunology, 2014, 05, .	1.5	1
522	Optic Nerve Disorders. , 2014, , 675-680.		0
523	Pregnancy outcomes in a woman with neuromyelitis optica. Neurology, 2014, 83, 1576-1577.	1.5	20
524	Contribution of spinal cord biopsy to diagnosis of aquaporin-4 antibody positive neuromyelitis optica spectrum disorder. Multiple Sclerosis Journal, 2014, 20, 882-888.	1.4	18
525	Gadolinium enhancement patterns of tumefactive demyelinating lesions: correlations with brain biopsy findings and pathophysiology. Journal of Neurology, 2014, 261, 1902-1910.	1.8	24
526	Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology, 2014, 82, 474-481.	1.5	743
527	Rehabilitation for paraplegia caused by neuromyelitis optica: a case report. Spinal Cord, 2014, 52, S14-S15.	0.9	7
528	Autocrine MMP-2/9 secretion increases the BBB permeability in neuromyelitis optica. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 419-430.	0.9	47
529	White matter atrophy in brain of neuromyelitis optica: a voxel-based morphometry study. Acta Radiologica, 2014, 55, 589-593.	0.5	17
530	Evaluation of McDonald MRI criteria for dissemination in space in Korean patients with clinically isolated syndromes. Multiple Sclerosis Journal, 2014, 20, 492-495.	1.4	13
531	Does this optic neuritis patient have neuromyelitis optica? An approach to optic neuritis in the context of neuromyelitis optica. Expert Review of Ophthalmology, 2014, 9, 205-216.	0.3	0
532	Rituximab as a first-line preventive treatment in pediatric NMOSDs. Neurology: Neuroimmunology and NeuroInflammation, 2014, 1, e46.	3.1	41
533	Aquaporin 4 IgG Serostatus and Outcome in Recurrent Longitudinally Extensive Transverse Myelitis. JAMA Neurology, 2014, 71, 48.	4.5	51
534	Prevalence and patterns of demyelinating central nervous system disorders in urban Mangalore, South India. Multiple Sclerosis Journal, 2014, 20, 1651-1653.	1.4	104
535	Aquaporin-4 antibody-positive myelitis initially biopsied for suspected spinal cord tumors: Diagnostic considerations. Multiple Sclerosis Journal, 2014, 20, 621-626.	1.4	10
536	Extensive cerebral white matter involvement in a patient with NMO spectrum disorder. Multiple Sclerosis Journal, 2014, 20, 1401-1403.	1.4	16
537	A clinical and radiological profile of neuromyelitis optica and spectrum disorders in an Indian cohort. Annals of Indian Academy of Neurology, 2014, 17, 77.	0.2	24

#	ARTICLE	IF	CITATIONS
538	Paraneoplastic neuromyelitis optica spectrum disorder associated with stomach carcinoid tumor. Hematology/ Oncology and Stem Cell Therapy, 2014, 7, 116-119.	0.6	29
539	Antibodies to MOG have a demyelination phenotype and affect oligodendrocyte cytoskeleton. Neurology: Neuroimmunology and NeuroInflammation, 2014, 1, e12.	3.1	158
540	A Case of Neuromyelitis Optica Spectrum Disorder With Early Successful Induction of Double Filtration Plasmapheresis. Therapeutic Apheresis and Dialysis, 2014, 18, 317-318.	0.4	1
541	Can Anti-AQP4 Antibody Damage the Blood-Brain Barrier?. European Neurology, 2014, 72, 273-277.	0.6	7
542	Antibodies to myelin oligodendrocyte glycoprotein in bilateral and recurrent optic neuritis. Neurology: Neuroimmunology and NeuroInflammation, 2014, 1, e40.	3.1	192
543	Leptin hormone level in serum of opticospinal, neuromyelitisoptica and multiple sclerosis patients. Clinical and Experimental Neuroimmunology, 2014, 5, 77-83.	0.5	7
544	Neuromyelitis optica IgG stimulates an immunological response in rat astrocyte cultures. Glia, 2014, 62, 692-708.	2.5	78
545	Interferons in the central nervous system: A few instruments play many tunes. Glia, 2014, 62, 339-355.	2.5	99
546	Anti-N-methyl-D-aspartate receptor encephalitis with multiphasic demyelination. Annals of Neurology, 2014, 76, 462-464.	2.8	18
547	Paraneoplastic Neuromyelitis Optica Spectrum Disorder Associated With Metastatic Carcinoid Expressing Aquaporin-4. JAMA Neurology, 2014, 71, 495.	4.5	51
548	Seroprevalence of Aquaporin-4 IgG in a Northern California Population Representative Cohort of Multiple Sclerosis. JAMA Neurology, 2014, 71, 1433.	4.5	73
549	Uhthoff's Phenomenon in Multiple Sclerosis and Neuromyelitis Optica. European Neurology, 2014, 72, 153-156.	0.6	13
550	Targeting B Cells in Neurological Autoimmune Diseases. Milestones in Drug Therapy, 2014, , 219-246.	0.1	0
551	Need for the upcoming revision of the current diagnostic criteria for NMO – response to the letter from Zhou et al.. Multiple Sclerosis Journal, 2014, 20, 1148-1148.	1.4	0
552	Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology, 2014, 83, 1122-1123.	1.5	17
553	Serum analysis by <sup>1</sup> H Nuclear Magnetic Resonance spectroscopy: a new tool for distinguishing neuromyelitis optica from multiple sclerosis. Multiple Sclerosis Journal, 2014, 20, 558-565.	1.4	38
554	Predictors of recurrence following an initial episode of transverse myelitis. Neurology: Neuroimmunology and NeuroInflammation, 2014, 1, e4.	3.1	35
555	Myocarditis and diffuse skeletal muscle oedema: new features of neuromyelitis optica spectrum disorder? A case report. Multiple Sclerosis Journal, 2014, 20, 120-122.	1.4	18

#	ARTICLE	IF	CITATIONS
556	An immunoassay that distinguishes real neuromyelitis optica signals from a labeling detected in patients receiving natalizumab. <i>BMC Neurology</i> , 2014, 14, 139.	0.8	8
557	Comparison between the cranial magnetic resonance imaging features of neuromyelitis optica spectrum disorder versus multiple sclerosis in Taiwanese patients. <i>BMC Neurology</i> , 2014, 14, 218.	0.8	19
558	Comparison of clinical characteristics between neuromyelitis optica spectrum disorders with and without spinal cord atrophy. <i>BMC Neurology</i> , 2014, 14, 246.	0.8	27
559	Interferon-Î2-related tumefactive brain lesion in a Caucasian patient with neuromyelitis optica and clinical stabilization with tocilizumab. <i>BMC Neurology</i> , 2014, 14, 247.	0.8	21
560	Etiologic Spectrum and Prognosis of Longitudinally Extensive Transverse Myelopathies. <i>European Neurology</i> , 2014, 72, 86-94.	0.6	22
561	Neuro-Ophthalmology Annual Review. <i>Asia-Pacific Journal of Ophthalmology</i> , 2014, 3, 104-125.	1.3	2
562	The Treatment of Neuromyelitis Optica. <i>Journal of Neuro-Ophthalmology</i> , 2014, 34, 70-82.	0.4	41
563	Multiple sclerosis, solitary sclerosis or something else?. <i>Multiple Sclerosis Journal</i> , 2014, 20, 1819-1824.	1.4	23
564	Clinical Manifestations and Spinal Cord Magnetic Resonance Imaging Findings in Chinese Neuromyelitis Optica Patients. <i>European Neurology</i> , 2014, 71, 35-41.	0.6	10
565	Sjögren syndrome and neuromyelitis optica spectrum disorder co-exist in a common autoimmune milieu. <i>Arquivos De Neuro-Psiquiatria</i> , 2014, 72, 619-624.	0.3	34
566	The two faces of neuromyelitis optica. <i>Neurology</i> , 2014, 82, 466-467.	1.5	21
568	Mycophenolate Mofetil in the Treatment of Neuromyelitis Optica Spectrum Disorder. <i>JAMA Neurology</i> , 2014, 71, 1372.	4.5	100
569	Utility of aquaporin-4 antibody assay in patients with neuromyelitis optica spectrum disorders. <i>Multiple Sclerosis Journal</i> , 2014, 20, 1147-1147.	1.4	0
570	Ocular Inflammation in Neurorheumatic Disease. <i>Seminars in Neurology</i> , 2014, 34, 444-457.	0.5	11
571	Distinction between MOG antibody“positive and AQP4 antibody“positive NMO spectrum disorders. <i>Neurology</i> , 2014, 83, 475-476.	1.5	16
572	Is neuromyelitis optica with advanced age of onset a paraneoplastic disorder?. <i>International Journal of Neuroscience</i> , 2014, 124, 509-511.	0.8	43
573	Combined Screening for Serum Anti-Nuclear and Anti-Aquaporin-4 Antibodies Improves Diagnostic Accuracy for Distinguishing Neuromyelitis Optica from Multiple Sclerosis. <i>European Neurology</i> , 2014, 72, 103-108.	0.6	20
574	A Rare Case of Neuromyelitis Optica Spectrum Disorder in Patient with Sjogrenâ€™s Syndrome. <i>Case Reports in Rheumatology</i> , 2014, 2014, 1-3.	0.2	3

#	ARTICLE	IF	CITATIONS
575	The Frequency of Anti-Aquaporin-4 Ig G Antibody in Neuromyelitis Optica and Its Spectrum Disorders at a Single Tertiary Referral Center in Malaysia. <i>Multiple Sclerosis International</i> , 2014, 2014, 1-10.	0.4	19
576	Aquaporin-4 Immunoglobulin G testing in 36 consecutive Jamaican patients with inflammatory central nervous system demyelinating disease. <i>Neurology International</i> , 2014, 6, 5395.	1.3	1
577	Structural brain abnormalities are related to retinal nerve fiber layer thinning and disease duration in neuromyelitis optica spectrum disorders. <i>Multiple Sclerosis Journal</i> , 2014, 20, 1189-1197.	1.4	70
578	Characterization of neuromyelitis optica and neuromyelitis optica spectrum disorder patients with a late onset. <i>Multiple Sclerosis Journal</i> , 2014, 20, 1086-1094.	1.4	87
579	NMO spectrum disorders: how wide is the spectrum?. <i>Multiple Sclerosis Journal</i> , 2014, 20, 1417-1419.	1.4	2
580	Inflammatory Optic Neuropathies. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2014, 20, 816-837.	0.4	14
581	Acute Cervical Segmental Denervation in Neuromyelitis Optica Spectrum Disorder. <i>Journal of Clinical Neuromuscular Disease</i> , 2014, 16, 90-97.	0.3	7
582	Autoimmune hepatitis in a patient affected by neuromyelitis optica: A new association. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2014, 38, e33-e35.	0.7	5
583	NMO spectrum disorders comprise the major portion of CNS inflammatory diseases in Thai patients: A cross sectional study. <i>Multiple Sclerosis and Related Disorders</i> , 2014, 3, 61-66.	0.9	7
584	Unilateral Visual Loss in a Previously Healthy 15-Year-Old Girl: Monosymptomatic Neuromyelitis Optica?. <i>Seminars in Pediatric Neurology</i> , 2014, 21, 145-151.	1.0	0
585	No evidence for genetic association between glutamate transporter EAAT2 and Devic's neuromyelitis optica in caucasians and afro-caribbeans. <i>Multiple Sclerosis and Related Disorders</i> , 2014, 3, 89-93.	0.9	0
586	Concomitant neuromyelitis optica and cytomegalovirus-associated retinitis in an immunocompetent female. <i>Acta Neurologica Belgica</i> , 2014, 114, 77-79.	0.5	1
587	Differential diagnoses to MS: experiences from an optic neuritis clinic. <i>Journal of Neurology</i> , 2014, 261, 98-105.	1.8	26
588	The diagnosis of multiple sclerosis and the various related demyelinating syndromes: A critical review. <i>Journal of Autoimmunity</i> , 2014, 48-49, 134-142.	3.0	263
589	Lower motor neuron involvement in longitudinally extensive transverse myelitis with and without aquaporin-4 antibodies. <i>Clinical Neurophysiology</i> , 2014, 125, 1925-1926.	0.7	1
590	Aquaporins: important but elusive drug targets. <i>Nature Reviews Drug Discovery</i> , 2014, 13, 259-277.	21.5	462
591	Differential Diagnosis of White Matter Lesions: Nonvascular Causesâ€™ Part II. <i>Clinical Neuroradiology</i> , 2014, 24, 93-110.	1.0	15
592	â€™Spinal amaurosisâ€™ (1841). On the early contribution of Edward Hocken to the concept of neuromyelitis optica. <i>Journal of Neurology</i> , 2014, 261, 400-404.	1.8	8



#	ARTICLE	IF	CITATIONS
593	Experimental mouse model of optic neuritis with inflammatory demyelination produced by passive transfer of neuromyelitis optica-immunoglobulin G. <i>Journal of Neuroinflammation</i> , 2014, 11, 16.	3.1	53
594	Unique neuromyelitis optica pathology produced in naïve rats by intracerebral administration of NMO-IgG. <i>Acta Neuropathologica</i> , 2014, 127, 539-551.	3.9	55
595	Overlapping demyelinating syndromes and anti-N-methyl-D-aspartate receptor encephalitis. <i>Annals of Neurology</i> , 2014, 75, 411-428.	2.8	405
596	MRI mimics of multiple sclerosis. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2014, 122, 291-316.	1.0	49
597	MRI in transverse myelitis. <i>Journal of Magnetic Resonance Imaging</i> , 2014, 40, 1267-1279.	1.9	70
598	Antibodies to AQP4. , 2014, , 605-611.		2
599	Anti-MOG antibodies in adult patients with demyelinating disorders of the central nervous system. <i>Journal of Neuroimmunology</i> , 2014, 270, 98-99.	1.1	51
600	The usefulness of brain MRI at onset in the differentiation of multiple sclerosis and seropositive neuromyelitis optica spectrum disorders. <i>Multiple Sclerosis Journal</i> , 2014, 20, 695-704.	1.4	69
601	Optic neuritis. <i>Lancet Neurology</i> , The, 2014, 13, 83-99.	4.9	463
602	Update on the diagnosis and treatment of neuromyelitis optica: Recommendations of the Neuromyelitis Optica Study Group (NEMOS). <i>Journal of Neurology</i> , 2014, 261, 1-16.	1.8	494
603	The Pathology of an Autoimmune Astrocytopathy: Lessons Learned from Neuromyelitis Optica. <i>Brain Pathology</i> , 2014, 24, 83-97.	2.1	336
604	Neuroimaging of Multiple Sclerosis, Acute Disseminated Encephalomyelitis, and Other Demyelinating Diseases. <i>Seminars in Roentgenology</i> , 2014, 49, 76-85.	0.2	24
605	Autoimmune encephalitis: Recent updates and emerging challenges. <i>Journal of Clinical Neuroscience</i> , 2014, 21, 722-730.	0.8	131
606	Imaging Approach to the Cord T2 Hyperintensity (Myelopathy). <i>Radiologic Clinics of North America</i> , 2014, 52, 427-446.	0.9	18
607	Body fluid biomarkers in multiple sclerosis. <i>Lancet Neurology</i> , The, 2014, 13, 113-126.	4.9	204
609	Case of elderly-onset neuromyelitis optica spectrum disorder mimicking cervical spondylotic myelopathy. <i>Neurology and Clinical Neuroscience</i> , 2014, 2, 18-19.	0.2	3
610	The diagnostic value of aquaporin-4 antibodies in central nervous system diseases. <i>Neurochemical Journal</i> , 2014, 8, 214-220.	0.2	2
611	NMO spectrum of disorders: A paradigm for astrocyte-targeting autoimmunity and its implications for MS and other CNS inflammatory diseases. <i>Journal of Autoimmunity</i> , 2014, 54, 93-99.	3.0	25

#	ARTICLE	IF	CITATIONS
612	Antibodies to neural and non-neural autoantigens in Japanese patients with CNS demyelinating disorders. <i>Journal of Neuroimmunology</i> , 2014, 274, 155-160.	1.1	4
613	Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease. <i>Neurology</i> , 2014, 83, 142-150.	1.5	275
614	Desórdenes del espectro de la neuromielitis óptica: estudio retrospectivo multicéntrico. <i>Neurología Argentina</i> , 2014, 6, 207-211.	0.1	0
615	No association between CCL2 gene polymorphisms and risk of inflammatory demyelinating diseases in a Korean population. <i>Tissue Antigens</i> , 2014, 84, 223-228.	1.0	3
616	Gray matter involvement in multiple sclerosis and neuromyelitis optica. <i>Clinical and Experimental Neuroimmunology</i> , 2014, 5, 69-76.	0.5	3
617	Aquaporin-4 autoimmunity masquerading as a brainstem tumor. <i>Journal of Neurosurgery: Pediatrics</i> , 2014, 14, 301-305.	0.8	4
618	Japanese cases of neuromyelitis optica spectrum disorder associated with myasthenia gravis and a review of the literature. <i>Clinical Neurology and Neurosurgery</i> , 2014, 125, 217-221.	0.6	13
619	Clinically isolated syndromes and the relationship to multiple sclerosis. <i>Journal of Clinical Neuroscience</i> , 2014, 21, 2065-2071.	0.8	61
620	Targeting of aquaporin 4 into lipid rafts and its biological significance. <i>Brain Research</i> , 2014, 1583, 237-244.	1.1	9
621	Application of the 2012 revised diagnostic definitions for paediatric multiple sclerosis and immune-mediated central nervous system demyelination disorders. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014, 85, 790-794.	0.9	8
622	Inhibitor(s) of the classical complement pathway in mouse serum limit the utility of mice as experimental models of neuromyelitis optica. <i>Molecular Immunology</i> , 2014, 62, 104-113.	1.0	57
624	Pain in neuromyelitis optica—prevalence, pathogenesis and therapy. <i>Nature Reviews Neurology</i> , 2014, 10, 529-536.	4.9	77
625	Magnetic resonance imaging of intramedullary spinal cord lesions: A pictorial review. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2014, 58, 569-581.	0.9	13
626	Neuromyelitis optica spectrum disorders without and with autoimmune diseases. <i>BMC Neurology</i> , 2014, 14, 162.	0.8	39
627	Myelitis in systemic lupus erythematosus frequently manifests as longitudinal and sometimes occurs at low disease activity. <i>Lupus</i> , 2014, 23, 1178-1186.	0.8	29
628	Targeting B cells and autoantibodies in the therapy of autoimmune diseases. <i>Seminars in Immunopathology</i> , 2014, 36, 289-299.	2.8	13
629	Comparative clinical characteristics of neuromyelitis optica spectrum disorders with and without medulla oblongata lesions. <i>Journal of Neurology</i> , 2014, 261, 954-962.	1.8	36
630	Postural orthostatic tachycardia syndrome: additional phenotypic feature of neuromyelitis optica spectrum disorder. <i>Neurological Sciences</i> , 2014, 35, 1623-1625.	0.9	7

#	ARTICLE	IF	CITATIONS
631	Horner Syndrome in a Case of Neuromyelitis Optica. <i>Neuro-Ophthalmology</i> , 2014, 38, 78-81.	0.4	4
632	Neuromyelitis optica pathology in rats following intraperitoneal injection of NMO-IgG and intracerebral needle injury. <i>Acta Neuropathologica Communications</i> , 2014, 2, 48.	2.4	47
633	Neuromyelitis optica (Devic's syndrome). <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2014, 122, 581-599.	1.0	53
634	Groupwise multi-atlas segmentation of the spinal cord's internal structure. <i>Medical Image Analysis</i> , 2014, 18, 460-471.	7.0	49
635	Diagnosis and classification of neuromyelitis optica (Devic's Syndrome). <i>Autoimmunity Reviews</i> , 2014, 13, 531-533.	2.5	40
636	Chronic inflammatory demyelinating polyradiculoneuropathy and variants: where we are and where we should go. <i>Journal of the Peripheral Nervous System</i> , 2014, 19, 2-13.	1.4	89
637	Investigation of the KIR4.1 potassium channel as a putative antigen in patients with multiple sclerosis: a comparative study. <i>Lancet Neurology</i> , The, 2014, 13, 795-806.	4.9	76
638	The impact of neuromyelitis optica on the recognition of emotional facial expressions: A preliminary report. <i>Social Neuroscience</i> , 2014, 9, 1-6.	0.7	8
639	KIF1B polymorphisms associated with the risk of inflammatory demyelinating disease in Korean population. <i>Genes and Genomics</i> , 2014, 36, 559-564.	0.5	0
640	Association between neuromyelitis optica and tuberculosis in a Chinese population. <i>BMC Neurology</i> , 2014, 14, 33.	0.8	22
641	CD58 polymorphisms associated with the risk of neuromyelitis optica in a Korean population. <i>BMC Neurology</i> , 2014, 14, 57.	0.8	28
642	Characterization of the spectrum of Korean inflammatory demyelinating diseases according to the diagnostic criteria and AQP4-Ab status. <i>BMC Neurology</i> , 2014, 14, 93.	0.8	15
643	Î²2-adrenergic agonists modulate TNF-Î± induced astrocytic inflammatory gene expression and brain inflammatory cell populations. <i>Journal of Neuroinflammation</i> , 2014, 11, 21.	3.1	36
644	Cell-surface central nervous system autoantibodies: Clinical relevance and emerging paradigms. <i>Annals of Neurology</i> , 2014, 76, 168-184.	2.8	159
645	Demyelination in multiple sclerosis. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2014, 122, 89-99.	1.0	69
646	Human aquaporin 4 gene polymorphisms in Chinese patients with neuromyelitis optica. <i>Journal of Neuroimmunology</i> , 2014, 274, 192-196.	1.1	17
647	Onset of secondary progressive phase and long-term evolution of multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014, 85, 67-75.	0.9	224
648	Neuromyelitis optica and the evolving spectrum of autoimmune aquaporin-4 channelopathies. <i>Clinical and Experimental Neuroimmunology</i> , 2014, 5, 175-187.	0.5	18

#	ARTICLE	IF	CITATIONS
649	Pearls & Oy-sters: A cause of intractable vomiting. <i>Neurology</i> , 2014, 83, e141-4.	1.5	1
650	Longitudinally extensive NMO spinal cord pathology produced by passive transfer of NMO-IgG in mice lacking complement inhibitor CD59. <i>Journal of Autoimmunity</i> , 2014, 53, 67-77.	3.0	51
651	Neuromyelitis optica: clinical features, immunopathogenesis and treatment. <i>Clinical and Experimental Immunology</i> , 2014, 176, 149-164.	1.1	277
652	Magnetic resonance imaging in neuromyelitis optica. <i>Multiple Sclerosis Journal</i> , 2014, 20, 1153-1164.	1.4	55
653	Visual evoked potentials in neuromyelitis optica and its spectrum disorders. <i>Multiple Sclerosis Journal</i> , 2014, 20, 617-620.	1.4	47
654	Finding the missing link in neuromyelitis optica presenting with recurrent transverse myelitis flares. <i>Journal of Clinical Neuroscience</i> , 2014, 21, 861-862.	0.8	0
655	Features of anti-aquaporin 4 antibody-seronegative Thai patients with neuromyelitis optica spectrum disorders: A comparison with seropositive cases. <i>Journal of the Neurological Sciences</i> , 2014, 341, 17-21.	0.3	19
656	Pathologic yawning in neuromyelitis optica spectrum disorders. <i>Multiple Sclerosis and Related Disorders</i> , 2014, 3, 527-532.	0.9	9
657	Astrocyte loss and astrogliosis in neuroinflammatory disorders. <i>Neuroscience Letters</i> , 2014, 565, 39-41.	1.0	65
658	Brain gadolinium enhancement along the ventricular and leptomeningeal regions in patients with aquaporin-4 antibodies in cerebral spinal fluid. <i>Journal of Neuroimmunology</i> , 2014, 269, 62-67.	1.1	25
659	Lack of association between AQP4 polymorphisms and risk of inflammatory demyelinating disease in a Korean population. <i>Gene</i> , 2014, 536, 302-307.	1.0	9
660	The spectrum of post-vaccination inflammatory CNS demyelinating syndromes. <i>Autoimmunity Reviews</i> , 2014, 13, 215-224.	2.5	165
662	On the relationship between human papilloma virus vaccine and autoimmune diseases. <i>Autoimmunity Reviews</i> , 2014, 13, 736-741.	2.5	70
663	Relapsing optic neuritis: a multicentre study of 62 patients. <i>Multiple Sclerosis Journal</i> , 2014, 20, 848-853.	1.4	41
664	Clinical spectrum of neuromyelitis optica 2013. <i>Neurology and Clinical Neuroscience</i> , 2014, 2, 23-27.	0.2	2
665	Cortical Thinning Correlates with Cognitive Change in Multiple Sclerosis but not in Neuromyelitis Optica. <i>European Radiology</i> , 2014, 24, 2334-2343.	2.3	34
666	The neurology of Sjögren's syndrome and the rheumatology of peripheral neuropathy and myelitis. <i>Practical Neurology</i> , 2014, 14, 14-22.	0.5	70
667	An elderly woman with leg weakness. <i>Practical Neurology</i> , 2014, 14, 119-122.	0.5	3

#	ARTICLE	IF	CITATIONS
670	Patient with Neuromyelitis Optica Spectrum Disorder Combined with Sjögren's Syndrome Relapse Free Following Tacrolimus Treatment. <i>Internal Medicine</i> , 2014, 53, 2377-2380.	0.3	7
671	Anti-aquaporin-4 Antibody-Seronegative NMO Spectrum Disorder with Baló's Concentric Lesions. <i>Internal Medicine</i> , 2014, 53, 529-529.	0.3	0
672	A Case of Neuromyelitis Optica Masquerading as Miller Fisher Syndrome. <i>Case Reports in Neurology</i> , 2014, 6, 226-231.	0.3	3
673	Acute, multifocal neurological symptoms. , 0, , 209-227.		0
674	A Case of Anti-aquaporin-4 Antibody-Seronegative NMO Spectrum Disorder with Baló's Concentric Lesions. <i>Internal Medicine</i> , 2014, 53, 531-531.	0.3	0
675	Experimental Models of Neuromyelitis Optica. <i>Brain Pathology</i> , 2014, 24, 74-82.	2.1	48
677	Spinal Anesthesia for Cesarean Delivery in a Woman with Neuromyelitis Optica. <i>A &amp; A Case Reports</i> , 2014, 2, 108-110.	0.7	5
678	Purified human C1-esterase inhibitor is safe in acute relapses of neuromyelitis optica. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2014, 1, e5.	3.1	46
680	Treatment of neuromyelitis optica. <i>Current Opinion in Ophthalmology</i> , 2015, 26, 476-483.	1.3	15
681	The Clinical Characteristics of Primary Sjögren's Syndrome With Neuromyelitis Optica Spectrum Disorder in China. <i>Medicine (United States)</i> , 2015, 94, e1145.	0.4	33
682	Next-generation sequencing identifies altered whole blood microRNAs in neuromyelitis optica spectrum disorder which may permit discrimination from multiple sclerosis. <i>Journal of Neuroinflammation</i> , 2015, 12, 196.	3.1	27
683	Case of neuromyelitis optica spectrum disorder with atopic factors. <i>Clinical and Experimental Neuroimmunology</i> , 2015, 6, 170-171.	0.5	0
684	Neuromyelitis optica spectrum disorder developing 40 years after myasthenia gravis remission. <i>Clinical and Experimental Neuroimmunology</i> , 2015, 6, 426-429.	0.5	0
685	Late-onset neuromyelitis optica spectrum disorder in AQP4-seropositive patients in a Chinese population. <i>BMC Neurology</i> , 2015, 15, 160.	0.8	31
686	Black Hairy Tongue Treated With Oral Antibiotics: A Case Report. <i>Journal of the American Geriatrics Society</i> , 2015, 63, 412-413.	1.3	6
688	Methotrexate is effective for the treatment of neuromyelitis optica spectrum disorders in Asian patients. <i>Clinical and Experimental Neuroimmunology</i> , 2015, 6, 149-153.	0.5	2
689	Neuromyelitis Optica Spectrum Disorder Associated With Autoimmune Hemolytic Anemia and Lymphoma. <i>Neurologist</i> , 2015, 20, 33-34.	0.4	12
690	Bevacizumab is safe in acute relapses of neuromyelitis optica. <i>Clinical and Experimental Neuroimmunology</i> , 2015, 6, 413-418.	0.5	39

#	ARTICLE	IF	CITATIONS
691	Hypoxemia, Sleep Disturbances, and Depression Correlated with Fatigue in Neuromyelitis Optica Spectrum Disorder. <i>CNS Neuroscience and Therapeutics</i> , 2015, 21, 599-606.	1.9	39
692	Copy number variations in multiple sclerosis and neuromyelitis optica. <i>Annals of Neurology</i> , 2015, 78, 762-774.	2.8	34
693	Spinal cord ring enhancement in patients with neuromyelitis optica. <i>Acta Neurologica Scandinavica</i> , 2015, 132, 37-41.	1.0	16
694	The Fc Receptor-Like 3 Polymorphisms (rs7528684, rs945635, rs3761959 and rs2282284) and The Risk of Neuromyelitis Optica in A Chinese Population. <i>Medicine (United States)</i> , 2015, 94, e1320.	0.4	8
695	Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorder Patients in Turkish Cohort. <i>Neurologist</i> , 2015, 20, 61-66.	0.4	8
696	Galactorrhea in a Patient With Aquaporin-4 Antibodyâ€“positive Neuromyelitis Optica Spectrum Disorder. <i>Neurologist</i> , 2015, 20, 101-103.	0.4	6
697	Bilateral Sixth Nerve Palsies in Anti-Aquaporin 4 Antibody Syndrome. <i>Journal of Neuro-Ophthalmology</i> , 2015, 35, 102-105.	0.4	1
698			

#	ARTICLE	IF	CITATIONS
709	A Case Study of Intractable Vomiting with Final Diagnosis of Neuromyelitis Optica. Case Reports in Pediatrics, 2015, 2015, 1-7.	0.2	4
710	The Correlation between Aquaporin-4 Antibody and the Visual Function of Patients with Demyelinating Optic Neuritis at Onset. Journal of Ophthalmology, 2015, 2015, 1-5.	0.6	7
711	Optic Neuritis: A Model for the Immuno-pathogenesis of Central Nervous System Inflammatory Demyelinating Diseases. Current Immunology Reviews, 2015, 11, 85-92.	1.2	9
712	Diagnosis Approach of Optic Neuritis. Journal of Neurology & Neurophysiology, 2015, 06, .	0.1	2
713	Neuromyelitis optica overlapping systemic sclerosis with anti-centromere antibodies. Journal of the Neurological Sciences, 2015, 353, 191-192.	0.3	4
714	Neuromyelitis optica in Portugal (NEMIPORT) – A multicentre study. Clinical Neurology and Neurosurgery, 2015, 134, 79-84.	0.6	5
715	Epidemiological, clinical, and immunological characteristics of neuromyelitis optica: A review. Journal of the Neurological Sciences, 2015, 355, 7-17.	0.3	49
716	Differential Diagnosis of Acute Myelopathies: An Update. Clinical Neuroradiology, 2015, 25, 183-187.	1.0	9
717	Relapse of neuromyelitis optica during pregnancy – Treatment options and literature review. Clinical Neurology and Neurosurgery, 2015, 130, 159-161.	0.6	19
718	Long-term Therapy With Interleukin 6 Receptor Blockade in Highly Active Neuromyelitis Optica Spectrum Disorder. JAMA Neurology, 2015, 72, 756.	4.5	206
719	Use of Advanced Magnetic Resonance Imaging Techniques in Neuromyelitis Optica Spectrum Disorder. JAMA Neurology, 2015, 72, 815.	4.5	59
720	Spinal cord MRI in multiple sclerosis – diagnostic, prognostic and clinical value. Nature Reviews Neurology, 2015, 11, 327-338.	4.9	177
721	Olfactory dysfunction in neuromyelitis optica spectrum disorders. Journal of Neurology, 2015, 262, 1890-1898.	1.8	15
722	Cerebrospinal fluid aquaporin-4 immunoglobulin G disrupts blood brain barrier. Annals of Clinical and Translational Neurology, 2015, 2, 857-863.	1.7	37
723	Significance of gray matter brain lesions in multiple sclerosis and neuromyelitis optica. Neuropathology, 2015, 35, 481-486.	0.7	10
724	Myelodysplastic syndrome with progressive multifocal predominantly pontine demyelination. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e90.	3.1	0
725	Sleep abnormality in neuromyelitis optica spectrum disorder. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e94.	3.1	29
726	Aquaporin-4 positive myelitis associated with Sjögren syndrome and colonic adenocarcinoma. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e103.	3.1	4

#	ARTICLE	IF	CITATIONS
727	The poor recovery of neuromyelitis optica spectrum disorder is associated with a lower level of CXCL12 in the human brain. <i>Journal of Neuroimmunology</i> , 2015, 289, 56-61.	1.1	14
728	Highly encephalitogenic aquaporin 4-specific T cells and NMO-IgG jointly orchestrate lesion location and tissue damage in the CNS. <i>Acta Neuropathologica</i> , 2015, 130, 783-798.	3.9	55
729	No Overlap among Serum GAD65, NMDAR and AQP4 Antibodies in Patients with Neuromyelitis Optica Spectrum Disorders. <i>NeuroImmunoModulation</i> , 2015, 22, 337-341.	0.9	6
731	Decreased serum vitamin D levels in Japanese patients with multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2015, 279, 40-45.	1.1	32
732	Latitude and HLA-DRB1 alleles independently affect the emergence of cerebrospinal fluid IgG abnormality in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2015, 21, 1112-1120.	1.4	13
733	Neuromyelitis optica and multiple sclerosis: Seeing differences through optical coherence tomography. <i>Multiple Sclerosis Journal</i> , 2015, 21, 678-688.	1.4	209
734	Neuromyelitis optica spectrum disorders associated with other autoimmune diseases. <i>Rheumatology International</i> , 2015, 35, 243-253.	1.5	34
735	Sex Disparities in Neuro-Ophthalmologic Disorders. <i>Current Eye Research</i> , 2015, 40, 247-265.	0.7	7
736	Cerebrospinal Fluid in Clinical Neurology. , 2015, , .		16
737	Neurological outcome and predictive factors of idiopathic optic neuritis in China. <i>Journal of the Neurological Sciences</i> , 2015, 349, 94-98.	0.3	9
738	Increased cerebrospinal fluid osteopontin levels and its involvement in macrophage infiltration in neuromyelitis optica. <i>BBA Clinical</i> , 2015, 3, 126-134.	4.1	16
740	Presence of anti-Ro/SSA antibody may be associated with anti-aquaporin-4 antibody positivity in neuromyelitis optica spectrum disorder. <i>Journal of the Neurological Sciences</i> , 2015, 348, 132-135.	0.3	32
741	Inflammation of the Spinal Cord. , 2015, , 315-367.		2
742	Neuromyelitis optica: a positive appraisal of seronegative cases. <i>European Journal of Neurology</i> , 2015, 22, 1511.	1.7	29
743	Aquaporin 4 antibody [NMO Ab] status in patients with severe optic neuritis in India. <i>International Ophthalmology</i> , 2015, 35, 801-806.	0.6	10
744	Crosstalk between the nociceptive and immune systems in host defence and disease. <i>Nature Reviews Neuroscience</i> , 2015, 16, 389-402.	4.9	148
745	Retinal Glia. <i>Colloquium Series on Neuroglia in Biology and Medicine From Physiology To Disease</i> , 2015, 2, 1-644.	0.5	5
746	SCT for severe autoimmune diseases: consensus guidelines of the European Society for Blood and Marrow Transplantation for immune monitoring and biobanking. <i>Bone Marrow Transplantation</i> , 2015, 50, 173-180.	1.3	71



#	ARTICLE	IF	CITATIONS
747	Multimodal Quantitative MR Imaging of the Thalamus in Multiple Sclerosis and Neuromyelitis Optica. <i>Radiology</i> , 2015, 277, 784-792.	3.6	35
748	Treatment Outcomes With Rituximab in 100 Patients With Neuromyelitis Optica. <i>JAMA Neurology</i> , 2015, 72, 989.	4.5	157
749	Rituximab Therapy in Neuromyelitis Optica. <i>JAMA Neurology</i> , 2015, 72, 974.	4.5	3
750	Azathioprine plus corticosteroid treatment in Chinese patients with neuromyelitis optica. <i>Journal of Clinical Neuroscience</i> , 2015, 22, 1178-1182.	0.8	40
751	Aquaporin-4 autoimmunity. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2015, 2, e110.	3.1	173
752	Experimental models of neuromyelitis optica: current status, challenges and future directions. <i>Neuroscience Bulletin</i> , 2015, 31, 735-744.	1.5	25
753	International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. <i>Neurology</i> , 2015, 85, 177-189.	1.5	3,275
754	Paraneoplastic neuromyelitis optica spectrum disorders: three new cases and a review of the literature. <i>International Journal of Neuroscience</i> , 2016, 126, 1-9.	0.8	29
755	Very late-onset neuromyelitis optica spectrum disorder beyond the age of 75. <i>Journal of Neurology</i> , 2015, 262, 1379-1384.	1.8	47
756	Familial forms of multiple sclerosis and neuromyelitis optica at an MS center in Rio de Janeiro State, Brazil. <i>Journal of the Neurological Sciences</i> , 2015, 356, 196-201.	0.3	23
757	Corticosteroid and tacrolimus treatment in neuromyelitis optica related disorders. <i>Multiple Sclerosis Journal</i> , 2015, 21, 669-669.	1.4	17
758	Anti-aquaporin-4 antibody-positive dorsal midbrain syndrome. <i>Multiple Sclerosis Journal</i> , 2015, 21, 477-480.	1.4	9
759	Pediatric Spinal Infection and Inflammation. <i>Neuroimaging Clinics of North America</i> , 2015, 25, 173-191.	0.5	21
760	Multiple sclerosis and pregnancy in the 'treatment era'. <i>Nature Reviews Neurology</i> , 2015, 11, 280-289.	4.9	99
761	Diagnostic value of aquaporin 4 antibody in assessing idiopathic inflammatory demyelinating central nervous system diseases in Egyptian patients. <i>Journal of Clinical Neuroscience</i> , 2015, 22, 670-675.	0.8	3
762	Intravenous immunoglobulin may reduce relapse frequency in neuromyelitis optica. <i>Journal of Neuroimmunology</i> , 2015, 282, 92-96.	1.1	40
763	Anti-thyroid antibodies and cerebrospinal fluid findings in neuromyelitis optica spectrum disorders. <i>Journal of Neuroimmunology</i> , 2015, 281, 38-43.	1.1	16
764	Syndrome of inappropriate antidiuretic hormone secretion in patients with aquaporin-4 antibody. <i>Journal of Neurology</i> , 2015, 262, 101-107.	1.8	22

#	ARTICLE	IF	CITATIONS
765	High Spatial Resolution Imaging Mass Spectrometry of Human Optic Nerve Lipids and Proteins. <i>Journal of the American Society for Mass Spectrometry</i> , 2015, 26, 940-947.	1.2	32
766	Elderlyâ€™Onset Neuromyelitis Optica Spectrum Disorders. <i>Journal of the American Geriatrics Society</i> , 2015, 63, 411-412.	1.3	6
767	Neuromyelitis optica phenotype associated with therapy-responsive acute peripheral neuropathy. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2015, 2, e83.	3.1	9
768	Anti-MOG antibodies are present in a subgroup of patients with a neuromyelitis optica phenotype. <i>Journal of Neuroinflammation</i> , 2015, 12, 46.	3.1	149
769	Differential patterns of spinal cord and brain atrophy in NMO and MS. <i>Neurology</i> , 2015, 84, 1465-1472.	1.5	70
770	Longitudinally extensive transverse myelitis in neuromyelitis optica: a prospective study of 13 Caucasian patients and literature review. <i>Acta Neurologica Belgica</i> , 2015, 115, 635-642.	0.5	7
771	Demographic and clinical features of neuromyelitis optica: A review. <i>Multiple Sclerosis Journal</i> , 2015, 21, 845-853.	1.4	278
772	Late post-transplant anti-aquaporin-4 Ab-positive optic neuritis in a patient with AML. <i>Bone Marrow Transplantation</i> , 2015, 50, 1125-1126.	1.3	7
773	The cerebrospinal fluid immunoglobulin transcriptome and proteome in neuromyelitis optica reveals central nervous system-specific B cell populations. <i>Journal of Neuroinflammation</i> , 2015, 12, 19.	3.1	48
774	Anti-JC virus antibodies in rituximab-treated patients with neuromyelitis optica spectrum disorder. <i>Journal of Neurology</i> , 2015, 262, 696-700.	1.8	12
775	Intractable hiccup and vomiting, neuropathic pruritus and tonic spasms in a case of neuromyelitis optica spectrum disorder. <i>Acta Neurologica Belgica</i> , 2015, 115, 797-799.	0.5	7
776	Retinal damage and vision loss in African American multiple sclerosis patients. <i>Annals of Neurology</i> , 2015, 77, 228-236.	2.8	53
777	MRI characteristics of neuromyelitis optica spectrum disorder. <i>Neurology</i> , 2015, 84, 1165-1173.	1.5	523
778	Association of circulating follicular helper T cells with disease course of NMO spectrum disorders. <i>Journal of Neuroimmunology</i> , 2015, 278, 239-246.	1.1	47
779	Neuromyelitis optica spectrum disorders: beyond longitudinally extensive transverse myelitis. <i>Clinical Radiology</i> , 2015, 70, 630-637.	0.5	8
780	A comparative optical coherence tomography study in neuromyelitis optica spectrum disorder and multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2015, 21, 1781-1793.	1.4	64
781	Progressive cerebral atrophy in neuromyelitis optica. <i>Multiple Sclerosis Journal</i> , 2015, 21, 1872-1875.	1.4	9
782	Gray Matter Volume Reduction Is Associated with Cognitive Impairment in Neuromyelitis Optica. <i>American Journal of Neuroradiology</i> , 2015, 36, 1822-1829.	1.2	28

#	ARTICLE	IF	CITATIONS
783	Clinical Profile of Anti-Myelin Oligodendrocyte Glycoprotein Antibody Seropositive Cases of Optic Neuritis. <i>Neuro-Ophthalmology</i> , 2015, 39, 213-219.	0.4	29
784	Antibodies to MOG in adults with inflammatory demyelinating disease of the CNS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2015, 2, e163.	3.1	203
785	Challenges in randomized controlled trials and emerging multiple sclerosis therapeutics. <i>Neuroscience Bulletin</i> , 2015, 31, 745-754.	1.5	6
786	Changes in B and T-cell subsets and NMO-IgG/AQP-4 levels after immunoglobulins and rituximab treatment for an acute attack of neuromyelitis optica. <i>NeurologiĀa (English Edition)</i> , 2015, 30, 276-282.	0.2	2
787	Neuroproteomics and microRNAs studies in multiple sclerosis: transforming research and clinical knowledge in biomarker research. <i>Expert Review of Proteomics</i> , 2015, 12, 637-650.	1.3	10
788	Features of anti-aquaporin 4 antibody-seropositive Chinese patients with neuromyelitis optica spectrum optic neuritis. <i>Journal of Neurology</i> , 2015, 262, 2293-2304.	1.8	29
790	Structural MRI substrates of cognitive impairment in neuromyelitis optica. <i>Neurology</i> , 2015, 85, 1491-1499.	1.5	63
791	Secondary progressive NMO, or concomitant NMO and a primary neurodegenerative disorder?. <i>Multiple Sclerosis Journal</i> , 2015, 21, 1876-1878.	1.4	2
792	Hypertrophic pachymeningitis accompanying neuromyelitis optica spectrum disorder: A case report. <i>Journal of Neuroimmunology</i> , 2015, 287, 27-28.	1.1	6
793	Atypical Optic Neuritis. <i>Current Neurology and Neuroscience Reports</i> , 2015, 15, 76.	2.0	18
794	Dramatic recovery of steroid-refractory relapsed multiple sclerosis following Fingolimod discontinuation using selective immune adsorption. <i>BMC Neurology</i> , 2015, 15, 125.	0.8	22
795	B lymphocytes in neuromyelitis optica. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2015, 2, e104.	3.1	132
796	Neuromyelitis optica spectrum disorder and multiple sclerosis: Differentiation by a multimodal approach. <i>Multiple Sclerosis and Related Disorders</i> , 2015, 4, 515-520.	0.9	10
797	Biotinidase deficiency mimicking neuromyelitis optica: Initially exhibiting symptoms in adulthood. <i>Multiple Sclerosis Journal</i> , 2015, 21, 1604-1607.	1.4	54
798	Neuromyelitis Optica with Cutaneous Findings: Case Report and Review of the Literature. <i>Dermatology</i> , 2015, 230, 289-292.	0.9	6
799	Acquired pathology of the pediatric spine and spinal cord. <i>Pediatric Radiology</i> , 2015, 45, 420-432.	1.1	5
800	Tumefactive demyelinating lesions as a first clinical event: Clinical, imaging, and follow-up observations. <i>Journal of the Neurological Sciences</i> , 2015, 358, 118-124.	0.3	40
801	Favorable outcome of granulocyte colony-stimulating factor use in neuromyelitis optica patients presenting with agranulocytosis in the setting of rituximab. <i>Journal of Neuroimmunology</i> , 2015, 287, 29-30.	1.1	7

#	ARTICLE	IF	CITATIONS
802	Understanding risk of relapse and risk of disability after childhood transverse myelitis. <i>Neurology</i> , 2015, 84, 332-334.	1.5	5
803	Anti-aquaporin-4 autoantibodies in systemic lupus erythematosus persist for years and induce astrocytic cytotoxicity but not CNS disease. <i>Journal of Neuroimmunology</i> , 2015, 289, 8-11.	1.1	30
804	Overlapping CNS inflammatory diseases: differentiating features of NMO and MS. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015, 86, 20-25.	0.9	72
805	Diagnostic utility of aquaporin-4 in the analysis of active demyelinating lesions. <i>Neurology</i> , 2015, 84, 148-158.	1.5	49
806	Dermatomyositis as a presentation of neuromyelitis optica spectrum disorder. <i>Journal of Neuroimmunology</i> , 2015, 278, 108-111.	1.1	12
807	Quantitative analysis of aquaporin-4 antibody in longitudinally extensive transverse myelitis. <i>Journal of Neuroimmunology</i> , 2015, 278, 26-29.	1.1	9
808	Biomarkers for neuromyelitis optica. <i>Clinica Chimica Acta</i> , 2015, 440, 64-71.	0.5	31
809	Aquaporin-4 autoimmunity in a child without optic neuritis and myelitis. <i>Brain and Development</i> , 2015, 37, 149-152.	0.6	5
810	Cambios en las Subpoblaciones de Linfocitos B y T en el T�tulo de Anticuerpos Anti-Acuaporina-4 tras el Tratamiento de un Brote Agudo con Inmunoglobulinas y Rituximab. <i>Neurolog�a</i> , 2015, 30, 276-282.	0.3	4
811	Embarazo y posparto en una paciente con neuromielitis �ptica de Devic y lupus eritematoso sist�mico, y revisi�n de la literatura. <i>Neurologia Argentina</i> , 2015, 7, 120-123.	0.1	0
812	Antibodies to MOG and AQP4 in adults with neuromyelitis optica and suspected limited forms of the disease. <i>Multiple Sclerosis Journal</i> , 2015, 21, 866-874.	1.4	241
813	Severe demyelination but no astrocytopathy in clinically definite neuromyelitis optica with anti-myelin-oligodendrocyte glycoprotein antibody. <i>Multiple Sclerosis Journal</i> , 2015, 21, 656-659.	1.4	63
814	Diseases of the Spinal Cord. , 2015, , .		2
815	Risk factors for multiple sclerosis, neuromyelitis optica and transverse myelitis. <i>Multiple Sclerosis Journal</i> , 2015, 21, 703-709.	1.4	26
816	Neuromyelitis optica associated with painful paroxysmal dystonia: case report and literature review. <i>Acta Neurologica Belgica</i> , 2015, 115, 169-171.	0.5	5
817	Optic neuritis in Hong Kong: a 1-year follow-up study. <i>International Ophthalmology</i> , 2015, 35, 303-310.	0.6	7
818	Seronegative Neuromyelitis Optica: A Case Report of a Hispanic Male. <i>Case Reports in Neurology</i> , 2016, 8, 102-107.	0.3	4
819	Eculizumab�. , 2016, , .		0

#	ARTICLE	IF	CITATIONS
820	Intractable Hiccups and Nausea as a Principal Symptom of Neuromyelitis Optica in a Patient with a Prior History of Miller-Fisher Syndrome. <i>Journal of General and Family Medicine</i> , 2016, 17, 99-104.	0.3	0
821	Circulating Memory T Follicular Helper Cells in Patients with Neuromyelitis Optica/Neuromyelitis Optica Spectrum Disorders. <i>Mediators of Inflammation</i> , 2016, 2016, 1-13.	1.4	39
822	A 66-Year-Old Woman with a Progressive, Longitudinally Extensive, Tract Specific, Myelopathy. <i>Case Reports in Neurological Medicine</i> , 2016, 2016, 1-9.	0.3	2
824	Astrocyte Differentiation of Human Pluripotent Stem Cells: New Tools for Neurological Disorder Research. <i>Frontiers in Cellular Neuroscience</i> , 2016, 10, 215.	1.8	120
825	The Immunology of Neuromyelitis Optica—Current Knowledge, Clinical Implications, Controversies and Future Perspectives. <i>International Journal of Molecular Sciences</i> , 2016, 17, 273.	1.8	95
826	Comparative Analysis for the Presence of IgG Anti-Aquaporin-1 in Patients with NMO-Spectrum Disorders. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1195.	1.8	10
827	Seronegative Neuromyelitis Optica After Cardiac Transplantation. <i>Baylor University Medical Center Proceedings</i> , 2016, 29, 70-72.	0.2	1
828	Latitude and HLA-DRB1*04:05 independently influence disease severity in Japanese multiple sclerosis: a cross-sectional study. <i>Journal of Neuroinflammation</i> , 2016, 13, 239.	3.1	30
829	Retinal Morphology and Sensitivity Are Primarily Impaired in Eyes with Neuromyelitis Optica Spectrum Disorder (NMOSD). <i>PLoS ONE</i> , 2016, 11, e0167473.	1.1	7
830	Change of Th17 Lymphocytes and Treg/Th17 in Typical and Atypical Optic Neuritis. <i>PLoS ONE</i> , 2016, 11, e0146270.	1.1	5
831	Hydroxycholesterol Levels in the Serum and Cerebrospinal Fluid of Patients with Neuromyelitis Optica Revealed by LC-Ag+CIS/MS/MS and LC-ESI/MS/MS with Picolinic Derivatization: Increased Levels and Association with Disability during Acute Attack. <i>PLoS ONE</i> , 2016, 11, e0167819.	1.1	12
832	Cerebral Cortex Involvement in Neuromyelitis Optica Spectrum Disorder. <i>Journal of Clinical</i>		

#	ARTICLE	IF	CITATIONS
839	Incidence of AQP4-IgG seropositive neuromyelitis optica spectrum disorders in the Netherlands: About one in a million. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2016, 2, 205521731562565.	0.5	10
840	Widespread cortical thinning in patients with neuromyelitis optica spectrum disorder. <i>European Journal of Neurology</i> , 2016, 23, 1165-1173.	1.7	22
841	Prediction of disease severity in neuromyelitis optica by the levels of interleukin (IL)-6 produced during remission phase. <i>Clinical and Experimental Immunology</i> , 2016, 183, 480-489.	1.1	60
842	Neuromyelitis optica spectrum disorders: comparison of clinical and magnetic resonance imaging characteristics of AQP4-IgG versus MOG-IgG seropositive cases in the Netherlands. <i>European Journal of Neurology</i> , 2016, 23, 580-587.	1.7	99
843	Neuromyelitis optica and the evolving spectrum of autoimmune aquaporin-4 channelopathies: a decade later. <i>Annals of the New York Academy of Sciences</i> , 2016, 1366, 20-39.	1.8	184
844	Epidemiology of aquaporin-4 autoimmunity and neuromyelitis optica spectrum. <i>Annals of Neurology</i> , 2016, 79, 775-783.	2.8	263
845	Neuroglial alterations in the zebrafish brain exposed to cadmium chloride. <i>Journal of Applied Toxicology</i> , 2016, 36, 1629-1638.	1.4	38
846	Screening, Synthesis, and In Vitro Evaluation of Vinyl Sulfones as Inhibitors of Complement-Dependent Cytotoxicity in Neuromyelitis Optica. <i>ChemMedChem</i> , 2016, 11, 377-381.	1.6	2
847	Impact of Autologous Mesenchymal Stem Cell Infusion on Neuromyelitis Optica Spectrum Disorder: A Pilot, 2-Year Observational Study. <i>CNS Neuroscience and Therapeutics</i> , 2016, 22, 677-685.	1.9	26
848	Anti-myelin Oligodendrocyte Glycoprotein Antibodies in a Patient with Recurrent Optic Neuritis Involving the Cerebral White Matter and Brainstem. <i>Internal Medicine</i> , 2016, 55, 1351-1354.	0.3	3
849	Patient-reported outcome measure for neuromyelitis optica: pretesting of preliminary instrument and protocol for further development in accordance with international guidelines. <i>BMJ Open</i> , 2016, 6, e011142.	0.8	7
850	Neuromyelitis Optica Spectrum Disorder: Disease Course and Long-Term Visual Outcome. <i>Journal of Neuro-Ophthalmology</i> , 2016, 36, 356-362.	0.4	12
851	No association of <i>AQP4</i> polymorphisms with neuromyelitis optica and multiple sclerosis. <i>Translational Neuroscience</i> , 2016, 7, 76-83.	0.7	5
852	Increased frequency and severity of restless legs syndrome in patients with neuromyelitis optica spectrum disorder. <i>Sleep Medicine</i> , 2016, 17, 121-123.	0.8	9
853	Neuromyelitis optica accompanied by nephrotic syndrome and autoimmune-related pancytopenia. <i>Multiple Sclerosis and Related Disorders</i> , 2016, 7, 8-11.	0.9	6
854	Tocilizumab in Autoimmune Encephalitis Refractory to Rituximab: An Institutional Cohort Study. <i>Neurotherapeutics</i> , 2016, 13, 824-832.	2.1	197
855	Vitamin D level status in Thai neuromyelitis optica patients. <i>Journal of Neuroimmunology</i> , 2016, 295-296, 75-78.	1.1	13
856	Neuromyelitis optica spectrum disorders. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2016, 3, e225.	3.1	134

#	ARTICLE	IF	CITATIONS
857	9 Diffusion Weighted Imaging and Diffusion Tensor Imaging in Demyelination and Toxic Diseases. , 2016, , .		0
858	Glial fibrillary acidic protein as a marker of astrocytic activation in the cerebrospinal fluid of patients with amyotrophic lateral sclerosis. <i>Journal of Clinical Neuroscience</i> , 2016, 26, 75-78.	0.8	18
859	Disrupted balance of T cells under natalizumab treatment in multiple sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2016, 3, e210.	3.1	28
860	Evaluation of the 2015 diagnostic criteria for neuromyelitis optica spectrum disorder. <i>Neurology</i> , 2016, 86, 1772-1779.	1.5	72
862	Evoked potentials are useful for diagnosis of neuromyelitis optica spectrum disorder. <i>Journal of the Neurological Sciences</i> , 2016, 364, 97-101.	0.3	14
863	Isotretandrine Reduces Astrocyte Cytotoxicity in Neuromyelitis Optica by Blocking the Binding of NMO-IgG to Aquaporin 4. <i>NeuroImmunoModulation</i> , 2016, 23, 98-108.	0.9	9
864	Anti-thyroid antibodies and thyroid function in neuromyelitis optica spectrum disorders. <i>Journal of the Neurological Sciences</i> , 2016, 366, 3-7.	0.3	24
865	Spinal Cord in Multiple Sclerosis: Magnetic Resonance Imaging Features and Differential Diagnosis. <i>Seminars in Ultrasound, CT and MRI</i> , 2016, 37, 396-410.	0.7	9
866	Treatment Choices in Optic Neuritis: Corticosteroids, Intravenous Immunoglobulin, Plasma Exchange, or Other?. <i>Neuropediatrics</i> , 2016, 47, 137-138.	0.3	1
867	Autoimmune myelopathies. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2016, 133, 327-351.	1.0	42
868	Immunopathology. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2016, 133, 95-106.	1.0	15
869	Paraneoplastic and idiopathic autoimmune neurologic disorders. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2016, 133, 165-183.	1.0	20
870	Autoimmune sleep disorders. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2016, 133, 317-326.	1.0	22
871	Autoimmune AQP4 channelopathies and neuromyelitis optica spectrum disorders. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2016, 133, 377-403.	1.0	69
872	Common and Rare Manifestations of Neuromyelitis Optica Spectrum Disorder. <i>Current Allergy and Asthma Reports</i> , 2016, 16, 42.	2.4	24
873	Neuromyelitis optica spectrum disorder (NMOSD): A new concept. <i>Revue Neurologique</i> , 2016, 172, 256-262.	0.6	31
874	Specific MRI findings help distinguish acute transverse myelitis of Neuromyelitis Optica from spinal cord infarction. <i>Multiple Sclerosis and Related Disorders</i> , 2016, 9, 62-67.	0.9	43
875	Factors that impact health-related quality of life in neuromyelitis optica spectrum disorder: anxiety, disability, fatigue and depression. <i>Journal of Neuroimmunology</i> , 2016, 293, 54-58.	1.1	57

#	ARTICLE	IF	CITATIONS
876	The Acute Pediatric Spine and Spinal Cord. , 2016, , 317-336.		0
877	Neuromyelitis optica spectrum disorder coinciding with hematological immune disease: A case report. Multiple Sclerosis and Related Disorders, 2016, 9, 101-103.	0.9	4
878	Exosomal proteome analysis of cerebrospinal fluid detects biosignatures of neuromyelitis optica and multiple sclerosis. Clinica Chimica Acta, 2016, 462, 118-126.	0.5	55
879	Application of diffusional kurtosis imaging to detect occult brain damage in multiple sclerosis and neuromyelitis optica. NMR in Biomedicine, 2016, 29, 1536-1545.	1.6	19
880	Serum sPECAM-1 and sVCAM-1 levels are associated with conversion to multiple sclerosis in patients with optic neuritis. Journal of Neuroimmunology, 2016, 300, 11-14.	1.1	7
881	Efficacy and Safety of Rituximab Therapy in Neuromyelitis Optica Spectrum Disorders. JAMA Neurology, 2016, 73, 1342.	4.5	220
882	Neuromyelitis optica: Association with paroxysmal painful tonic spasms. Neurologiā (English Edition), 2016, 31, 511-515.	0.2	12
883	CFHR1-Modified Neural Stem Cells Ameliorated Brain Injury in a Mouse Model of Neuromyelitis Optica Spectrum Disorders. Journal of Immunology, 2016, 197, 3471-3480.	0.4	23
884	A neurodegenerative perspective on mitochondrial optic neuropathies. Acta Neuropathologica, 2016, 132, 789-806.	3.9	135
885	Serum 25-hydroxyvitamin D 3 is associated with disease status in patients with neuromyelitis optica spectrum disorders in south China. Journal of Neuroimmunology, 2016, 299, 118-123.	1.1	15
886	Comparison of efficacy and tolerability of azathioprine, mycophenolate mofetil, and cyclophosphamide among patients with neuromyelitis optica spectrum disorder: A prospective cohort study. Journal of the Neurological Sciences, 2016, 370, 224-228.	0.3	56
887	How long does it take to diagnose patients with neuromyelitis optica (NMO) using the 2006 diagnostic criteria?. Multiple Sclerosis and Related Disorders, 2016, 9, 14-16.	0.9	5
888	The role of AQP4 in neuromyelitis optica: More answers, more questions. Journal of Neuroimmunology, 2016, 298, 63-70.	1.1	37
889	Imaging of noninfectious inflammatory disorders of the spinal cord. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2016, 136, 733-746.	1.0	3
890	The 8th Pan-Asian Committee for Treatment and Research in Multiple Sclerosis. Clinical and Experimental Neuroimmunology, 2016, 7, 99-102.	0.5	0
891	In vivo imaging reveals rapid astrocyte depletion and axon damage in a model of neuromyelitis optica-related pathology. Annals of Neurology, 2016, 79, 794-805.	2.8	45
892	Voiding dysfunction in patients with neuromyelitis optica spectrum disorders. Neurourology and Urodynamics, 2016, 35, 39-43.	0.8	19
893	Commentary on painful tonic spasms and brainstem involvement in a patient with neuromyelitis optica spectrum disorder. Neurologia I Neurochirurgia Polska, 2016, 50, 517-518.	0.6	0



#	ARTICLE	IF	CITATIONS
894	Clinical characteristics of disabling attacks at onset in patients with neuromyelitis optica spectrum disorder. <i>Journal of the Neurological Sciences</i> , 2016, 368, 209-213.	0.3	9
895	Neuromyelitis optica spectrum disorders in children and adolescents. <i>Neurology</i> , 2016, 87, S59-66.	1.5	78
896	Quotient of cerebrospinal fluid/serum immunoglobulin G as a predictive factor for nonresponders to intravenous methylprednisolone therapy in patients with relapsing neuromyelitis optica spectrum disorder: Implication for early initiation of plasmapheresis. <i>Clinical and Experimental Neuroimmunology</i> , 2016, 7, 272-280.	0.5	2
897	Neuromyelitis optica and tactile and visual hallucinations in an elderly patient. <i>Age and Ageing</i> , 2016, 46, 156-157.	0.7	1
898	Circulating microRNAs as biomarkers for rituximab therapy, in neuromyelitis optica (NMO). <i>Journal of Neuroinflammation</i> , 2016, 13, 179.	3.1	38
899	Other noninfectious inflammatory disorders. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2016, 135, 425-446.	1.0	8
900	Role of regulatory b cells in neuroimmunologic disorders. <i>Journal of Neuroscience Research</i> , 2016, 94, 693-701.	1.3	42
901	Neuromyelitis Optica (Devic's Syndrome): an Appraisal. <i>Current Rheumatology Reports</i> , 2016, 18, 54.	2.1	13
902	Immunology of neuromyelitis optica during pregnancy. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2016, 3, e288.	3.1	45
903	Intravital assessment of myelin molecular order with polarimetric multiphoton microscopy. <i>Scientific Reports</i> , 2016, 6, 31685.	1.6	13
904	Diagnostic Utility of Systematic Aquaporin-4 Antibodies Determination in the First Event of Immune-Mediated Optic Neuritis. <i>European Neurology</i> , 2016, 76, 227-233.	0.6	5
905	Multiple Autoantibodies and Neuromyelitis Optica Spectrum Disorders. <i>NeuroImmunoModulation</i> , 2016, 23, 151-156.	0.9	8
906	Mapping autoantigen epitopes: molecular insights into autoantibody-associated disorders of the nervous system. <i>Journal of Neuroinflammation</i> , 2016, 13, 219.	3.1	39
907	Longitudinal Study of Retinal Nerve Fiber Layer Thickness and Macular Volume in Patients With Neuromyelitis Optica Spectrum Disorder. <i>Journal of Neuro-Ophthalmology</i> , 2016, 36, 363-368.	0.4	21
908	Finding NMO: The Evolving Diagnostic Criteria of Neuromyelitis Optica. <i>Journal of Neuro-Ophthalmology</i> , 2016, 36, 238-245.	0.4	23
909	Discriminating long myelitis of neuromyelitis optica from sarcoidosis. <i>Annals of Neurology</i> , 2016, 79, 437-447.	2.8	148
911	Demyelinating diseases in Asia. <i>Current Opinion in Neurology</i> , 2016, 29, 222-228.	1.8	40
912	Neuromyelitis optica and pregnancy. <i>Acta Neurologica Belgica</i> , 2016, 116, 431-438.	0.5	9

#	ARTICLE	IF	CITATIONS
913	MRI differential diagnosis of suspected multiple sclerosis. <i>Clinical Radiology</i> , 2016, 71, 815-827.	0.5	37
914	Three cases of neuromyelitis optica spectrum disorder. <i>Acta Radiologica Open</i> , 2016, 5, 205846011664145.	0.3	1
915	Clinical utility of testing AQP4-IgG in CSF. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2016, 3, e231.	3.1	113
916	Onset of neuromyelitis optica in the elderly. <i>Journal Francais D'Ophthalmologie</i> , 2016, 39, e129-e132.	0.2	0
917	Antibodies in acquired demyelinating disorders in children. <i>Multiple Sclerosis and Demyelinating Disorders</i> , 2016, 1, .	1.1	4
918	Membrane-based Therapeutic Plasma Exchange: A New Frontier for Nephrologists. <i>Seminars in Dialysis</i> , 2016, 29, 382-390.	0.7	13
920	Neuromyelitis optica: Evaluation of 871 attacks and 1,153 treatment courses. <i>Annals of Neurology</i> , 2016, 79, 206-216.	2.8	315
921	Pregnancy-related relapse risk factors in women with anti-AQP4 antibody positivity and neuromyelitis optica spectrum disorder. <i>Multiple Sclerosis Journal</i> , 2016, 22, 1413-1420.	1.4	64
922	Myopathy associated with neuromyelitis optica spectrum disorders. <i>International Journal of Neuroscience</i> , 2016, 126, 863-866.	0.8	12
923	Seronegative neuromyelitis optica presenting with life-threatening respiratory failure. <i>Journal of Spinal Cord Medicine</i> , 2016, 39, 734-736.	0.7	4
924	T-cell responses to distinct AQP4 peptides in patients with neuromyelitis optica (NMO). <i>Multiple Sclerosis and Related Disorders</i> , 2016, 6, 28-36.	0.9	24
925	Neuromyelitis optica spectrum disorders in Algeria: A preliminary study in the region of Tizi Ouzou. <i>Multiple Sclerosis and Related Disorders</i> , 2016, 6, 37-40.	0.9	14
926	Antibodies to MOG and AQP4 in children with neuromyelitis optica and limited forms of the disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 897-905.	0.9	98
927	Autoantibody to MOG suggests two distinct clinical subtypes of NMOSD. <i>Science China Life Sciences</i> , 2016, 59, 1270-1281.	2.3	47
928	Rituximab monitoring and redosing in pediatric neuromyelitis optica spectrum disorder. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2016, 3, e188.	3.1	60
929	Plasma exchange response in 34 patients with severe optic neuritis. <i>Journal of Neurology</i> , 2016, 263, 883-887.	1.8	53
930	Urinary symptoms and neurological disabilities are differentially correlated between multiple sclerosis and neuromyelitis optica. <i>Clinical and Experimental Neuroimmunology</i> , 2016, 7, 52-58.	0.5	8
931	Natalizumab in relapsing-remitting multiple sclerosis. <i>Expert Review of Neurotherapeutics</i> , 2016, 16, 471-481.	1.4	8

#	ARTICLE	IF	CITATIONS
932	Brain parenchymal damage in neuromyelitis optica spectrum disorder – A multimodal MRI study. <i>European Radiology</i> , 2016, 26, 4413-4422.	2.3	45
933	Genetic analysis of the aquaporin-4 gene for anti-AQP4 antibody-positive neuromyelitis optica in a Japanese population. <i>Japanese Journal of Ophthalmology</i> , 2016, 60, 198-205.	0.9	14
934	Effectiveness of multi-disciplinary rehabilitation for patients with Neuromyelitis Optica. <i>Journal of Spinal Cord Medicine</i> , 2016, 39, 311-316.	0.7	10
935	Therapeutic options in neuromyelitis optica spectrum disorders. <i>Expert Review of Neurotherapeutics</i> , 2016, 16, 319-329.	1.4	25
936	NMO spectrum disorders: clinical or molecular classification?. <i>Nature Reviews Neurology</i> , 2016, 12, 129-130.	4.9	10
937	Differentiation of neuromyelitis optica spectrum disorders from ultra-longitudinally extensive transverse myelitis in a cohort of Chinese patients. <i>Journal of Neuroimmunology</i> , 2016, 291, 96-100.	1.1	3
938	Comparison of myelin water fraction values in periventricular white matter lesions between multiple sclerosis and neuromyelitis optica spectrum disorder. <i>Multiple Sclerosis Journal</i> , 2016, 22, 1616-1620.	1.4	22
939	Cognitive impairment differs between neuromyelitis optica spectrum disorder and multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2016, 22, 1850-1858.	1.4	34
940	Serum peptide reactivities may distinguish neuromyelitis optica subgroups and multiple sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2016, 3, e204.	3.1	53
941	Myelitis: Differences between multiple sclerosis and other aetiologies. <i>Neurología (English Edition)</i> , 2016, 31, 71-75.	0.2	1
942	Autoantibodies to tetraspanins (CD9, CD81 and CD82) in demyelinating diseases. <i>Journal of Neuroimmunology</i> , 2016, 291, 78-81.	1.1	3
943	Linear lesions may assist early diagnosis of neuromyelitis optica and longitudinally extensive transverse myelitis, two subtypes of NMOSD. <i>Journal of the Neurological Sciences</i> , 2016, 360, 88-93.	0.3	8
944	Mielitis. Diferencias entre esclerosis múltiple y otras etiologías. <i>Neurología</i> , 2016, 31, 71-75.	0.3	6
945	Clinical features of neuromyelitis optica in children. <i>Neurology</i> , 2016, 86, 245-252.	1.5	100
946	Anti-MOG antibody: The history, clinical phenotype, and pathogenicity of a serum biomarker for demyelination. <i>Autoimmunity Reviews</i> , 2016, 15, 307-324.	2.5	229
947	Isolated new onset “atypical” optic neuritis in the NMO clinic: serum antibodies, prognoses and diagnoses at follow-up. <i>Journal of Neurology</i> , 2016, 263, 370-379.	1.8	51
948	Present and Future Therapies in Neuromyelitis Optica Spectrum Disorders. <i>Neurotherapeutics</i> , 2016, 13, 70-83.	2.1	90
949	Pregnancy outcomes in aquaporin-4-positive neuromyelitis optica spectrum disorder. <i>Neurology</i> , 2016, 86, 79-87.	1.5	95

#	ARTICLE	IF	CITATIONS
950	Status of diagnostic approaches to AQP4-IgG seronegative NMO and NMO/MS overlap syndromes. <i>Journal of Neurology</i> , 2016, 263, 140-149.	1.8	60
951	The clinical spectrum associated with myelin oligodendrocyte glycoprotein antibodies (anti-MOG-Ab) in Thai patients. <i>Multiple Sclerosis Journal</i> , 2016, 22, 964-968.	1.4	31
952	Abnormal distribution of AQP5 in labial salivary glands is associated with poor saliva secretion in patients with Sjögren's syndrome including neuromyelitis optica complicated patients. <i>Modern Rheumatology</i> , 2016, 26, 384-390.	0.9	40
953	OCT Findings in Neuromyelitis Optica Spectrum Disorders. , 2016, , 85-96.		2
954	Optical Coherence Tomography in Multiple Sclerosis. , 2016, , .		5
955	Neuromyelitis optica spectrum disorders may be misdiagnosed as Wernicke's encephalopathy. <i>International Journal of Neuroscience</i> , 2016, 126, 922-927.	0.8	9
956	Neuromyelitis optica spectrum disorders: long-term safety and efficacy of rituximab in Caucasian patients. <i>Multiple Sclerosis Journal</i> , 2016, 22, 511-519.	1.4	76
957	Comparative analysis of treatment outcomes in patients with neuromyelitis optica spectrum disorder using multifaceted endpoints. <i>Multiple Sclerosis Journal</i> , 2016, 22, 329-339.	1.4	110
958	Neuromyelitis optica spectrum disorders with multiple brainstem manifestations: a case report. <i>Neurological Sciences</i> , 2016, 37, 309-313.	0.9	9
959	Corticospinal tract integrity measured using transcranial magnetic stimulation and magnetic resonance imaging in neuromyelitis optica and multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2016, 22, 43-50.	1.4	17
960	Neuromyelitis optica: asociación con espasmos tónicos paroxísticos dolorosos. <i>Neurología</i> , 2016, 31, 511-515.	0.3	24
961	Association Between the Single Nucleotide Polymorphism and the Level of Aquaporin-4 Protein Expression in Han and Minority Chinese with Inflammatory Demyelinating Diseases of the Central Nervous System. <i>Molecular Neurobiology</i> , 2016, 53, 2878-2885.	1.9	2
962	Neuromyelitis optica spectrum disorder complicated with Sjogren syndrome successfully treated with tocilizumab: A case report. <i>Modern Rheumatology</i> , 2016, 26, 294-296.	0.9	29
963	Diagnósticos diferenciales y pronóstico de las mielitis longitudinales extensas en Buenos Aires, Argentina. <i>Neurología</i> , 2017, 32, 99-105.	0.3	10
964	Early and extensive spinal white matter involvement in neuromyelitis optica. <i>Brain Pathology</i> , 2017, 27, 249-265.	2.1	26
965	Therapeutic complement inhibition: a promising approach for treatment of neuroimmunological diseases. <i>Expert Review of Neurotherapeutics</i> , 2017, 17, 579-591.	1.4	13
966	The clinical characteristics of AQP4 antibody positive NMO/SD in a large cohort of Chinese Han patients. <i>Journal of Neuroimmunology</i> , 2017, 302, 49-55.	1.1	29
967	There is less MRI brain lesions and no characteristic MRI Brain findings in IIDDs patients with positive AQP4 serology among Malaysians. <i>Multiple Sclerosis and Related Disorders</i> , 2017, 12, 34-38.	0.9	3

#	ARTICLE	IF	CITATIONS
968	Demyelinating syndrome in SLE encompasses different subtypes: Do we need new classification criteria? Pooled results from systematic literature review and monocentric cohort analysis. <i>Autoimmunity Reviews</i> , 2017, 16, 244-252.	2.5	41
969	Etiologic spectrum and functional outcome of the acute inflammatory myelitis. <i>Acta Neurologica Belgica</i> , 2017, 117, 507-513.	0.5	11
970	Elevated cerebrospinal fluid uric acid during relapse of neuromyelitis optica spectrum disorders. <i>Brain and Behavior</i> , 2017, 7, e00584.	1.0	13
971	MOG-antibody associated demyelinating disease of the CNS: A clinical and pathological study in Chinese Han patients. <i>Journal of Neuroimmunology</i> , 2017, 305, 19-28.	1.1	84
972	Short segment myelitis as a first manifestation of neuromyelitis optica spectrum disorders. <i>Multiple Sclerosis Journal</i> , 2017, 23, 413-419.	1.4	35
973	Variation in MS outcome. <i>Neurology</i> , 2017, 88, 1214-1215.	1.5	0
974	Comparison of brain and spinal cord magnetic resonance imaging features in neuromyelitis optica spectrum disorders patients with or without aquaporin-4 antibody. <i>Multiple Sclerosis and Related Disorders</i> , 2017, 13, 58-66.	0.9	14
975	Pathogenic implications of cerebrospinal fluid barrier pathology in neuromyelitis optica. <i>Acta Neuropathologica</i> , 2017, 133, 597-612.	3.9	53
976	Neuromyelitis optica spectrum disorder diagnostic criteria: Sensitivity and specificity are both important. <i>Multiple Sclerosis Journal</i> , 2017, 23, 182-184.	1.4	12
977	Headache in Neuromyelitis Optica. <i>Current Pain and Headache Reports</i> , 2017, 21, 20.	1.3	15
978	Metabolic changes in normal-appearing white matter in patients with neuromyelitis optica and multiple sclerosis: a comparative magnetic resonance spectroscopy study. <i>Acta Radiologica</i> , 2017, 58, 1132-1137.	0.5	14
979	Neutrophil perversion in demyelinating autoimmune diseases: Mechanisms to medicine. <i>Autoimmunity Reviews</i> , 2017, 16, 294-307.	2.5	39
980	Neuromyelitis optica presenting as acute bilateral ptosis. <i>Practical Neurology</i> , 2017, 17, 57-59.	0.5	0
981	Clinical characteristics of late-onset neuromyelitis optica spectrum disorder: A multicenter retrospective study in Korea. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1748-1756.	1.4	55
982	Pruritus may be a common symptom related to neuromyelitis optica spectrum disorders. <i>Multiple Sclerosis and Related Disorders</i> , 2017, 13, 1-3.	0.9	14
983	Neurodegeneration in multiple sclerosis and neuromyelitis optica. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 137-145.	0.9	205
984	Distinct clinical characteristics of atypical optic neuritis with seronegative aquaporin-4 antibody among Chinese patients. <i>British Journal of Ophthalmology</i> , 2017, 101, 1720-1724.	2.1	24
986	Association of CD58 gene polymorphisms with NMO spectrum disorders in a Han Chinese population. <i>Journal of Neuroimmunology</i> , 2017, 309, 23-30.	1.1	17

#	ARTICLE	IF	CITATIONS
987	Effectiveness and safety of immunosuppressive therapy in neuromyelitis optica spectrum disorder during pregnancy. <i>Journal of the Neurological Sciences</i> , 2017, 377, 72-76.	0.3	20
988	Long spinal cord lesions in a patient with pathologically proven multiple sclerosis. <i>Journal of Clinical Neuroscience</i> , 2017, 42, 106-108.	0.8	2
989	Low expression of complement inhibitory protein CD59 contributes to humoral autoimmunity against astrocytes. <i>Brain, Behavior, and Immunity</i> , 2017, 65, 173-182.	2.0	20
990	Disruption of the leptomeningeal blood barrier in neuromyelitis optica spectrum disorder. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2017, 4, e343.	3.1	55
991	Cognitive dysfunction in adult patients with neuromyelitis optica: a systematic review and meta-analysis. <i>Journal of Neurology</i> , 2017, 264, 1549-1558.	1.8	25
992	High serum creatinine is associated with reduction of vision impaired in patients with NMOSD. <i>Journal of Neuroimmunology</i> , 2017, 310, 32-37.	1.1	2
993	Effectiveness of low dose of rituximab compared with azathioprine in Chinese patients with neuromyelitis optica: an over 2-year follow-up study. <i>Acta Neurologica Belgica</i> , 2017, 117, 695-702.	0.5	42
994	Aquaporin-4 antibody positive neuromyelitis optica spectrum disorder associated with esophageal cancer. <i>Journal of Neuroimmunology</i> , 2017, 309, 38-40.	1.1	16
995	Aquaporin-4-IgG-positive neuromyelitis optica spectrum disorder with recurrent short partial transverse myelitis and favorable prognosis: Two new cases. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1950-1954.	1.4	5
996	Suspected bacterial meningomyelitis: The first presenting clinical feature of neuromyelitis optica spectrum disorder. <i>Journal of Neuroimmunology</i> , 2017, 309, 68-71.	1.1	7
997	Incidence and prevalence of NMOSD in Australia and New Zealand. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 632-638.	0.9	108
998	NMO Spectrum Disorders. <i>Neurology International Open</i> , 2017, 01, E36-E47.	0.4	3
999	Diffusion tensor imaging of normal-appearing white matter in patients with neuromyelitis optica spectrum disorder and multiple sclerosis. <i>European Journal of Neurology</i> , 2017, 24, 966-973.	1.7	31
1000	Distinct brain imaging characteristics of autoantibody-mediated CNS conditions and multiple sclerosis. <i>Brain</i> , 2017, 140, 617-627.	3.7	208
1001	Differential diagnosis of neuromyelitis optica spectrum disorders. <i>Therapeutic Advances in Neurological Disorders</i> , 2017, 10, 265-289.	1.5	80
1002	Neuromyelitis optica and neuromyelitis optica spectrum disorders. <i>Current Opinion in Neurology</i> , 2017, 30, 208-215.	1.8	38
1003	Differential diagnosis and prognosis for longitudinally extensive myelitis in Buenos Aires, Argentina. <i>Neurología (English Edition)</i> , 2017, 32, 99-105.	0.2	4
1004	Neuromyelitis Optica: Immunopathogenesis, Clinical Manifestations, and Treatments. , 2017, , 187-202.		0

#	ARTICLE	IF	CITATIONS
1005	Neuromyelitis Spectrum Disorders. Mayo Clinic Proceedings, 2017, 92, 663-679.	1.4	224
1006	A curious case of neuromyelitis optica spectrum disorder co-existing with idiopathic intracranial hypertension. Journal of Clinical Neuroscience, 2017, 41, 104-106.	0.8	3
1007	Practice Current: How do you treat neuromyelitis optica?. Neurology: Clinical Practice, 2017, 7, 170-178.	0.8	7
1008	Enhancing Brain Lesions during Acute Optic Neuritis and/or Longitudinally Extensive Transverse Myelitis May Portend a Higher Relapse Rate in Neuromyelitis Optica Spectrum Disorders. American Journal of Neuroradiology, 2017, 38, 949-953.	1.2	8
1009	Retinal segmented layers with strong aquaporin-4 expression suffered more injuries in neuromyelitis optica spectrum disorders compared with optic neuritis with aquaporin-4 antibody seronegativity detected by optical coherence tomography. British Journal of Ophthalmology, 2017, 101, 1032-1037.	2.1	23
1010	Deep gray matter atrophy in neuromyelitis optica spectrum disorder and multiple sclerosis. European Journal of Neurology, 2017, 24, 437-445.	1.7	52
1011	Longitudinally extensive transverse myelitis immune-mediated in aquaporin-4 antibody negative patients: Disease heterogeneity. Journal of the Neurological Sciences, 2017, 373, 134-137.	0.3	6
1012	Effects of neuromyelitis optica IgG at the blood-brain barrier in vitro. Neurology: Neuroimmunology and NeuroInflammation, 2017, 4, e311.	3.1	153
1013	Finding NMO. Neurology: Neuroimmunology and NeuroInflammation, 2017, 4, e313.	3.1	4
1014	Frequency of autoimmune disorders and autoantibodies in patients with neuromyelitis optica. Acta Neuropsychiatrica, 2017, 29, 170-178.	1.0	28
1015	Diagnosis and management of Neuromyelitis Optica Spectrum Disorder (NMOSD) in Iran: A consensus guideline and recommendations. Multiple Sclerosis and Related Disorders, 2017, 18, 144-151.	0.9	33
1016	Radiculopathy in neuromyelitis optica. How does anti-AQP4 Ab involve PNS?. Multiple Sclerosis and Related Disorders, 2017, 18, 77-81.	0.9	17
1017	A NMOSD case with multifocal nervous system involvement in a single attack. Multiple Sclerosis and Related Disorders, 2017, 18, 82-84.	0.9	0
1018	Neuromyelitis optica spectrum disorders: An experience from tertiary care hospital of North-West India. Indian Journal of Medical Specialities, 2017, 8, 192-196.	0.1	2
1019	A population-based prospective study of optic neuritis. Multiple Sclerosis Journal, 2017, 23, 1893-1901.	1.4	81
1020	Epidemiology of neuromyelitis optica in Latin America. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2017, 3, 205521731773009.	0.5	34
1021	Diagnostics of the neuromyelitis optica spectrum disorders (NMOSD). Neurological Sciences, 2017, 38, 231-236.	0.9	14
1022	Cognitive impairment in neuromyelitis optica spectrum disorders: What do we know?. Multiple Sclerosis and Related Disorders, 2017, 18, 225-229.	0.9	20

#	ARTICLE	IF	CITATIONS
1023	Association of TNFSF4 Polymorphisms with Neuromyelitis Optica Spectrum Disorders in a Chinese Population. <i>Journal of Molecular Neuroscience</i> , 2017, 63, 396-402.	1.1	11
1024	Cortical blindness and not optic neuritis as a cause of vision loss in a Sjögren's syndrome (SS) patient with the neuromyelitis optica spectrum disorder (NMOSD). <i>Medicine (United States)</i> , 2017, 96, e7454.	0.4	9
1025	Anti-aquaporin-4 titer is not predictive of disease course in neuromyelitis optica spectrum disorder: A multicenter cohort study. <i>Multiple Sclerosis and Related Disorders</i> , 2017, 17, 198-201.	0.9	36
1026	Widely spread corticospinal tracts lesions in a case of neuromyelitis optica. <i>Clinical Neurology and Neurosurgery</i> , 2017, 161, 56-58.	0.6	5
1027	Autoimmune aquaporin-4 induced damage beyond the central nervous system. <i>Multiple Sclerosis and Related Disorders</i> , 2017, 18, 41-46.	0.9	18
1028	Prognostic factors and disease course in aquaporin-4 antibody-positive Chinese patients with acute optic neuritis. <i>Journal of Neurology</i> , 2017, 264, 2130-2140.	1.8	21
1029	STAT4 Polymorphisms are Associated with Neuromyelitis Optica Spectrum Disorders. <i>NeuroMolecular Medicine</i> , 2017, 19, 493-500.	1.8	11
1030	Neuromyelitis Optica. <i>Rheumatic Disease Clinics of North America</i> , 2017, 43, 579-591.	0.8	42
1031	Multimodal magnetic resonance imaging in relation to cognitive impairment in neuromyelitis optica spectrum disorder. <i>Scientific Reports</i> , 2017, 7, 9180.	1.6	21
1033	Clinical Reasoning: A man with rapidly ascending paralysis. <i>Neurology</i> , 2017, 89, e25-e31.	1.5	0
1034	Anti-C1q autoantibodies in patients with neuromyelitis optica spectrum disorders. <i>Journal of Neuroimmunology</i> , 2017, 310, 150-157.	1.1	6
1035	Patient perspectives on neuromyelitis optica spectrum disorders: Data from the PatientsLikeMe online community. <i>Multiple Sclerosis and Related Disorders</i> , 2017, 17, 116-122.	0.9	43
1036	Cervical cord myelin water imaging shows degenerative changes over one year in multiple sclerosis but not neuromyelitis optica spectrum disorder. <i>NeuroImage: Clinical</i> , 2017, 16, 17-22.	1.4	18
1037	Gender differences among Chinese patients with neuromyelitis optica spectrum disorders. <i>Multiple Sclerosis and Related Disorders</i> , 2017, 17, 5-8.	0.9	9
1038	A case of MOG antibody-positive bilateral optic neuritis and meningoganglionitis following a genital herpes simplex virus infection. <i>Multiple Sclerosis and Related Disorders</i> , 2017, 17, 148-150.	0.9	36
1039	Evaluation of the retinal nerve fiber layer in neuromyelitis optica spectrum disorders: A systematic review and meta-analysis. <i>Journal of the Neurological Sciences</i> , 2017, 383, 108-113.	0.3	17
1040	Neuromyelitis optica spectrum disorders in Iran. <i>Multiple Sclerosis and Related Disorders</i> , 2017, 18, 209-212.	0.9	47
1041	Painful tonic spasm in neuromyelitis optica spectrum disorders: Prevalence, clinical implications and treatment options. <i>Multiple Sclerosis and Related Disorders</i> , 2017, 17, 99-102.	0.9	22



#	ARTICLE	IF	CITATIONS
1042	Analysis of brain and spinal cord lesions to occult brain damage in seropositive and seronegative neuromyelitis optica. <i>European Journal of Radiology</i> , 2017, 94, 25-30.	1.2	4
1043	Myelitis in systemic lupus erythematosus. <i>Journal of Clinical Neuroscience</i> , 2017, 44, 18-22.	0.8	20
1044	Identification of the flotillin-1/2 heterocomplex as a target of autoantibodies in bona fide multiple sclerosis. <i>Journal of Neuroinflammation</i> , 2017, 14, 123.	3.1	20
1045	Magnetic Resonance Imaging and Clinical Features in Acute and Subacute Myelopathies. <i>Clinical Neuroradiology</i> , 2017, 27, 417-433.	1.0	30
1046	Hiccups as Herald: Neuromyelitis Optica Spectrum Disorder. <i>American Journal of Medicine</i> , 2017, 130, 1055-1058.	0.6	2
1047	Comparisons of presentations and outcomes of neuromyelitis optica patients with and without Sjögren's syndrome. <i>Neurological Sciences</i> , 2017, 38, 271-277.	0.9	13
1048	Diffusion-weighted imaging helps differentiate multiple sclerosis and neuromyelitis optica-related acute optic neuritis. <i>Journal of Magnetic Resonance Imaging</i> , 2017, 45, 1780-1785.	1.9	16
1049	Efficacy, safety, and pharmacokinetics of natalizumab in Japanese multiple sclerosis patients: A double-blind, randomized controlled trial and open-label pharmacokinetic study. <i>Multiple Sclerosis and Related Disorders</i> , 2017, 11, 25-31.	0.9	24
1050	Aquaporin-4 antibody in neuromyelitis optica: re-testing study in a large population from China. <i>International Journal of Neuroscience</i> , 2017, 127, 790-799.	0.8	5
1051	Isolated recurrent myelitis in a 7-year-old child with serum aquaporin-4 IgG antibodies. <i>Journal of Neurology</i> , 2017, 264, 179-181.	1.8	1
1052	Gender effect on neuromyelitis optica spectrum disorder with aquaporin4-immunoglobulin G. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1104-1111.	1.4	37
1053	Influence of female sex and fertile age on neuromyelitis optica spectrum disorders. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1092-1103.	1.4	60
1054	The impact of 2015 neuromyelitis optica spectrum disorders criteria on diagnostic rates. <i>Multiple Sclerosis Journal</i> , 2017, 23, 228-233.	1.4	53
1055	Association of CD40 Gene Polymorphisms with Susceptibility to Neuromyelitis Optica Spectrum Disorders. <i>Molecular Neurobiology</i> , 2017, 54, 5236-5242.	1.9	13
1057	Monoclonal antibody therapy for neuromyelitis optica spectrum disorder: current and future. <i>International Journal of Neuroscience</i> , 2017, 127, 735-744.	0.8	8
1058	Increased cerebrospinal fluid metalloproteinase-2 and interleukin-6 are associated with albumin quotient in neuromyelitis optica: Their possible role on blood-brain barrier disruption. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1072-1084.	1.4	48
1059	Effectiveness of mycophenolate mofetil as first-line therapy in AQP4-IgG, MOG-IgG, and seronegative neuromyelitis optica spectrum disorders. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1377-1384.	1.4	89
1060	Treatment of neuromyelitis optica and neuromyelitis optica spectrum disorders with rituximab using a maintenance treatment regimen and close CD19 B cell monitoring. A six-year follow-up. <i>Journal of the Neurological Sciences</i> , 2017, 372, 92-96.	0.3	25

#	ARTICLE	IF	CITATIONS
1061	Aquaporin modulators: a patent review (2010â€“2015). <i>Expert Opinion on Therapeutic Patents</i> , 2017, 27, 49-62.	2.4	49
1062	Anaplastic astrocytoma with aquaporin-4 positive in CSF. <i>Medicine (United States)</i> , 2017, 96, e9193.	0.4	6
1063	Validation of the Brief International Cognitive Assessment for Multiple Sclerosis in Japan. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2017, 3, 205521731774897.	0.5	16
1064	Autonomic Dysregulation, Cognitive Impairment, and Symptoms of Psychosis as an Unusual Presentation in an Anti-Aquaporin 4-Positive Patient. <i>Case Reports in Neurology</i> , 2017, 9, 12-16.	0.3	5
1065	Clinical presentation and prognosis in MOG-antibody disease: a UK study. <i>Brain</i> , 2017, 140, 3128-3138.	3.7	527
1066	Neuromyelitis Optica Spectrum Disorder Coinciding with Spinocerebellar Ataxia Type 31. <i>Case Reports in Neurology</i> , 2017, 9, 127-130.	0.3	4
1068	Magnetic resonance imaging brain findings in a case of aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder, presenting with intractable vomiting and hiccups. <i>Journal of Neurosciences in Rural Practice</i> , 2017, 08, 135-138.	0.3	3
1069	Commentary. <i>Journal of Neurosciences in Rural Practice</i> , 2017, 08, 138-139.	0.3	0
1070	Gastroparesis as the Sole Presenting Feature of Neuromyelitis Optica. <i>ACG Case Reports Journal</i> , 2017, 4, e109.	0.2	3
1071	Recurrent Longitudinally Extensive Myelitis and Aquaporin-4 Seronegativity â€“ The Expanding Spectrum of Neuromyelitis Optica. <i>Journal of Clinical and Diagnostic Research JCDR</i> , 2017, 11, OD05-OD07.	0.8	2
1072	Demyelinating syndrome in SLE: review of different disease subtypes and report of a case series. <i>Reumatismo</i> , 2017, 69, 175-183.	0.4	12
1074	Diagnostics diffÃ©rentiels de la sclÃ©rose en plaques. , 2017, , 113-143.		0
1075	Immunopathogenesis in Myasthenia Gravis and Neuromyelitis Optica. <i>Frontiers in Immunology</i> , 2017, 8, 1785.	2.2	37
1076	Different Phenotypes at Onset in Neuromyelitis Optica Spectrum Disorder Patients with Aquaporin-4 Autoimmunity. <i>Frontiers in Neurology</i> , 2017, 8, 62.	1.1	16
1077	Increased Circulating T Follicular Helper Cells Are Inhibited by Rituximab in Neuromyelitis Optica Spectrum Disorder. <i>Frontiers in Neurology</i> , 2017, 8, 104.	1.1	26
1078	The Contribution of Optical Coherence Tomography in Neuromyelitis Optica Spectrum Disorders. <i>Frontiers in Neurology</i> , 2017, 8, 493.	1.1	12
1079	The Prevalence of Anti-Aquaporin 4 Antibody in Patients with Idiopathic Inflammatory Demyelinating Diseases Presented to a Tertiary Hospital in Malaysia: Presentation and Prognosis. <i>Multiple Sclerosis International</i> , 2017, 2017, 1-6.	0.4	7
1080	Prevalence and clinical features of neuromyelitis optica spectrum disorders in northern Japan. <i>Neurology</i> , 2017, 89, 1995-2001.	1.5	75

#	ARTICLE	IF	CITATIONS
1081	Initial Pattern of Optic Nerve Enhancement in Korean Patients with Unilateral Optic Neuritis. Korean Journal of Ophthalmology: KJO, 2017, 31, 71.	0.5	11
1082	The Visual Evoked Potential in Idiopathic Inflammatory Demyelinating Diseases. , 2017, , .		3
1083	Neuromyelitis optica: phenotypic characteristics in a Brazilian case series. Arquivos De Neuro-Psiquiatria, 2017, 75, 81-86.	0.3	15
1084	Review of the Etiological Causes and Diagnosis of Myelitis and Its Medical Orientation Protocol. Journal of Neurology & Neurophysiology, 2017, 08, .	0.1	2
1085	Paraneoplastic Neuromyelitis Optica Spectrum Disorder as Presentation of Esophageal Adenocarcinoma. Annals of Thoracic Surgery, 2018, 105, e133-e135.	0.7	9
1086	Neuromyelitis optica spectrum disorder in the very young: An in depth review of the present data. Journal of the Neurological Sciences, 2018, 388, 232.	0.3	0
1087	A comparison of pediatric and adult neuromyelitis optica spectrum disorders: A review of clinical manifestation, diagnosis, and treatment. Journal of the Neurological Sciences, 2018, 388, 222-231.	0.3	25
1088	Short transverse myelitis in Chinese patients with neuromyelitis optica spectrum disorders. Multiple Sclerosis and Related Disorders, 2018, 21, 78-83.	0.9	12
1089	Refractory neuromyelitis optica spectrum disorder in systemic lupus erythematosus successfully treated with rituximab. Lupus, 2018, 27, 1374-1377.	0.8	6
1090	Environmental risk factors in neuromyelitis optica spectrum disorder: a caseâ€“control study. Acta Neurologica Belgica, 2018, 118, 277-287.	0.5	32
1091	Neuromyelitis optica spectrum disorder mimicking extensive leukodystrophy. Multiple Sclerosis Journal, 2018, 24, 1256-1258.	1.4	3
1092	Devic syndrome and pregnancy: A case series. Obstetric Medicine, 2018, 11, 171-177.	0.5	8
1093	Classification and diagnostic criteria for demyelinating diseases of the central nervous system: Where do we stand today?. Revue Neurologique, 2018, 174, 378-390.	0.6	15
1094	Rituximab-induced interstitial lung disease in a patient with aquaporin-4 immunoglobulin G-positive neuromyelitis optica spectrum disorder. Multiple Sclerosis and Related Disorders, 2018, 20, 192-193.	0.9	2
1095	Defining distinct features of anti-MOG antibody associated central nervous system demyelination. Therapeutic Advances in Neurological Disorders, 2018, 11, 175628641876208.	1.5	137
1096	Normal brain imaging accompanies neuroimmunologically justified, autoimmune encephalomyelitis. Neurology: Neuroimmunology and NeuroInflammation, 2018, 5, e456.	3.1	12
1097	MRI Features of Aquaporin-4 Antibodyâ€“Positive Longitudinally Extensive Transverse Myelitis: Insights into the Diagnosis of Neuromyelitis Optica Spectrum Disorders. American Journal of Neuroradiology, 2018, 39, 782-787.	1.2	21
1098	Spectrum of MRI brain lesion patterns in neuromyelitis optica spectrum disorder: a pictorial review. British Journal of Radiology, 2018, 91, 20170690.	1.0	20

#	ARTICLE	IF	CITATIONS
1099	The IL-10-producing regulatory B cells (B10 cells) and regulatory T cell subsets in neuromyelitis optica spectrum disorder. <i>Neurological Sciences</i> , 2018, 39, 543-549.	0.9	19
1100	Incidence of neuromyelitis optica spectrum disorder in the Central Denmark Region. <i>Acta Neurologica Scandinavica</i> , 2018, 137, 582-588.	1.0	17
1101	Eye movement abnormalities in AQP4-IgG positive neuromyelitis optica spectrum disorder. <i>Journal of the Neurological Sciences</i> , 2018, 384, 91-95.	0.3	5
1102	Application of the 2015 diagnostic criteria for neuromyelitis optica spectrum disorders in a cohort of Latin American patients. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 20, 109-114.	0.9	23
1103	The Gut Microbiome in Neuromyelitis Optica. <i>Neurotherapeutics</i> , 2018, 15, 92-101.	2.1	54
1104	Diagnosis and management of neuromyelitis optica spectrum disorders - An update. <i>Autoimmunity Reviews</i> , 2018, 17, 195-200.	2.5	89
1105	Inhibition of RGMa alleviates symptoms in a rat model of neuromyelitis optica. <i>Scientific Reports</i> , 2018, 8, 34.	1.6	17
1106	Neuromyelitis Optica Spectrum Disorders: Spectrum of MR Imaging Findings and Their Differential Diagnosis. <i>Radiographics</i> , 2018, 38, 169-193.	1.4	109
1107	Anti-Rituximab antibody in patients with NMOSDs treated with low dose Rituximab. <i>Journal of Neuroimmunology</i> , 2018, 316, 107-111.	1.1	22
1108	Neuromyelitis Optica and Herpes Simplex Virus 2. <i>Neurologist</i> , 2018, 23, 92-93.	0.4	8
1109	Insights into the aquaporin 4 of zebrafish ( <i>Danio rerio</i> ) through evolutionary analysis, molecular modeling and structural dynamics. <i>Gene Reports</i> , 2018, 11, 101-109.	0.4	11
1110	Severe aquaporin 4-IgG-positive neuromyelitis optica with disseminated herpes zoster in a pregnant woman successfully treated with intravenous immunoglobulin. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2018, 4, 205521731875811.	0.5	2
1111	<i>Mycobacterium avium</i> subspecies paratuberculosis and myelin basic protein specific epitopes are highly recognized by sera from patients with Neuromyelitis optica spectrum disorder. <i>Journal of Neuroimmunology</i> , 2018, 318, 97-102.	1.1	12
1112	Aquaporin-4-autoimmunity in patients with systemic lupus erythematosus: A predominantly population-based study. <i>Multiple Sclerosis Journal</i> , 2018, 24, 331-339.	1.4	45
1113	Neuropsychological outcomes of pediatric demyelinating diseases: a review. <i>Child Neuropsychology</i> , 2018, 24, 575-597.	0.8	8
1114	Different patterns of longitudinal brain and spinal cord changes and their associations with disability progression in NMO and MS. <i>European Radiology</i> , 2018, 28, 96-103.	2.3	24
1115	Multimodal characterization of gray matter alterations in neuromyelitis optica. <i>Multiple Sclerosis Journal</i> , 2018, 24, 1308-1316.	1.4	15
1116	Diagnostic Challenges in Pediatric Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder. <i>Journal of Pediatric Neurology</i> , 2018, 16, 185-191.	0.0	0

#	ARTICLE	IF	CITATIONS
1117	Infections in neuromyelitis optica spectrum disorder. <i>Journal of Clinical Neuroscience</i> , 2018, 47, 14-19.	0.8	29
1118	Differential brainstem atrophy patterns in multiple sclerosis and neuromyelitis optica spectrum disorders. <i>Journal of Magnetic Resonance Imaging</i> , 2018, 47, 1601-1609.	1.9	19
1119	An optimized framework for quantitative magnetization transfer imaging of the cervical spinal cord in vivo. <i>Magnetic Resonance in Medicine</i> , 2018, 79, 2576-2588.	1.9	15
1120	Fast and reproducible in vivo T <sub>1</sub> mapping of the human cervical spinal cord. <i>Magnetic Resonance in Medicine</i> , 2018, 79, 2142-2148.	1.9	20
1121	Common Clinical and Imaging Conditions Misdiagnosed as Multiple Sclerosis. <i>Neurologic Clinics</i> , 2018, 36, 69-117.	0.8	31
1122	Frequency of brain MRI abnormalities in neuromyelitis optica spectrum disorder at presentation: A cohort of Latin American patients. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 19, 73-78.	0.9	24
1123	Th2 axis-related cytokines in patients with neuromyelitis optica spectrum disorders. <i>CNS Neuroscience and Therapeutics</i> , 2018, 24, 64-69.	1.9	18
1124	A Young Woman With Sudden Urinary Retention and Sensory Deficits. <i>Arthritis Care and Research</i> , 2018, 70, 635-642.	1.5	3
1125	Multiple sclerosis, and other demyelinating and autoimmune inflammatory diseases of the central nervous system. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2018, 146, 67-84.	1.0	39
1126	Strategies of Virtual Screening in Medicinal Chemistry. <i>International Journal of Quantitative Structure-Property Relationships</i> , 2018, 3, 134-160.	1.1	12
1127	Neuromyelitis optica in Sub-Saharan Africa: the first case report from Togo. <i>Medicine Et Sante Tropicales</i> , 2018, 28, 221-223.	0.3	2
1128	Epidural Labor Analgesia for a Patient with Neuromyelitis Optica: A Case Report and Review of the Literature. <i>Case Reports in Anesthesiology</i> , 2018, 2018, 1-3.	0.2	1
1129	A multi-facet comparative analysis of neuromyelitis optica spectrum disorders in patients with seropositive and seronegative AQP4-IgG. <i>Medicine (United States)</i> , 2018, 97, e13100.	0.4	9
1130	SLE presenting as demyelinating autoimmune visual loss. <i>BMJ Case Reports</i> , 2018, 2018, bcr-2017-222158.	0.2	1
1131	Neuromyelitis Optica Spectrum Disorders Associated To Posterior Reversible Encephalopathy Syndrome: Pathogenesis, Diagnosis, Treatment and Evolution: A Case Report and Literature Review. <i>Journal of Neurology &amp; Neurophysiology</i> , 2018, 09, .	0.1	0
1132	Neuromyelitis optica and myelin oligodendrocyte glycoprotein. <i>Annals of Eye Science</i> , 0, 3, 22-22.	1.1	1
1133	CSF-S100B Is a Potential Candidate Biomarker for Neuromyelitis Optica Spectrum Disorders. <i>BioMed Research International</i> , 2018, 2018, 1-11.	0.9	13
1134	Nationwide prevalence and incidence study of neuromyelitis optica spectrum disorder in Denmark. <i>Neurology</i> , 2018, 91, e2265-e2275.	1.5	84

#	ARTICLE	IF	CITATIONS
1135	The Two-Faced Cytokine IL-6 in Host Defense and Diseases. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3528.	1.8	143
1136	Increased expression of the membrane-bound CD40 ligand on peripheral CD4+ T cells in the acute phase of AQP4-IgG-seropositive neuromyelitis optica spectrum disorders. <i>Journal of Neuroimmunology</i> , 2018, 325, 64-68.	1.1	6
1137	Epidemiología de la neuromielitis óptica en Costa Rica: un análisis multicéntrico. <i>Neurología Argentina</i> , 2018, 10, 185-193.	0.1	2
1138	Clinical Characteristics, Treatment Outcomes and Predictive Factors in Optic Neuritis. <i>Open Ophthalmology Journal</i> , 2018, 12, 247-255.	0.1	28
1139	Detection of aquaporin-4 antibodies for patients with CNS inflammatory demyelinating diseases other than typical MS in Lithuania. <i>Brain and Behavior</i> , 2018, 8, e01129.	1.0	5
1140	Reduced expression of the IL7Ra signaling pathway in Neuromyelitis optica. <i>Journal of Neuroimmunology</i> , 2018, 324, 81-89.	1.1	4
1141	The role of the laboratory in the expanding field of neuroimmunology: Autoantibodies to neural targets. <i>Journal of Immunological Methods</i> , 2018, 463, 1-20.	0.6	5
1142	The first Japanese report on neuromyelitis optica rediscovered: acute bilateral blindness, tetraparesis and respiratory insufficiency in a 35-year-old man (1891). <i>Journal of the Neurological Sciences</i> , 2018, 395, 121-125.	0.3	4
1143	Neuromyelitis optica spectrum disorders with and without connective tissue disorders. <i>BMC Neurology</i> , 2018, 18, 177.	0.8	10
1144	Apheresis therapies for NMOSD attacks. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2018, 5, e504.	3.1	173
1145	Treatment strategies for neuromyelitis optica. <i>Tzu Chi Medical Journal</i> , 2018, 30, 204.	0.4	3
1146	Myelocortical multiple sclerosis: a new disease subtype?. <i>Lancet Neurology</i> , The, 2018, 17, 832-834.	4.9	1
1147	Present Drug Therapy of Demyelinating Disorders. <i>Current Drug Therapy</i> , 2018, 13, 25-42.	0.2	0
1148	Successful treatment with olanzapine in severe hallucinatory-paranoid state during the course of treatment of inflammatory demyelination disease: a case report. <i>Clinical Neuropsychopharmacology and Therapeutics</i> , 2018, 9, 7-11.	0.3	0
1150	Differentiating Neuromyelitis Optica-Related and Multiple Sclerosis-Related Acute Optic Neuritis Using Conventional Magnetic Resonance Imaging Combined With Readout-Segmented Echo-Planar Diffusion-Weighted Imaging. <i>Journal of Computer Assisted Tomography</i> , 2018, 42, 502-509.	0.5	17
1151	Association of Optic Neuritis with CYP4F2 Gene Single Nucleotide Polymorphism and IL-17A Concentration. <i>Journal of Ophthalmology</i> , 2018, 2018, 1-8.	0.6	5
1152	NMO-IgG and AQP4 Peptide Can Induce Aggravation of EAMG and Immune-Mediated Muscle Weakness. <i>Journal of Immunology Research</i> , 2018, 2018, 1-10.	0.9	2
1153	Multiple sclerosis and neuromyelitis optica spectrum disorders in Malaysia: A comparison in different ethnic groups. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 25, 300-308.	0.9	13

#	ARTICLE	IF	CITATIONS
1154	Paraneoplastic NMOSD associated with EG junction adenocarcinoma expressing unprotected AQP4. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2018, 5, e482.	3.1	14
1155	T Follicular Helper Cells in Autoimmune Disorders. <i>Frontiers in Immunology</i> , 2018, 9, 1637.	2.2	164
1156	Orbital Ectopic Lymphoid Follicles with Germinal Centers in Aquaporin-4-IgG-Positive Neuromyelitis Optica Spectrum Disorders. <i>Frontiers in Immunology</i> , 2017, 8, 1947.	2.2	6
1157	Astrocytic Interleukin-15 Reduces Pathology of Neuromyelitis Optica in Mice. <i>Frontiers in Immunology</i> , 2018, 9, 523.	2.2	9
1158	Lower frequency of antibodies to MOG in Brazilian patients with demyelinating diseases: An ethnicity influence?. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 25, 87-94.	0.9	16
1159	Dose effects of mycophenolate mofetil in Chinese patients with neuromyelitis optica spectrum disorders: a case series study. <i>BMC Neurology</i> , 2018, 18, 47.	0.8	18
1160	Imaging Differences between Neuromyelitis Optica Spectrum Disorders and Multiple Sclerosis: A Multi-Institutional Study in Japan. <i>American Journal of Neuroradiology</i> , 2018, 39, 1239-1247.	1.2	22
1161	Vaccines and the association with relapses in patients with neuromyelitis optica spectrum disorder. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 23, 78-82.	0.9	38
1162	Neuromyelitis Optica Spectrum Disorders. , 2018, , 313-335.		1
1163	Acute Transverse Myelitis. , 2018, , 141-161.		1
1165	Directional coupling of oligodendrocyte connexinâ€47 and astrocyte connexinâ€43 gap junctions. <i>Glia</i> , 2018, 66, 2340-2352.	2.5	41
1166	Cerebrospinal fluid orexin-A levels in systemic lupus erythematosus patients presenting with excessive daytime sleepiness. <i>Lupus</i> , 2018, 27, 1847-1853.	0.8	5
1167	Differing Structural and Functional Patterns of Optic Nerve Damage in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder. <i>Ophthalmology</i> , 2019, 126, 445-453.	2.5	69
1168	A nationwide epidemiological study on the prevalence of multiple sclerosis and neuromyelitis optica spectrum disorder with important multi-ethnic differences in Malaysia. <i>Multiple Sclerosis Journal</i> , 2019, 25, 1452-1461.	1.4	36
1169	Lack of short-chain fatty acids and overgrowth of opportunistic pathogens define dysbiosis of neuromyelitis optica spectrum disorders: A Chinese pilot study. <i>Multiple Sclerosis Journal</i> , 2019, 25, 1316-1325.	1.4	40
1170	14th EUNOS Congress. <i>Neuro-Ophthalmology</i> , 2019, 43, 1-221.	0.4	2
1171	Genetic Factors in Neuroimmune Diseases. , 2019, , 357-386.		0
1172	The Roles of Regulatory T Cells in Central Nervous System Autoimmunity. <i>Contemporary Clinical Neuroscience</i> , 2019, , 167-193.	0.3	0

#	ARTICLE	IF	CITATIONS
1173	Atypical Inflammatory Demyelinating Syndromes of the Central Nervous System. <i>Contemporary Clinical Neuroscience</i> , 2019, , 543-566.	0.3	0
1174	Validation of the 2015 diagnostic criteria for neuromyelitis optica spectrum disorders in a cohort of South Indian patients. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 35, 164-169.	0.9	8
1175	A new M23-based ELISA assay for anti-aquaporin 4 autoantibodies: diagnostic accuracy and clinical correlation. <i>Autoimmunity Highlights</i> , 2019, 10, 5.	3.9	10
1176	Pediatric acquired demyelinating syndrome (ADS) in inpatient hospital settings: The hospitalization rate, costs, and outcomes in the US. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 34, 150-157.	0.9	2
1178	Acute Demyelinating Emergencies. , 2019, , 45-64.		0
1179	Clinical characteristics of autoimmune disorders in the central nervous system associated with myasthenia gravis. <i>Journal of Neurology</i> , 2019, 266, 2743-2751.	1.8	10
1180	Acute Demyelinating Disorders in the Neurocritical Care Unit. , 2019, , 414-420.		0
1181	Efficacy of different rituximab therapeutic strategies in patients with neuromyelitis optica spectrum disorders. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 36, 101430.	0.9	23
1182	Long-term outcome and prognosis in patients with neuromyelitis optica spectrum disorder from Serbia. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 36, 101413.	0.9	14
1183	Reduced Myelin Signal in Normal-appearing White Matter in Neuromyelitis Optica Measured by 7T Magnetic Resonance Imaging. <i>Scientific Reports</i> , 2019, 9, 14378.	1.6	13
1184	Demyelinating syndrome in systemic sclerosis and neuromyelitis optica. <i>BMC Neurology</i> , 2019, 19, 234.	0.8	9
1185	B cells in autoimmune and neurodegenerative central nervous system diseases. <i>Nature Reviews Neuroscience</i> , 2019, 20, 728-745.	4.9	190
1186	Serum Clusterin and Complement Factor H May Be Biomarkers Differentiate Primary Sjögren's Syndrome With and Without Neuromyelitis Optica Spectrum Disorder. <i>Frontiers in Immunology</i> , 2019, 10, 2527.	2.2	7
1187	Pregnancy-Related Immune Changes and Demyelinating Diseases of the Central Nervous System. <i>Frontiers in Neurology</i> , 2019, 10, 1070.	1.1	17
1188	GRP 78 antibodies are associated with clinical phenotype in neuromyelitis optica. <i>Annals of Clinical and Translational Neurology</i> , 2019, 6, 2079-2087.	1.7	18
1189	Pilot study on the effects of cognitive behavioral therapy on depression among Japanese patients with multiple sclerosis. <i>Clinical and Experimental Neuroimmunology</i> , 2019, 10, 180-185.	0.5	2
1190	Efficacy and Tolerability of Intravenous Immunoglobulin and Subcutaneous Immunoglobulin in Neurologic Diseases. <i>Clinical Therapeutics</i> , 2019, 41, 2112-2136.	1.1	15
1191	Proportions of Th17 cells and Th17-related cytokines in neuromyelitis optica spectrum disorders patients: A meta-analysis. <i>International Immunopharmacology</i> , 2019, 75, 105793.	1.7	28



#	ARTICLE	IF	CITATIONS
1192	Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial. <i>Lancet, The</i> , 2019, 394, 1352-1363.	6.3	433
1193	Neuromyelitis optica spectrum disorders: still evolving and broadening. <i>Current Opinion in Neurology</i> , 2019, 32, 385-394.	1.8	122
1194	The accuracy of flow cytometric cell-based assay to detect anti-myelin oligodendrocyte glycoprotein (MOG) antibodies determining the optimal method for positivity judgement. <i>Journal of Neuroimmunology</i> , 2019, 336, 577021.	1.1	20
1195	Plasmablasts and neuroimmunological disorders. <i>Immunological Medicine</i> , 2019, 42, 103-107.	1.4	2
1196	The GTF2I rs117026326 polymorphism is associated with neuromyelitis optica spectrum disorder but not with multiple sclerosis in a Northern Han Chinese population. <i>Journal of Neuroimmunology</i> , 2019, 337, 577045.	1.1	10
1197	Multidisciplinary rehabilitation for adults with neuromyelitis optica spectrum disorders: A pilot study. <i>Journal of Rehabilitation Medicine</i> , 2019, 51, 692-697.	0.8	6
1198	The imbalance between regulatory and memory B cells accompanied by an increased number of circulating T-follicular helper cells in MOGâ€“antibody-associated demyelination. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 36, 101397.	0.9	18
1199	Aquaporin-4-IgG positive neuromyelitis optica spectrum disorder and systemic autoimmune diseases overlap syndrome: a single-center experience. <i>Lupus</i> , 2019, 28, 1302-1311.	0.8	16
1200	Autologous nonmyeloablative hematopoietic stem cell transplantation for neuromyelitis optica. <i>Neurology</i> , 2019, 93, e1732-e1741.	1.5	67
1201	Suspected bacterial meningoencephalomyelitis as the trigger or presentation of neuromyelitis optica spectrum disorder flare. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 30, 38-41.	0.9	9
1202	General anaesthesia for caesarean section in a patient with neuromyelitis optica spectrum disorder (NMOSD). <i>International Journal of Surgery Case Reports</i> , 2019, 60, 72-74.	0.2	5
1203	Neuromyelitis Optica Spectrum Disorder and Anti-MOG Syndromes. <i>Biomedicines</i> , 2019, 7, 42.	1.4	90
1204	Normal-Appearing Cerebellar Damage in Neuromyelitis Optica Spectrum Disorder. <i>American Journal of Neuroradiology</i> , 2019, 40, 1156-1161.	1.2	6
1205	Epidemiology of NMOSD in Sweden from 1987 to 2013. <i>Neurology</i> , 2019, 93, e181-e189.	1.5	51
1206	Peripheral and central nervous system involvement in a patient with primary SjÃ“rgrenâ€™s syndrome: a case report. <i>Journal of Medical Case Reports</i> , 2019, 13, 165.	0.4	7
1207	Neuromyelitis optica spectrum disorder coincident with renal clear cell carcinoma. <i>Medicine (United Tj ETQq1 1 0.784314 rgBT /Over</i>	0.4	6
1208	Epidemiology of neuromyelitis optica spectrum disorder in Denmark (1998â€“2008, 2007â€“2014). <i>Brain and Behavior</i> , 2019, 9, e01338.	1.0	12
1209	Clinical Approach to Pediatric Transverse Myelitis, Neuromyelitis Optica Spectrum Disorder and Acute Flaccid Myelitis. <i>Children</i> , 2019, 6, 70.	0.6	12

#	ARTICLE	IF	CITATIONS
1210	Early B cell tolerance defects in neuromyelitis optica favour anti-AQP4 autoantibody production. <i>Brain</i> , 2019, 142, 1598-1615.	3.7	62
1211	HLA-alleles class I and II associated with genetic susceptibility to neuromyelitis optica in Brazilian patients. <i>Arquivos De Neuro-Psiquiatria</i> , 2019, 77, 239-247.	0.3	11
1212	Magnetic resonance imaging in myelopathy: a pictorial review. <i>Clinical Imaging</i> , 2019, 57, 56-68.	0.8	10
1213	Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder. <i>New England Journal of Medicine</i> , 2019, 381, 614-625.	13.9	536
1214	Role of Glutamatergic Excitotoxicity in Neuromyelitis Optica Spectrum Disorders. <i>Frontiers in Cellular Neuroscience</i> , 2019, 13, 142.	1.8	19
1215	Neuromyelitis optica spectrum disorder occurred after interferon alpha therapy in malignant melanoma. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 32, 33-36.	0.9	4
1216	Neurological autoimmune disorders with prominent gastrointestinal manifestations: A review of presentation, evaluation, and treatment. <i>Neurogastroenterology and Motility</i> , 2019, 31, e13611.	1.6	11
1217	Nontarget metabolomics profiling of neuromyelitis optica spectrum disorder. <i>Biomedical Chromatography</i> , 2019, 33, e4533.	0.8	6
1218	Evidence of Müller Glial Dysfunction in Patients with Aquaporin-4 Immunoglobulin G-Positive Neuromyelitis Optica Spectrum Disorder. <i>Ophthalmology</i> , 2019, 126, 801-810.	2.5	54
1219	Demyelinating Disease and Pregnancy. , 2019, , 145-156.		1
1220	Repetitive intrathecal injection of human NMO-IgG with complement exacerbates disease severity with NMO pathology in experimental allergic encephalomyelitis mice. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 30, 225-230.	0.9	6
1221	Comparison of Ocular Motor Findings Between Neuromyelitis Optica Spectrum Disorder and Multiple Sclerosis Involving the Brainstem and Cerebellum. <i>Cerebellum</i> , 2019, 18, 511-518.	1.4	8
1222	Brain MRI Findings in Pediatric-Onset Neuromyelitis Optica Spectrum Disorder: Challenges in Differentiation from Acute Disseminated Encephalomyelitis. <i>American Journal of Neuroradiology</i> , 2019, 40, 726-731.	1.2	8
1223	Acute Myelopathy from ADEM to Zika. <i>Neurographics</i> , 2019, 9, 127-142.	0.0	3
1224	Case report: an area postrema syndrome revealing a neuromyelitis optica spectrum disorder associated with central nervous system tuberculosis in a young Togolese (black African) woman. <i>BMC Neurology</i> , 2019, 19, 58.	0.8	10
1225	Human C5-specific single-chain variable fragment ameliorates brain injury in a model of NMOSD. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2019, 6, e561.	3.1	6
1226	Outcome prediction models in AQP4-IgG positive neuromyelitis optica spectrum disorders. <i>Brain</i> , 2019, 142, 1310-1323.	3.7	131
1227	Paraneoplastic neuromyelitis optica and ovarian teratoma: A case series. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 31, 97-100.	0.9	19

#	ARTICLE	IF	CITATIONS
1228	Cerebral cortex impairment in neuromyelitis optica spectrum disorder: A case report and literature review. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 32, 9-12.	0.9	10
1229	Clinical, neuroimaging and therapeutic response in AQP4-positive NMO patients from India. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 30, 85-93.	0.9	17
1230	Radiomics in multiple sclerosis and neuromyelitis optica spectrum disorder. <i>European Radiology</i> , 2019, 29, 4670-4677.	2.3	25
1231	Increased cerebrospinal fluid neurofilament light chain in central nervous system inflammatory demyelinating disease. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 30, 123-128.	0.9	21
1232	Plasma exchange: an effective add-on treatment of optic neuritis in neuromyelitis optica spectrum disorders. <i>International Ophthalmology</i> , 2019, 39, 2477-2483.	0.6	24
1233	Association of Optic Neuritis with Neuromyelitis Optica Spectrum Disorder and Multiple Sclerosis in Korea. <i>Korean Journal of Ophthalmology: KJO</i> , 2019, 33, 82.	0.5	27
1234	<i>Neurology and Psychiatry of Women.</i> , 2019, , .		1
1235	Understanding Childhood Neuroimmune Diseases of the Central Nervous System. <i>Frontiers in Pediatrics</i> , 2019, 7, 511.	0.9	23
1236	Late-onset neuromyelitis optica spectrum disorder. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2019, 6, .	3.1	44
1237	A pilot safety study of ublituximab, a monoclonal antibody against CD20, in acute relapses of neuromyelitis optica spectrum disorder. <i>Medicine (United States)</i> , 2019, 98, e15944.	0.4	42
1238	Rehabilitation of neuromyelitis optica. <i>Medicine (United States)</i> , 2019, 98, e17465.	0.4	2
1239	Complex intensive treatment shows promise against a complex aggressive disease. <i>Neurology</i> , 2019, 93, 776-777.	1.5	0
1240	Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder. <i>New England Journal of Medicine</i> , 2019, 381, 2114-2124.	13.9	383
1241	The Balance in T Follicular Helper Cell Subsets Is Altered in Neuromyelitis Optica Spectrum Disorder Patients and Restored by Rituximab. <i>Frontiers in Immunology</i> , 2019, 10, 2686.	2.2	25
1242	Comparison of psychiatric disturbances in patients with multiple sclerosis and neuromyelitis optica. <i>Medicine (United States)</i> , 2019, 98, e17184.	0.4	12
1243	What You Need to Know About AQP4, MOG, and NMOSD. <i>Seminars in Neurology</i> , 2019, 39, 718-731.	0.5	34
1244	Clinical Course and Treatment Response of Neuromyelitis Optica Spectrum Disease: An 8-Year Experience. <i>Asia-Pacific Journal of Ophthalmology</i> , 2019, 8, 206-210.	1.3	8
1245	Chiasmal and Retrochiasmal Disorders. <i>International Ophthalmology Clinics</i> , 2019, 59, 59-81.	0.3	1

#	ARTICLE	IF	CITATIONS
1246	Visual Loss. , 2019, , 101-196.		3
1247	Innate Immune Responses and Viral-Induced Neurologic Disease. Journal of Clinical Medicine, 2019, 8, 3.	1.0	22
1249	Workup for Optic Atrophy. , 2019, , 167-199.		0
1250	Altered volume and microstructural integrity of hippocampus in NMOSD. Multiple Sclerosis and Related Disorders, 2019, 28, 132-137.	0.9	12
1251	Neurological update: MOG antibody disease. Journal of Neurology, 2019, 266, 1280-1286.	1.8	171
1253	Management of Demyelinating Disorders in Pregnancy. Neurologic Clinics, 2019, 37, 17-30.	0.8	19
1254	Simultaneous bilateral optic neuritis in China: clinical, serological and prognostic characteristics. Acta Ophthalmologica, 2019, 97, e426-e434.	0.6	5
1255	Optic Neuritis as the Presenting Feature of Neuromyelitis Optica (NMO): Diagnosis and Management. , 2019, , 11-22.		0
1256	Neuromyelitis optica spectrum disorders (NMO-SD) in a Sub-Saharan Africa country: A preliminary study of sixteen Senegalese cases. Multiple Sclerosis and Related Disorders, 2019, 27, 179-183.	0.9	11
1257	Disruption of blood-brain barrier integrity associated with brain lesions in Chinese neuromyelitis optica spectrum disorder patients. Multiple Sclerosis and Related Disorders, 2019, 27, 254-259.	0.9	9
1258	Altered neurovascular coupling in neuromyelitis optica. Human Brain Mapping, 2019, 40, 976-986.	1.9	26
1259	Neuromyelitis optica spectrum disorder: Pathogenesis, treatment, and experimental models. Multiple Sclerosis and Related Disorders, 2019, 27, 412-418.	0.9	101
1260	The role of flavonoids in autoimmune diseases: Therapeutic updates. , 2019, 194, 107-131.		113
1261	Resolution of inflammation in neuromyelitis optica spectrum disorders. Multiple Sclerosis and Related Disorders, 2019, 27, 34-41.	0.9	31
1262	Neuromyelitis Optica Spectrum Disorder in a Patient With Systemic Lupus Erythematosus. Journal of Clinical Rheumatology, 2019, 25, e38-e40.	0.5	0
1263	Magnetic resonance imaging in immune-mediated myelopathies. Journal of Neurology, 2020, 267, 1233-1244.	1.8	1
1264	CNS Inflammatory Demyelinating Disorders: MS, NMOSD and MOG Antibody Associated Disease. Journal of Investigative Medicine, 2020, 68, 321-330.	0.7	36
1265	Functional Connectivity Alterations in Neuromyelitis Optica Spectrum Disorder. Clinical Neuroradiology, 2020, 30, 559-568.	1.0	14

#	ARTICLE	IF	CITATIONS
1266	Differential diagnosis of multiple sclerosis and other inflammatory CNS diseases. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 37, 101452.	0.9	57
1267	Lower serum interleukinâ€22 and interleukinâ€35 levels are associated with disease status in neuromyelitis optica spectrum disorders. <i>CNS Neuroscience and Therapeutics</i> , 2020, 26, 251-259.	1.9	4
1268	Review: Recent advances in the understanding of the pathophysiology of neuromyelitis optica spectrum disorder. <i>Neuropathology and Applied Neurobiology</i> , 2020, 46, 199-218.	1.8	33
1269	Autoimmune and Autoantibody-Associated Encephalomyelopathies. , 2020, , 1067-1114.		1
1270	Therapeutic Plasma Exchange in Neuromyelitis Optica Spectrum Disorders and Related Disorders in Resourceâ€Limited Settings: Outcomes in a Multiethnic Singleâ€Center Population. <i>Therapeutic Apheresis and Dialysis</i> , 2020, 24, 312-323.	0.4	6
1271	Clinical features and prognosis of late-onset neuromyelitis optica spectrum disorders in a Latin American cohort. <i>Journal of Neurology</i> , 2020, 267, 1260-1268.	1.8	40
1272	Diagnosis and management of central nervous system SjÃ¶rgren's syndrome. , 2020, , 189-209.		0
1273	The differential expression of natural killer cells in NMOSD and MS. <i>Journal of Clinical Neuroscience</i> , 2020, 71, 9-14.	0.8	15
1274	Subcortical structural abnormalities in female neuromyelitis optica patients with neuropathic pain. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 37, 101432.	0.9	5
1275	IRAK1 polymorphisms are associated with susceptibility to neuromyelitis optica spectrum disorder. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 37, 101438.	0.9	4
1276	Glia of the human retina. <i>Glia</i> , 2020, 68, 768-796.	2.5	173
1277	Quantitative brain lesion distribution may distinguish MOG-ab and AQP4-ab neuromyelitis optica spectrum disorders. <i>European Radiology</i> , 2020, 30, 1470-1479.	2.3	11
1278	Clinical and therapeutic predictors of disease outcomes in AQP4-IgG+ neuromyelitis optica spectrum disorder. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 38, 101868.	0.9	29
1279	The clinical value of the albumin quotient in patients with neuromyelitis optica spectrum disorder. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 38, 101880.	0.9	4
1280	Tacrolimus is effective for neuromyelitis optica spectrum disorders with or without anti-AQP4 antibody. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 39, 101907.	0.9	9
1281	Efficacy and safety of mycophenolate mofetil therapy in neuromyelitis optica spectrum disorders: a systematic review and meta-analysis. <i>Scientific Reports</i> , 2020, 10, 16727.	1.6	25
1282	Genetic factors for susceptibility to and manifestations of neuromyelitis optica. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 2082-2093.	1.7	20
1283	Experimental mouse model of NMOSD produced by facilitated brain delivery of NMO-IgG by microbubble-enhanced low-frequency ultrasound in experimental allergic encephalomyelitis mice. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 46, 102473.	0.9	4

#	ARTICLE	IF	CITATIONS
1284	Neuromyelitis optica. <i>Nature Reviews Disease Primers</i> , 2020, 6, 85.	18.1	232
1285	Therapeutic plasma exchange vs conventional treatment with intravenous high dose steroid for neuromyelitis optica spectrum disorders (NMOSD): a systematic review and meta-analysis. <i>Journal of Neurology</i> , 2021, 268, 4549-4562.	1.8	20
1286	Recent progress in maintenance treatment of neuromyelitis optica spectrum disorder. <i>Journal of Neurology</i> , 2021, 268, 4522-4536.	1.8	34
1287	NMOSD acute attack: Understanding, treatment and innovative treatment prospect. <i>Journal of Neuroimmunology</i> , 2020, 348, 577387.	1.1	22
1288	A case of anti-AQP4 antibodyâ€“positive neuromyelitis optica spectrum disorder with MRI-proven lesions in lumbar nerve roots. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 46, 102557.	0.9	4
1289	Leber hereditary optic neuropathyâ€”new insights and old challenges. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2021, 259, 2461-2472.	1.0	24
1290	Incidence of neuromyelitis optica spectrum disorder (NMOSD) in China: A national population-based study. <i>The Lancet Regional Health - Western Pacific</i> , 2020, 2, 100021.	1.3	27
1291	Potential role of the gut microbiota in neuromyelitis optica spectrum disorder: Implication for intervention. <i>Journal of Clinical Neuroscience</i> , 2020, 82, 193-199.	0.8	7
1292	Safety and efficacy of mycophenolate mofetil in treating neuromyelitis optica spectrum disorders: a protocol for systematic review and meta-analysis. <i>BMJ Open</i> , 2020, 10, e040371.	0.8	2
1293	Application of the 2015 neuromyelitis optica spectrum disorders diagnostic criteria in a cohort of Chinese patients. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 46, 102459.	0.9	2
1294	High-throughput investigation of molecular and cellular biomarkers in NMOSD. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .	3.1	20
1295	Neuroinflammation at single cell level: What is new?. <i>Journal of Leukocyte Biology</i> , 2020, 108, 1129-1137.	1.5	11
1296	Eculizumab in the treatment of neuromyelitis optica spectrum disorder. <i>Immunotherapy</i> , 2020, 12, 1053-1066.	1.0	7
1297	Hematopoietic Stem Cell Transplantation in Neuromyelitis Optica-Spectrum Disorders (NMO-SD): State-of-the-Art and Future Perspectives. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5304.	1.8	22
1298	Latin American consensus recommendations for management and treatment of neuromyelitis optica spectrum disorders in clinical practice. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 45, 102428.	0.9	42
1299	Painful tonic spasm in Chinese patients with neuromyelitis optica spectrum disorder: Prevalence, subtype, and features. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 45, 102408.	0.9	12
1300	Recent developments in MOG-IgG associated neurological disorders. <i>Therapeutic Advances in Neurological Disorders</i> , 2020, 13, 175628642094513.	1.5	45
1301	Mimics of Optic Neuritis in Neuromyelitis Optica Spectrum Disorder: A Case Report. <i>Neuro-Ophthalmology</i> , 2020, 45, 1-5.	0.4	1

#	ARTICLE	IF	CITATIONS
1302	Lupus and NMOSD: The Blending of Humoral Autoimmunity. Case Reports in Rheumatology, 2020, 2020, 1-7.	0.2	3
1303	Review of approved NMO therapies based on mechanism of action, efficacy and long-term effects. Multiple Sclerosis and Related Disorders, 2020, 46, 102538.	0.9	32
1304	Management Strategies of Patients with Neuromyelitis Optica Spectrum Disorder During the COVID-19 Pandemic Era. Therapeutics and Clinical Risk Management, 2020, Volume 16, 759-767.	0.9	6
1305	Metabolomic Profiling in Neuromyelitis Optica Spectrum Disorder Biomarker Discovery. Metabolites, 2020, 10, 374.	1.3	7
1306	Brain MRI characteristics in neuromyelitis optica spectrum disorders: A large multi-center retrospective study in China. Multiple Sclerosis and Related Disorders, 2020, 46, 102475.	0.9	13
1307	Effect of plasma exchange in neuromyelitis optica spectrum disorder: A systematic review and meta-analysis. Annals of Clinical and Translational Neurology, 2020, 7, 2094-2102.	1.7	15
1308	Paraneoplastic acute demyelinating disease with monoclonal gammopathy of unknown significance expressing aquaporin-4. British Journal of Haematology, 2020, 191, e101-e103.	1.2	1
1309	Gender issues of antibody-mediated diseases in neurology: (NMOSD/autoimmune encephalitis/MG). Therapeutic Advances in Neurological Disorders, 2020, 13, 175628642094980.	1.5	23
1310	Interleukin-6 in neuromyelitis optica spectrum disorder pathophysiology. Neurology: Neuroimmunology and Neuroinflammation, 2020, 7, .	3.1	112
1311	Worldwide Incidence and Prevalence of Neuromyelitis Optica. Neurology, 2021, 96, 59-77.	1.5	101
1312	3D Compressed Convolutional Neural Network Differentiates Neuromyelitis Optical Spectrum Disorders From Multiple Sclerosis Using Automated White Matter Hyperintensities Segmentations. Frontiers in Physiology, 2020, 11, 612928.	1.3	8
1313	Naive B cells in neuromyelitis optica spectrum disorders: impact of steroid use and relapses. Brain Communications, 2020, 2, fcaa197.	1.5	7
1314	Serum albumin level is associated with the severity of neurological dysfunction of NMOSD patients. Multiple Sclerosis and Related Disorders, 2020, 43, 102130.	0.9	7
1315	Scrambler therapy improves pain in neuromyelitis optica. Neurology, 2020, 94, e1900-e1907.	1.5	22
1316	Familial neuromyelitis optica spectrum disorder in a pair of sisters. QJM - Monthly Journal of the Association of Physicians, 2020, 113, 743-746.	0.2	1
1317	Allogeneic haematopoietic stem cell transplantation in a refractory case of neuromyelitis optica spectrum disorder. Multiple Sclerosis and Related Disorders, 2020, 42, 102110.	0.9	9
1318	The Potential Immunoregulatory Roles of Vitamin D in Neuromyelitis Optica Spectrum Disorder. Multiple Sclerosis and Related Disorders, 2020, 43, 102156.	0.9	10
1319	Proteomic profiles of major serum proteins in seropositive NMO patients alter after Rituximab treatment. Journal of Proteins and Proteomics, 2020, 11, 93-103.	1.0	2

#	ARTICLE	IF	CITATIONS
1320	Clinical utility of AQP4-IgG titers and measures of complement-mediated cell killing in NMOSD. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .	3.1	29
1321	Different Exosomal microRNA Profile in Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorders. <i>Frontiers in Immunology</i> , 2020, 11, 1064.	2.2	8
1322	Spinal Cord Involvement in MS and Other Demyelinating Diseases. <i>Biomedicines</i> , 2020, 8, 130.	1.4	9
1323	Plasma Exchange or Immunoabsorption in Demyelinating Diseases: A Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2020, 9, 1597.	1.0	22
1324	The 2015 IPND Criteria Increases the Yield in Diagnosis of Neuromyelitis Optica Spectrum Disorder in Thai Patients Compared to the 2006 Diagnostic Criteria. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 43, 102218.	0.9	7
1325	Radiological characteristics of neuromyelitis optica spectrum disorder in Kuwait. <i>Clinical Neurology and Neurosurgery</i> , 2020, 196, 106047.	0.6	2
1326	Characterization of pain syndromes in patients with neuromyelitis optica. <i>European Journal of Pain</i> , 2020, 24, 1548-1568.	1.4	16
1327	A comparative study on clinical characterizations between acute myelitis onset of neuromyelitis optica spectrum disease and idiopathic transverse myelitis. <i>Neurological Research</i> , 2020, 42, 612-617.	0.6	2
1328	Visualizing the Central Nervous System: Imaging Tools for Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders. <i>Frontiers in Neurology</i> , 2020, 11, 450.	1.1	29
1329	Classical Triad and Periventricular Lesions Do Not Necessarily Indicate Wernicke's Encephalopathy: A Case Report and Review of the Literature. <i>Frontiers in Neurology</i> , 2020, 11, 451.	1.1	4
1330	Monoclonal Antibody-Based Treatments for Neuromyelitis Optica Spectrum Disorders: From Bench to Bedside. <i>Neuroscience Bulletin</i> , 2020, 36, 1213-1224.	1.5	7
1331	Magnetic-Resonance Diffusion-Tensor Tractography in the Diagnosis of Tumefactive Spinal-Cord Lesions in Neuromyelitis Optica. <i>Diagnostics</i> , 2020, 10, 401.	1.3	0
1332	Transitional B cells involved in autoimmunity and their impact on neuroimmunological diseases. <i>Journal of Translational Medicine</i> , 2020, 18, 131.	1.8	43
1333	Imaging of Neuromyelitis Optica Spectrum Disorders. <i>Seminars in Ultrasound, CT and MRI</i> , 2020, 41, 319-331.	0.7	2
1335	Brain magnetic resonance imaging features in multiple sclerosis and neuromyelitis optica spectrum disorders patients with or without aquaporin-4 antibody in a Latin American population. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 42, 102049.	0.9	4
1336	ANTIBODIES AND RECEPTORS: From Neuromuscular Junction to Central Nervous System. <i>Neuroscience</i> , 2020, 439, 48-61.	1.1	20
1337	HTLV-1 in Ophthalmology. <i>Frontiers in Microbiology</i> , 2020, 11, 388.	1.5	22
1338	Comparison of Neuropathic Pain in Neuromyelitis Optica Spectrum Disorder and Multiple Sclerosis.		



#	ARTICLE	IF	CITATIONS
1339	Changes in mitochondrial function in patients with neuromyelitis optica; correlations with motor and cognitive disabilities. <i>PLoS ONE</i> , 2020, 15, e0230691.	1.1	9
1340	Current and emerging biologics for the treatment of neuromyelitis optica spectrum disorders. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 1061-1072.	1.4	15
1341	Retrospective Observation of Low-Dose Rituximab Treatment in Chinese Patients With Neuromyelitis Optica Spectrum Disorders in a Real-World Setting. <i>Frontiers in Neurology</i> , 2020, 11, 642.	1.1	13
1342	Tanshinone IIA alleviates brain damage in a mouse model of neuromyelitis optica spectrum disorder by inducing neutrophil apoptosis. <i>Journal of Neuroinflammation</i> , 2020, 17, 198.	3.1	8
1343	The S1P-S1PR Axis in Neurological Disorders—Insights into Current and Future Therapeutic Perspectives. <i>Cells</i> , 2020, 9, 1515.	1.8	30
1344	Safety and efficacy of plasma exchange for the treatment of optic neuritis in neuromyelitis optica spectrum disorders. <i>Medicine (United States)</i> , 2020, 99, e21067.	0.4	2
1345	Multiple sclerosis with intractable vomiting and atypical area postrema lesion. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 45, 102348.	0.9	6
1346	Effect of autologous hematopoietic stem cell transplantation on multiple sclerosis and neuromyelitis optica spectrum disorder: a PRISMA-compliant meta-analysis. <i>Bone Marrow Transplantation</i> , 2020, 55, 1928-1934.	1.3	30
1347	The Demonstration of an Aqp4/Tgf-Beta 1 Pathway in Murine Astrocytes Holds Implications for Both Neuromyelitis Optica and Progressive Multiple Sclerosis. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1035.	1.8	4
1348	Urinary Symptoms and Bladder Dysfunction in Patients with Neuromyelitis Optica Spectrum Disorders: Evaluation with Urodynamics and Management. <i>Journal of Neurosciences in Rural Practice</i> , 2020, 11, 245-249.	0.3	7
1349	Aseptic meningitis as an atypical manifestation of neuromyelitis optica spectrum disorder flare. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 41, 102013.	0.9	17
1350	Radiation Myelopathy of the Cervical Spine in the Setting of Neuromyelitis Optica Spectrum Disorder After Low-Dose Radiation Therapy for Non-Hodgkin Lymphoma of the Cervical Lymph Nodes. <i>Advances in Radiation Oncology</i> , 2020, 5, 1071-1075.	0.6	0
1351	Differentiate aquaporin-4 antibody negative neuromyelitis optica spectrum disorders from multiple sclerosis by multimodal advanced MRI techniques. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 41, 102035.	0.9	4
1352	Cost effectiveness of rituximab and mycophenolate mofetil for neuromyelitis optica spectrum disorder in Thailand: Economic evaluation and budget impact analysis. <i>PLoS ONE</i> , 2020, 15, e0229028.	1.1	6
1354	Questioning the existence of monophasic neuromyelitis optica spectrum disorder by defining a novel long-term relapse-free form from a large Chinese population. <i>Journal of Neurology</i> , 2020, 267, 1197-1205.	1.8	15
1355	Solution structure and oligomeric state of the E. coliglycerol facilitator. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 2020, 1862, 183191.	1.4	6
1356	Role of Diffusional Kurtosis Imaging in Differentiating Neuromyelitis Optica-Related and Multiple Sclerosis-Related Acute Optic Neuritis: Comparison With Diffusion-Weighted Imaging. <i>Journal of Computer Assisted Tomography</i> , 2020, 44, 47-52.	0.5	6
1357	Decreased mRNA Expressions of CD40L in Patients with Neuromyelitis Optica Spectrum Disorder. <i>Journal of Molecular Neuroscience</i> , 2020, 70, 610-617.	1.1	1

#	ARTICLE	IF	CITATIONS
1358	Short segment myelitis as the initial and only manifestation of aquaporin-4 immunoglobulin G-positive neuromyelitis optica spectrum disorders. <i>Therapeutic Advances in Neurological Disorders</i> , 2020, 13, 175628641989859.	1.5	8
1359	Longitudinal ultra-high field MRI of brain lesions in neuromyelitis optica spectrum disorders. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 42, 102066.	0.9	4
1360	Possible clinical role of MOG antibody testing in children presenting with acute neurological symptoms. <i>Neurological Sciences</i> , 2020, 41, 2553-2559.	0.9	2
1361	Eculizumab: A Review in Neuromyelitis Optica Spectrum Disorder. <i>Drugs</i> , 2020, 80, 719-727.	4.9	41
1362	Is transient hyperCKemia a new feature of neuromyelitis optica spectrum disorders? A retrospective study in 439 patients. <i>Journal of Neuroimmunology</i> , 2020, 343, 577228.	1.1	2
1363	Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial. <i>Lancet Neurology</i> , The, 2020, 19, 402-412.	4.9	278
1364	Is Asian type MS an MS phenotype, an NMO spectrum disorder, or a MOG-IgG related disease?. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 42, 102082.	0.9	8
1365	Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial. <i>Lancet Neurology</i> , The, 2020, 19, 391-401.	4.9	183
1366	Impact of blood-brain barrier disruption on newly diagnosed neuromyelitis optica spectrum disorder symptoms and prognosis. <i>Annals of Palliative Medicine</i> , 2020, 9, 324-330.	0.5	11
1367	Diagnostic value of bright spotty lesions on MRI after a first episode of acute myelopathy. <i>Journal of Neuroradiology</i> , 2021, 48, 28-36.	0.6	24
1368	Spinal cord and brain MRI should be routinely performed during follow-up in patients with NMOSD "No. <i>Multiple Sclerosis Journal</i> , 2021, 27, 15-16.	1.4	5
1369	Identification and measurement of cervical spinal cord atrophy in neuromyelitis optica spectrum disorders (NMOSD) and correlation with clinical characteristics and cervical spinal cord MRI data. <i>Revue Neurologique</i> , 2021, 177, 85-92.	0.6	5
1370	Imaging in Pediatric Multiple Sclerosis. <i>Clinical Neuroradiology</i> , 2021, 31, 61-71.	1.0	6
1371	A literature review of biosensors for multiple sclerosis: Towards personalized medicine and point-of-care testing. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 48, 102675.	0.9	6
1372	At the dawn of personalised medicine in neuromyelitis optica spectrum disorder: the impact of the disease activity on pregnancy. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 1-1.	0.9	1
1373	CD8 + T cell subpopulations and pro-inflammatory cytokines in neuromyelitis optica spectrum disorder. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 43-53.	1.7	15
1374	Cerebrospinal fluid lactate level in aquaporin-4 antibody positive neuromyelitis optica spectrum disorders: a hint on differential diagnosis and possible immunopathogenesis. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 47, 102629.	0.9	0
1375	Emerging Targeted Therapies for Neuromyelitis Optica Spectrum Disorders. <i>BioDrugs</i> , 2021, 35, 7-17.	2.2	11

#	ARTICLE	IF	CITATIONS
1376	Epidemiological findings of neuromyelitis optica spectrum disorders in a Venezuelan study. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 47, 102652.	0.9	7
1377	Frequency of comorbidities in Neuromyelitis Optica spectrum disorder. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 48, 102685.	0.9	10
1378	B cell depletion therapies in autoimmune disease: advances and mechanistic insights. <i>Nature Reviews Drug Discovery</i> , 2021, 20, 179-199.	21.5	296
1379	Serum antinuclear antibodies associate with worse prognosis in AQP4- $\epsilon$ positive neuromyelitis optica spectrum disorder. <i>Brain and Behavior</i> , 2021, 11, e01865.	1.0	12
1380	Case 6-2021: A 65-Year-Old Man with Eye Pain and Decreased Vision. <i>New England Journal of Medicine</i> , 2021, 384, 745-753.	13.9	2
1381	Neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein associated disorder-optic neuritis: a comprehensive review of diagnosis and treatment. <i>Eye</i> , 2021, 35, 753-768.	1.1	35
1382	Common genetic variants in PRRC2A are associated with both neuromyelitis optica spectrum disorder and multiple sclerosis in Han Chinese population. <i>Journal of Neurology</i> , 2021, 268, 506-515.	1.8	7
1383	Aquaporin 4 distribution in the brain and its relevance for the radiological appearance of neuromyelitis optica spectrum disease. <i>Journal of Neuroradiology</i> , 2021, 48, 170-175.	0.6	4
1384	Neurological Involvement in Patients With Primary Sjögren's Syndrome. <i>Journal of Clinical Rheumatology</i> , 2021, 27, 50-55.	0.5	10
1385	Identification and temporal trends of patients with neuromyelitis optica spectrum disorder in a US insurance claims database. <i>Journal of Medical Economics</i> , 2021, 24, 581-588.	1.0	2
1386	Spinal Cord Lesions. , 2021, , 839-874.		0
1387	Sleep disorders and the hypothalamus. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2021, 182, 369-385.	1.0	9
1388	Reflections from a NMOSD case with serum AQP4-Ab negativity but CSF positivity: narrative review of how to interpret AQP4-Ab test results. <i>Annals of Translational Medicine</i> , 2021, .	0.7	0
1389	The role and mechanisms of Microglia in Neuromyelitis Optica Spectrum Disorders. <i>International Journal of Medical Sciences</i> , 2021, 18, 3059-3065.	1.1	9
1390	Neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein <sc>IgG</sc> associated disorder: A comprehensive neuro-ophthalmic review. <i>Clinical and Experimental Ophthalmology</i> , 2021, 49, 186-202.	1.3	9
1391	Early age of onset predicts severity of visual impairment in patients with neuromyelitis optica spectrum disorder. <i>Multiple Sclerosis Journal</i> , 2021, 27, 1749-1759.	1.4	4
1392	Sleep Disturbances Associated with Neurological Autoimmunity. <i>Neurotherapeutics</i> , 2021, 18, 181-201.	2.1	11
1393	Physical therapy for a patient with neuromyelitis optica during the acute phase: A case report. <i>SAGE Open Medical Case Reports</i> , 2021, 9, 2050313X2110136.	0.2	0

#	ARTICLE	IF	CITATIONS
1394	HLA genotype-clinical phenotype correlations in multiple sclerosis and neuromyelitis optica spectrum disorders based on Japan MS/NMOSD Biobank data. <i>Scientific Reports</i> , 2021, 11, 607.	1.6	19
1395	Benefits of eculizumab in AQP4+ neuromyelitis optica spectrum disorder: Subgroup analyses of the randomized controlled phase 3 PREVENT trial. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 47, 102641.	0.9	26
1396	Neuromyelitis optica with rapid respiratory failure: a case report. <i>Acute Medicine &amp; Surgery</i> , 2021, 8, e655.	0.5	3
1397	Pathogenesis of autoimmune demyelination: from multiple sclerosis to neuromyelitis optica spectrum disorders and myelin oligodendrocyte glycoprotein antibody-associated disease. <i>Clinical and Translational Immunology</i> , 2021, 10, e1316.	1.7	31
1398	Spectrum of Myelitis in Systemic Lupus Erythematosus: Experience from a Single Tertiary Care Centre over 25 Years. <i>Mediterranean Journal of Rheumatology</i> , 2021, 31, 31.	0.3	3
1399	The aquaporin4-IgG status and how it affects the clinical features and treatment response in NMOSD patients in Egypt. <i>BMC Neurology</i> , 2021, 21, 53.	0.8	4
1400	Epidemiology and clinical features of demyelinating disorders in India. <i>Neurology and Clinical Neuroscience</i> , 2021, 9, 266-273.	0.2	2
1401	Serological Levels of Anti-clathrin Antibodies Are Decreased in Patients With Pseudoexfoliation Glaucoma. <i>Frontiers in Immunology</i> , 2021, 12, 616421.	2.2	4
1402	Long-Term Safety and Efficacy of Eculizumab in Aquaporin-4 IgG-Positive NMOSD. <i>Annals of Neurology</i> , 2021, 89, 1088-1098.	2.8	55
1403	Hiccups, severe vomiting and longitudinally extensive transverse myelitis in a patient with prostatic adenocarcinoma and Aquaporin-4 antibodies. <i>Journal of Neuroimmunology</i> , 2021, 352, 577488.	1.1	5
1404	Anti-aquaporin 4 IgG Is Not Associated With Any Clinical Disease Characteristics in Neuromyelitis Optica Spectrum Disorder. <i>Frontiers in Neurology</i> , 2021, 12, 635419.	1.1	11
1405	Telitacicept Following Plasma Exchange in the Treatment of Subjects With Recurrent NMOSD: Study Protocol for a Single-Center, Single-Arm, Open-Label Study. <i>Frontiers in Neurology</i> , 2021, 12, 596791.	1.1	10
1406	Serum Neurofilament Light and GFAP Are Associated With Disease Severity in Inflammatory Disorders With Aquaporin-4 or Myelin Oligodendrocyte Glycoprotein Antibodies. <i>Frontiers in Immunology</i> , 2021, 12, 647618.	2.2	32
1407	Staging of astrocytopathy and complement activation in neuromyelitis optica spectrum disorders. <i>Brain</i> , 2021, 144, 2401-2415.	3.7	39
1408	Disability Outcomes in the N-MOMentum Trial of Inebilizumab in Neuromyelitis Optica Spectrum Disorder. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2021, 8, .	3.1	20
1410	Recent Advances in Neuromyelitis Optica Spectrum Disorder: Pathogenesis, Mechanisms and Potential Treatments. <i>Current Pharmaceutical Design</i> , 2022, 28, 272-279.	0.9	3
1411	Neuromyelitis Optica Spectrum Disorder Treatment—Current and Future Prospects. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2801.	1.8	13
1412	Intracerebral Hemorrhage in Patients with Neuromyelitis Optica: Case Report with Literature Review for Possible Pathological Association. <i>Case Reports in Neurology</i> , 2021, 13, 157-165.	0.3	0

#	ARTICLE	IF	CITATIONS
1413	Recent advances in the treatment of neuromyelitis optica spectrum disorders. <i>Current Opinion in Rheumatology</i> , 2021, 33, 233-239.	2.0	3
1414	Drug Treatment of Neuromyelitis Optica Spectrum Disorders: Out with the Old, in with the New?. <i>ImmunoTargets and Therapy</i> , 2021, Volume 10, 87-101.	2.7	15
1415	Super-resolving Microscopy in Neuroscience. <i>Chemical Reviews</i> , 2021, 121, 11971-12015.	23.0	40
1416	Extensive Cerebral Cortical Involvement in Aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorder. <i>Journal of Neurosciences in Rural Practice</i> , 2021, 12, 431-434.	0.3	0
1417	Myelin Oligodendrocyte Glycoprotein Antibody-Associated Optic Neuritis: A Review. <i>Journal of Neuro-Ophthalmology</i> , 2021, Publish Ahead of Print, e786-e795.	0.4	0
1418	Differential patterns of parafoveal and peripapillary vessel density in multiple sclerosis and neuromyelitis optica spectrum disorder. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 49, 102780.	0.9	18
1419	Comparison of clinical characteristics and prognoses in patients with different AQP4-Ab and MOG-Ab serostatus with neuromyelitis optica spectrum disorders. <i>Journal of Neuroimmunology</i> , 2021, 353, 577494.	1.1	8
1421	Neuropsychiatric involvement in systemic lupus erythematosus: A review. <i>Autoimmunity Reviews</i> , 2021, 20, 102780.	2.5	50
1422	Targeting Neuromyelitis Optica Pathogenesis: Results from Randomized Controlled Trials of Biologics. <i>Neurotherapeutics</i> , 2021, 18, 1623-1636.	2.1	2
1423	The possible role of Interleukin-6 as a regulator of insulin sensitivity in patients with neuromyelitis optica spectrum disorder. <i>BMC Neurology</i> , 2021, 21, 167.	0.8	7
1424	Elucidating distinct clinico-radiologic signatures in the borderland between neuromyelitis optica and multiple sclerosis. <i>Journal of Neurology</i> , 2022, 269, 269-279.	1.8	3
1425	Autoimmune Neurologic Emergencies. <i>Neurologic Clinics</i> , 2021, 39, 589-614.	0.8	0
1426	Toll-Like Receptor Homolog CD180 Expression Is Diminished on Natural Autoantibody-Producing B Cells of Patients with Autoimmune CNS Disorders. <i>Journal of Immunology Research</i> , 2021, 2021, 1-11.	0.9	4
1427	Eculizumab in Asian patients with anti-aquaporin-IgG-positive neuromyelitis optica spectrum disorder: A subgroup analysis from the randomized phase 3 PREVENT trial and its open-label extension. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 50, 102849.	0.9	7
1428	Neuromyelitis optica spectrum disorder as a paraneoplastic syndrome: a rare and challenging diagnosis. <i>BMJ Case Reports</i> , 2021, 14, e239389.	0.2	3
1429	Freiburg Neuropathology Case Conference. <i>Clinical Neuroradiology</i> , 2021, 31, 529-535.	1.0	2
1430	Comparative study of AQP4-NMOSD, MOGAD and seronegative NMOSD: a single-center Belgian cohort. <i>Acta Neurologica Belgica</i> , 2022, 122, 135-144.	0.5	11
1431	The prevalence of anti-neurofascin-155 antibodies in patients with neuromyelitis optica spectrum disorders. <i>Clinical and Experimental Immunology</i> , 2021, 206, 1-11.	1.1	5

#	ARTICLE	IF	CITATIONS
1432	A nation-wide survey of Japanese pediatric MOG antibody-associated diseases. <i>Brain and Development</i> , 2021, 43, 705-713.	0.6	7
1433	The immune regulatory effects of tetrahedral framework nucleic acid on human T cells via the mitogen-activated protein kinase pathway. <i>Cell Proliferation</i> , 2021, 54, e13084.	2.4	8
1434	Evaluation of Month of Birth in Neuromyelitis Optica Spectrum Disorders (NMSOD) and Multiple Sclerosis (MS). <i>Multiple Sclerosis International</i> , 2021, 2021, 1-7.	0.4	1
1435	Rehabilitation and pharmacotherapy of neuromyelitis optica spectrum disorder: A case report. <i>World Journal of Clinical Cases</i> , 2021, 9, 3951-3959.	0.3	1
1436	Rheumatoid arthritis with aquaporin-4 antibody-positive neuromyelitis optica receiving rituximab therapy. <i>Archives of Rheumatology</i> , 0, , .	0.3	0
1437	Recent advances on optic nerve magnetic resonance imaging and post-processing. <i>Magnetic Resonance Imaging</i> , 2021, 79, 76-84.	1.0	18
1438	The relationship between anti-Ro autoantibody positivity and the frequency of neurological involvement in Sjögren's syndrome. <i>Cumhuriyet Medical Journal</i> , 0, , .	0.1	0
1439	Serum neurofilament light chain and glial fibrillary acidic protein in AQP4- IgG-seropositive neuromyelitis optica spectrum disorders and multiple sclerosis: A cohort study. <i>Journal of Neurochemistry</i> , 2021, 159, 913-922.	2.1	11
1440	Quantitative Magnetic Resonance Imaging Analysis of Early Markers of Upper Cervical Cord Atrophy in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder. <i>Multiple Sclerosis International</i> , 2021, 2021, 1-6.	0.4	0
1441	Clinical and neuroimaging findings in MOGAD-MRI and OCT. <i>Clinical and Experimental Immunology</i> , 2021, 206, 266-281.	1.1	24
1442	Cells to the Rescue: Emerging Cell-Based Treatment Approaches for NMOSD and MOGAD. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7925.	1.8	4
1443	Epstein-Barr virus infection in a woman with aquaporin-4 seropositive neuromyelitis optica. <i>Journal of Neuroimmunology</i> , 2021, 356, 577581.	1.1	2
1444	Establishing a second-generation artificial intelligence-based system for improving diagnosis, treatment, and monitoring of patients with rare diseases. <i>European Journal of Human Genetics</i> , 2021, 29, 1485-1490.	1.4	42
1445	Monoclonal Antibody Therapy in Neuromyelitis Optica Spectrum Disorders: a Meta-analysis of Randomized Control Trials. <i>Frontiers in Pharmacology</i> , 2021, 12, 652759.	1.6	7
1446	Modified models to distinguish central nervous system demyelinating diseases with brain lesions. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 52, 102965.	0.9	1
1447	Magnetic resonance imaging in neuromyelitis optica spectrum disorder. <i>Clinical and Experimental Immunology</i> , 2021, 206, 251-265.	1.1	14
1448	Effects of Tocilizumab Therapy on Circulating B Cells and T Helper Cells in Patients With Neuromyelitis Optica Spectrum Disorder. <i>Frontiers in Immunology</i> , 2021, 12, 703931.	2.2	7
1449	Contemporary views on disorders of neuromyelitis optica spectrum. Clinical case from personal practice. <i>Ukrains Kyi Visnyk Psykhonevrolohii</i> , 2021, , 90-94.	0.0	0

#	ARTICLE	IF	CITATIONS
1450	Multi-Level Analyses of Genome-Wide Association Study to Reveal Significant Risk Genes and Pathways in Neuromyelitis Optica Spectrum Disorder. <i>Frontiers in Genetics</i> , 2021, 12, 690537.	1.1	7
1451	Immune reconstitution therapy in NMO. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 52, 102971.	0.9	3
1452	Incidence and prevalence of neuromyelitis optica spectrum disorders in Slovakia. <i>Neurological Research</i> , 2022, 44, 38-46.	0.6	3
1453	Disorders of vision in multiple sclerosis. <i>Australasian journal of optometry, The</i> , 2022, 105, 3-12.	0.6	7
1454	Anti-AQP4 autoantibodies promote ATP release from astrocytes and induce mechanical pain in rats. <i>Journal of Neuroinflammation</i> , 2021, 18, 181.	3.1	28
1455	Explaining the individual challenges of women affected by neuromyelitis optica and multiple sclerosis: A comparative content analysis Study. <i>Clinical Neurology and Neurosurgery</i> , 2021, 207, 106789.	0.6	0
1456	Comparative analysis of clinical and imaging data between patients with myelin oligodendrocyte glycoprotein antibody disease and patients with aquaporin 4 antibody-positive neuromyelitis optica spectrum disorder. <i>Journal of Neurology</i> , 2022, 269, 1641-1650.	1.8	3
1457	Elderly onset neuromyelitis optica spectrum disorder: a case report. <i>Journal of Neurology</i> , 2021, 268, 4897-4898.	1.8	2
1458	At this Junction. <i>Survey of Ophthalmology</i> , 2021, , .	1.7	0
1459	An Eye on Movement Disorders. <i>Movement Disorders Clinical Practice</i> , 2021, 8, 1168-1180.	0.8	3
1460	Longitudinally extensive transverse myelitis in childhood: Clinical features, treatment approaches, and long-term neurological outcomes. <i>Clinical Neurology and Neurosurgery</i> , 2021, 207, 106764.	0.6	1
1461	Mujer con diagnóstico de novo de espectro de neuromielitis óptica con anticuerpos para AQP4 positivo. Un Reporte de Caso. <i>Revista Cuarzo</i> , 2021, 27, 35-44.	0.1	0
1462	Analysis of Predictive Risk Factors in Aquaporin-4-IgG Positive Highly Active Neuromyelitis Optica Spectrum Disorders. <i>Frontiers in Neurology</i> , 2021, 12, 731835.	1.1	5
1463	The costs of care from a US claims database in patients with neuromyelitis optica spectrum disorder. <i>Journal of the Neurological Sciences</i> , 2021, 427, 117553.	0.3	3
1464	Neuromyelitis optica (NMO)-IgG-driven organelle reorganization in human iPSC-derived astrocytes. <i>FASEB Journal</i> , 2021, 35, e21894.	0.2	3
1465	<i>Helicobacter pylori</i> Infection and Extragastric Diseases—A Focus on the Central Nervous System. <i>Cells</i> , 2021, 10, 2191.	1.8	30
1466	Patients with neuromyelitis optica spectrum disorder (NMO) are associated with adverse outcome after total hip arthroplasty: a matched case-control study. <i>Orphanet Journal of Rare Diseases</i> , 2021, 16, 369.	1.2	0
1467	Treatment of Neuromyelitis Optica Spectrum Disorders. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8638.	1.8	29

#	ARTICLE	IF	CITATIONS
1468	Burden and cost of comorbidities in patients with neuromyelitis optica spectrum disorder. <i>Journal of the Neurological Sciences</i> , 2021, 427, 117530.	0.3	6
1469	Relapsing neuromyelitis optica in an adolescent girl. <i>BMJ Case Reports</i> , 2021, 14, e242402.	0.2	0
1470	Type I interferon detection in autoimmune diseases: challenges and clinical applications. <i>Expert Review of Clinical Immunology</i> , 2021, 17, 883-903.	1.3	6
1471	A pilot trial of autologous hematopoietic stem cell transplant in neuromyelitis optic spectrum disorder. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 53, 102990.	0.9	13
1472	The occurrence of myelin oligodendrocyte glycoprotein antibodies in aquaporin-4-antibody seronegative Neuromyelitis Optica Spectrum Disorder: A systematic review and meta-analysis. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 53, 103030.	0.9	12
1473	Distinct patterns of MRI lesions in MOG antibody disease and AQP4 NMOSD: a systematic review and meta-analysis. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 54, 103118.	0.9	5
1474	Neuromyelitis optica spectrum disorder with active replication of hepatitis B virus and seropositive anti-aquaporin-4 antibody. <i>Medicine (United States)</i> , 2021, 100, e27207.	0.4	2
1475	Eculizumab monotherapy for NMOSD: Data from PREVENT and its open-label extension. <i>Multiple Sclerosis Journal</i> , 2022, 28, 480-486.	1.4	32
1476	Patient-reported burden of symptoms in neuromyelitis optica: A secondary analysis on pain and quality of life. <i>Journal of the Neurological Sciences</i> , 2021, 428, 117546.	0.3	6
1477	Diagnostic Imaging Approach to Pediatric Myelopathy. <i>Advances in Clinical Radiology</i> , 2021, 3, 265-274.	0.1	0
1478	AQP4-IgG positive paraneoplastic NMOSD: A case report and review. <i>Brain and Behavior</i> , 2021, 11, e2282.	1.0	9
1479	A preliminary study of association of cigarette smoking with risk of neuromyelitis optica spectrum disorder. <i>Medicine (United States)</i> , 2021, 100, e27234.	0.4	2
1480	EBI2-expressing B cells in neuromyelitis optica spectrum disorder with AQP4-IgG: Association with acute attacks and serum cytokines. <i>Journal of Neuroimmunology</i> , 2021, 358, 577637.	1.1	1
1481	Etiological and Radiological Spectrum of Longitudinal Myelitis: A Hospital-Based Study in North East India. <i>Journal of Neurosciences in Rural Practice</i> , 2021, 12, 739-744.	0.3	4
1482	Neuromyelitis optica spectrum disorders: from pathophysiology to therapeutic strategies. <i>Journal of Neuroinflammation</i> , 2021, 18, 208.	3.1	105
1483	MRI Patterns Distinguish AQP4 Antibody Positive Neuromyelitis Optica Spectrum Disorder From Multiple Sclerosis. <i>Frontiers in Neurology</i> , 2021, 12, 722237.	1.1	8
1484	Simultaneous new onset of neuromyelitis optica spectrum disorder in identical twins. <i>BMJ Neurology Open</i> , 2021, 3, e000174.	0.7	1
1485	Excess weight, central adiposity and pro-inflammatory diet consumption in patients with neuromyelitis optica spectrum disorder. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 54, 103110.	0.9	7



#	ARTICLE	IF	CITATIONS
1486	Multi-parametric MRI phenotype with trustworthy machine learning for differentiating CNS demyelinating diseases. <i>Journal of Translational Medicine</i> , 2021, 19, 377.	1.8	6
1487	Retinal optical coherence tomography and magnetic resonance imaging in neuromyelitis optica spectrum disorders and MOG-antibody associated disorders: an updated review. <i>Expert Review of Neurotherapeutics</i> , 2021, 21, 1101-1123.	1.4	7
1488	Neuromyelitis optica with brain stem involvement in a middle-aged Ethiopian woman: a case report and review of literature. <i>Journal of Medical Case Reports</i> , 2021, 15, 489.	0.4	0
1489	Progressive brain microstructural damage in patients with multiple sclerosis but not in patients with neuromyelitis optica spectrum disorder: A cross-sectional and follow-up tract-based spatial statistics study. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 55, 103178.	0.9	6
1490	Are Zika virus cross-reactive antibodies against aquaporin-4 associated to Neuromyelitis Optica Spectrum Disorder?. <i>Journal of Neuroimmunology</i> , 2021, 360, 577697.	1.1	1
1491	Evidence for and against subclinical disease activity and progressive disease in MOG antibody disease and neuromyelitis optica spectrum disorder. <i>Journal of Neuroimmunology</i> , 2021, 360, 577702.	1.1	13
1492	Neuromyelitis optica spectrum disorder (NMOSD) associated with cancer: A systematic review. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 56, 103227.	0.9	20
1493	Optic neuritis in Asian type opticospinal multiple sclerosis (OSMS-ON) in a non-Asian population: A functional-structural paradox. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 56, 103260.	0.9	2
1494	Pruritus as an initial symptom of neuromyelitis optica spectrum disorder. A peruvian case report. <i>Neuroimmunology Reports</i> , 2021, 1, 100021.	0.2	0
1496	Retinal glia. , 2022, , 51-66.		0
1497	Clinical Approach to Autoimmune and Inflammatory Ophthalmologic Disease. , 2021, , 447-467.		0
1498	A window into the future? MRI for evaluation of neuromyelitis optica spectrum disorder throughout the disease course. <i>Therapeutic Advances in Neurological Disorders</i> , 2021, 14, 175628642110143.	1.5	16
1500	Paraneoplastic Neuromyelitis Optica Spectrum Disorder Associated with Atypical Thymic Carcinoid: A Case Report. <i>Annals of Thoracic and Cardiovascular Surgery</i> , 2022, 28, 362-365.	0.3	2
1501	Neuromyelitis optica, aquaporin-4 antibodies, and neuroendocrine disorders. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2021, 181, 173-186.	1.0	4
1502	Research Progress on the Relationship between Vascular Endothelial Growth Factor (VEGF) and Nervous System Diseases. <i>Advances in Clinical Medicine</i> , 2021, 11, 821-825.	0.0	0
1503	Neuromyelitis optica is an HLA associated disease different from Multiple Sclerosis: a systematic review with meta-analysis. <i>Scientific Reports</i> , 2021, 11, 152.	1.6	18
1504	Neuroinflammatory and Demyelinating Disorders of Childhood. , 2020, , 651-677.		4
1505	Anatomy, Imaging, and Pathology of the Visual Pathways. , 2011, , 855-924.		1

#	ARTICLE	IF	CITATIONS
1506	The HLA DRB1*03:01 allele is associated with NMO regardless of the NMO-IgG status in Brazilian patients from Rio de Janeiro. <i>Journal of Neuroimmunology</i> , 2017, 310, 1-7.	1.1	22
1507	Neuromyelitis optica spectrum disorders with antibodies to myelin oligodendrocyte glycoprotein or aquaporin-4: Clinical and paraclinical characteristics in Algerian patients. <i>Journal of the Neurological Sciences</i> , 2017, 381, 240-244.	0.3	29
1508	Beneficial effects of intravenous immunoglobulin as an add-on therapy to azathioprine for NMO-IgG-seropositive neuromyelitis optica spectrum disorders. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 42, 102109.	0.9	8
1511	Syndrome of inappropriate antidiuretic hormone accompanied by bilateral hypothalamic and anterior thalamic lesions with serum antiaquaporin 4 antibody. <i>BMJ Case Reports</i> , 2017, 2017, bcr-2017-219721.	0.2	8
1512	Diagnosis of longitudinally extensive transverse myelitis. <i>BMJ Case Reports</i> , 2011, 2011, bcr1020103444-bcr1020103444.	0.2	10
1513	Microglia complement astrocytes in neuromyelitis optica. <i>Journal of Clinical Investigation</i> , 2020, 130, 3961-3964.	3.9	7
1514	Eosinophil pathogenicity mechanisms and therapeutics in neuromyelitis optica. <i>Journal of Clinical Investigation</i> , 2013, 123, 2306-2316.	3.9	111
1515	Immune-Mediated Myelopathies. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2018, 24, 497-522.	0.4	6
1516	Diagnosis, Differential Diagnosis, and Misdiagnosis of Multiple Sclerosis. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2019, 25, 611-635.	0.4	15
1517	Distribution of Aquaporins 1 and 4 in the Central Nervous System. <i>Current Health Sciences Journal</i> , 2019, 45, 218-226.	0.2	5
1518	Genetic and Infectious Profiles of Japanese Multiple Sclerosis Patients. <i>PLoS ONE</i> , 2012, 7, e48592.	1.1	65
1519	Altered Topological Organization of White Matter Structural Networks in Patients with Neuromyelitis Optica. <i>PLoS ONE</i> , 2012, 7, e48846.	1.1	37
1520	Incidence and Prevalence of Major Central Nervous System Involvement in Systemic Lupus Erythematosus: A 3-Year Prospective Study of 370 Patients. <i>PLoS ONE</i> , 2013, 8, e55843.	1.1	83
1521	Connexin 43 Astrocytopathy Linked to Rapidly Progressive Multiple Sclerosis and Neuromyelitis Optica. <i>PLoS ONE</i> , 2013, 8, e72919.	1.1	89
1522	A Longitudinal Brain Magnetic Resonance Imaging Study of Neuromyelitis Optica Spectrum Disorder. <i>PLoS ONE</i> , 2014, 9, e108320.	1.1	32
1523	Structural Alterations of Segmented Macular Inner Layers in Aquaporin4-Antibody-Positive Optic Neuritis Patients in a Chinese Population. <i>PLoS ONE</i> , 2016, 11, e0157645.	1.1	16
1524	Accuracy of the Fluorescence-Activated Cell Sorting Assay for the Aquaporin-4 Antibody (AQP4-Ab): Comparison with the Commercial AQP4-Ab Assay Kit. <i>PLoS ONE</i> , 2016, 11, e0162900.	1.1	12
1525	Impact of the anti-aquaporin-4 autoantibody on inner retinal structure, function and structure-function associations in Japanese patients with optic neuritis. <i>PLoS ONE</i> , 2017, 12, e0171880.	1.1	8

#	ARTICLE	IF	CITATIONS
1526	Metabolomic profiling of CSF in multiple sclerosis and neuromyelitis optica spectrum disorder by nuclear magnetic resonance. <i>PLoS ONE</i> , 2017, 12, e0181758.	1.1	50
1531	Macular changes of neuromyelitis optica through spectral-domain optical coherence tomography. <i>International Journal of Ophthalmology</i> , 2016, 9, 1638-1645.	0.5	8
1532	Anti-IL-6 Therapies for Neuromyelitis Optica Spectrum Disorders: A Systematic Review of Safety and Efficacy. <i>Current Neuropharmacology</i> , 2020, 19, 220-232.	1.4	24
1533	Syndrome of inappropriate antidiuretic hormone secretion associated with seronegative neuromyelitis optica spectrum disorder. <i>Kidney Research and Clinical Practice</i> , 2017, 36, 100-104.	0.9	13
1534	Immunization of mice with a peptide derived from the HTLV-1 TAX1BP1 protein induces cross-reactive antibodies against aquaporin 4. <i>Autoimmunity</i> , 2015, 48, 453-9.	1.2	6
1536	Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease: Current Insights into the Disease Pathophysiology, Diagnosis and Management. <i>International Journal of Molecular Sciences</i> , 2021, 22, 100.	1.8	74
1537	A diagnostic challenge in a young woman with intractable hiccups and vomiting: a case of neuromyelitis optica. <i>Journal of Community Hospital Internal Medicine Perspectives</i> , 2015, 5, 28850.	0.4	7
1538	Neuromielitis Óptica (enfermedad de Devic). <i>Acta Medica Colombiana: AMC: Organo De La Asociacion Colombiana De Medicina Interna</i> , 2010, 35, 21-25.	0.0	3
1539	Magnetic resonance imaging of optic nerve. <i>Indian Journal of Radiology and Imaging</i> , 2015, 25, 421-438.	0.3	48
1540	Neuromyelitis optica spectrum disorders: An update. <i>Annals of Indian Academy of Neurology</i> , 2015, 18, 11.	0.2	20
1541	Systematic imaging review: Multiple Sclerosis. <i>Annals of Indian Academy of Neurology</i> , 2015, 18, 24.	0.2	20
1542	Acquired demyelinating disorders of central nervous system: A pediatric cohort. <i>Annals of Indian Academy of Neurology</i> , 2015, 18, 48.	0.2	9
1543	"Person in the barrel" syndrome: Unusual heralding presentation of squamous cell carcinoma of the lung. <i>Annals of Indian Academy of Neurology</i> , 2016, 19, 152.	0.2	3
1544	Serological markers associated with neuromyelitis optica spectrum disorders in South India. <i>Annals of Indian Academy of Neurology</i> , 2016, 19, 505.	0.2	24
1545	Higher frequency of brain abnormalities in neuromyelitis optica spectrum disorder patients without primary Sjögren's syndrome. <i>Neural Regeneration Research</i> , 2016, 11, 1633.	1.6	4
1546	Association of GTF2IRD1 and GTF2I polymorphisms with neuromyelitis optica spectrum disorders in Han Chinese patients. <i>Neural Regeneration Research</i> , 2019, 14, 346.	1.6	6
1547	Relapsing Devic's disease in a child. <i>Journal of Pediatric Neurosciences</i> , 2013, 8, 146.	0.2	4
1548	Diagnostic modalities in multiple sclerosis: Perspectives in children. <i>Biomedical Journal</i> , 2014, 37, 50.	1.4	11

#	ARTICLE	IF	CITATIONS
1549	Plasma exchange as a first line therapy in acute attacks of neuromyelitis optica spectrum disorders. <i>Annals of Indian Academy of Neurology</i> , 2019, 22, 389.	0.2	24
1550	Symptomatic narcolepsy as a presenting feature of neuromyelitis optica. <i>Annals of Indian Academy of Neurology</i> , 2018, 21, 156.	0.2	9
1551	Association between sun exposure, Vitamin D intake, serum Vitamin D level, and immunoglobulin G level in patients with neuromyelitis optica spectrum disorder. <i>International Journal of Preventive Medicine</i> , 2018, 9, 68.	0.2	8
1552	Comprehensive review of neuromyelitis optica and clinical characteristics of neuromyelitis optica patients in Puerto Rico. , 2018, 9, 242.		16
1553	IL-21 and Related Diseases. <i>Journal of Clinical &amp; Cellular Immunology</i> , 2011, , .	1.5	3
1554	Autoimmune Aquaporin-4 Channelopathy Presented with Psychiatric Symptoms: A Case Report. <i>Neuropsychiatry</i> , 2018, 08, .	0.4	2
1555	Optic Nerve and Spinal Cord Are the Major Lesions in Each Relapse of Japanese Multiple Sclerosis. <i>ISRN Neurology</i> , 2011, 2011, 1-4.	1.5	2
1557	Unrecognized neuromyelitis optica spectrum disorder with pontine and corpus callosum microhemorrhage. <i>Vojnosanitetski Pregled</i> , 2022, 79, 1270-1273.	0.1	0
1558	Next Generation Sequencing of Cerebrospinal Fluid B Cell Repertoires in Multiple Sclerosis and Other Neuro-Inflammatory Diseases—A Comprehensive Review. <i>Diagnostics</i> , 2021, 11, 1871.	1.3	2
1561	Group 2 innate lymphoid cells suppress the pathology of neuromyelitis optica spectrum disorder. <i>FASEB Journal</i> , 2021, 35, e21856.	0.2	3
1562	Early Initiation of Tocilizumab Treatment Against Moderate-to-Severe Myelitis in Neuromyelitis Optica Spectrum Disorder. <i>Frontiers in Immunology</i> , 2021, 12, 660230.	2.2	10
1563	Low Frequency Ultrasound With Injection of NMO-IgG and Complement Produces Lesions Different From Experimental Autoimmune Encephalomyelitis Mice. <i>Frontiers in Immunology</i> , 2021, 12, 727750.	2.2	1
1564	Age at onset predicts outcome in aquaporin-4-IgG positive neuromyelitis optica spectrum disorder from a United Kingdom population. <i>Journal of the Neurological Sciences</i> , 2021, 431, 120039.	0.3	5
1565	Clinicoradiological comparative study of Aquaporin-4-IgG seropositive neuromyelitis optica spectrum disorder (NMO) and MOG antibody associated disease (MOGAD): A prospective observational study and review of literature. <i>Journal of Neuroimmunology</i> , 2021, 361, 577742.	1.1	8
1566	Uncommon inflammatory/immune-related myelopathies. <i>Journal of Neuroimmunology</i> , 2021, 361, 577750.	1.1	4
1567	Disseminated Encephalomyelitis and Multiple Sclerosis Differentiation. <i>Pediatric Neurology Briefs</i> , 2007, 21, 68.	0.2	0
1569	Aquaporins in the Brain. , 2009, , 391-404.		0
1571	Commentary: Neurological perspective. <i>BMJ: British Medical Journal</i> , 2009, 339, b5250-b5250.	2.4	0

#	ARTICLE	IF	CITATIONS
1572	NMO-IgG detected in CSF in seronegative neuromyelitis optica. Yearbook of Neurology and Neurosurgery, 2010, 2010, 146.	0.0	0
1577	Relevance of Autoantibodies for the Classification and Pathogenesis of Neurological Diseases. , 0, , .		0
1578	Multiple Sklerose und verwandte Erkrankungen. , 2012, , 353-363.		0
1581	Infektionen. , 2012, , 483-550.		0
1582	Therapeutic apheresis for neuromyelitis optica and neuromyelitis optica spectrum disorders. Nihon Toseki Igakkai Zasshi, 2012, 45, 413-419.	0.2	2
1584	Two cases of lymphoepithelial cyst of the pancreas. Okayama Igakkai Zasshi, 2012, 124, 53-57.	0.0	0
1585	Visual Loss. , 2012, , 164-169.		0
1586	What Is Disease Progression?. , 2013, , 11-30.		0
1591	Diversity of Neuromyelitis Optica: Inner City Hospital Experience and Review of Literature. Journal of Neurology & Neurophysiology, 2014, 05, .	0.1	0
1592	Neuromyelitis Optica Spectrum Disorders, Immunology of. , 2014, , 428-432.		0
1593	The Physiological Functions of Aquaporins. Biophysics, 2014, 02, 19-32.	0.2	1
1596	Longitudinal Ekstensif Transvers Miyelit: Olgu Sunumu. Sisli Etfal Hastanesi Tip Bulteni, 2014, , 146-9.	0.1	0
1597	Neuromielitis Óptica en el embarazo: reporte de un caso. Revista Universitas Medica, 2016, 55, 456-465.	0.0	0
1598	Neuromyelitis optica spectrum disorder and Sjögren syndrome are overlapping disorders and participate in the same autoimmunity context?. Arquivos De Neuro-Psiquiatria, 2014, 72, 577-579.	0.3	2
1599	Myelin Disorders: Devic's Syndrome. , 2015, , 153-156.		0
1600	Autoimmunerkrankungen. , 2015, , 577-607.		0
1601	Infectious and Inflammatory Diseases of the Spine in Children. , 2015, , 1-55.		0
1603	Infektionen. , 2015, , 505-575.		0

#	ARTICLE	IF	CITATIONS
1604	Chronic Noninfectious Inflammatory CNS Diseases. , 2015, , 277-291.		0
1605	Neuromyelitis Optica. , 2015, , 656-659.		0
1606	Immunohistochemistry. , 2015, , 143-158.		1
1607	A Case of Neuromyelitis Optica Spectrum Disorder Aggravated after Varicella Zoster Infection. Journal of the Korean Child Neurology Society, 2015, 23, 67-70.	0.0	0
1608	Clinical Use of OCT and MSON Mimics. , 2016, , 59-83.		0
1609	Neuromyelitis Optica. , 2016, , 192.		0
1610	Bloodâ€“Brain Barrier and Bloodâ€“Nerve Barrier. , 2016, , 55-69.		1
1611	Becoming blind in one eye. , 2016, , 1-10.		0
1612	Optic Neuritis in Children. , 2016, , 427-438.		0
1613	Neuromyelitis Optica: Diagnosis and Treatment. , 2016, , 135-152.		0
1614	Roles of plasmablasts in IgG4-related disease and various immune-based diseases. World Journal of Rheumatology, 2016, 6, 16.	0.5	0
1615	Neuromyelitis Optica (Devicâ€™s Disease): A New Concept for an Old Disease. , 2016, , 351-359.		0
1616	Neuromyelitis optica (Devic's disease) - a rare demyelinating disease. Medicina Pro Praxi, 2016, 13, 43-46.	0.0	0
1617	Neuromyelitis Optica Spectrum Disorder Presented with Acute Memory Loss. Journal of the Korean Neurological Association, 2016, 34, 213-216.	0.0	0
1619	Differential Diagnosis between Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder. Journal of the Korean Neurological Association, 2016, 34, 290-296.	0.0	4
1621	Infectious, Autoimmune and Other Immune-Mediated Causes of Myelitis. , 2017, , 123-160.		1
1622	Successful treatment of neuromyelitis optica spectrum disorder combined with bilateral optic neuritis via plasma exchange. Nihon Toseki Igakkai Zasshi, 2017, 50, 555-559.	0.2	1
1623	Immunopathological Effects of Aquaporin-4 Ig G in Neuromyelitis Optica Spectrum Disorders. MOJ Immunology, 2017, 5, .	11.0	0

#	ARTICLE	IF	CITATIONS
1624	Narcolepsy Followed by Intractable Vomiting Caused by Recurrent Brain Involvement in Neuromyelitis Optica Spectrum Disorder. <i>Journal of the Korean Neurological Association</i> , 2017, 35, 215-218.	0.0	0
1625	General Introduction: What Is Progressive Multiple Sclerosis?. , 2018, , 1-29.		0
1626	Troubles visuels de cause non ophtalmologique. , 2018, , 193-214.e8.		0
1627	Successful treatment of steroid-resistant anti-aquaporin 4 antibody-positive optic neuritis with double-filtration plasmapheresis: a case report. <i>Nihon Toseki Igakkai Zasshi</i> , 2018, 51, 379-385.	0.2	0
1628	Diagnostic Dilemmas. , 2019, , 473-532.		0
1629	NEUROMYELITIS OPTICA SPECTRUM DISORDERS: DIAGNOSIS AND TREATMENT, THE EXPERIENCE OF CLINICAL OBSERVATIONS. <i>Učenyje Zapiski Sankt-Peterburgskogo Gosudarstvennogo Medicinskogo Universiteta Im Akad I P Pavlova</i> , 2018, 25, 7-13.	0.0	2
1630	Neuromyelitis Optica Spectrum Disorder. <i>Contemporary Clinical Neuroscience</i> , 2019, , 523-541.	0.3	1
1631	Autoimmune Astrocytopathy. <i>Contemporary Clinical Neuroscience</i> , 2019, , 329-355.	0.3	0
1632	Biomarkers for Multiple Sclerosis. <i>RSC Drug Discovery Series</i> , 2019, , 55-75.	0.2	0
1633	NEUROMYELITIS OPTICA-A RARE CASE. <i>Journal of Evolution of Medical and Dental Sciences</i> , 2019, 8, 653-655.	0.1	0
1635	Comparison of Bladder Dysfunction and Urinary Symptoms Between Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder. <i>Caspian Journal of Neurological Sciences</i> , 2019, 5, 105-110.	0.1	1
1636	Emerging Trends in Optic Neuritis and Associated Demyelinating Diseases. <i>Current Practices in Ophthalmology</i> , 2020, , 1-15.	0.1	0
1637	Neuromyelitis Optica Spectrum Disorders. <i>Current Clinical Neurology</i> , 2020, , 227-234.	0.1	0
1638	The neuromyelitis optica spectrum disorders. <i>Neurologie Pro Praxi</i> , 2019, 20, 368-372.	0.0	0
1639	Neuromyelitis Optica Spectrum Disorders. , 2020, , 67-94.		0
1640	Relapse of Neuromyelitis Optica Spectrum Disorder Presented with Suspected Bacterial Meningomyelitis. <i>Journal of the Korean Neurological Association</i> , 2020, 38, 129-132.	0.0	0
1641	Aquaporin-4-IgG Positive Neuromyelitis Optica Spectrum Disorder from Ethiopia: A Case Report. <i>Ethiopian Journal of Health Sciences</i> , 2020, 30, 847-852.	0.2	1
1643	Astrocytic outer retinal layer thinning is not a feature in AQP4-IgG seropositive neuromyelitis optica spectrum disorders. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, 188-195.	0.9	13

#	ARTICLE	IF	CITATIONS
1644	Hope for patients with neuromyelitis optica spectrum disorders “ from mechanisms to trials. <i>Nature Reviews Neurology</i> , 2021, 17, 759-773.	4.9	57
1645	G-CSF “ A double edge sword in neutrophil mediated immunity. <i>Seminars in Immunology</i> , 2021, 54, 101516.	2.7	37
1646	Population Pharmacokinetic Modeling of Inebilizumab in Subjects with Neuromyelitis Optica Spectrum Disorders, Systemic Sclerosis, or Relapsing Multiple Sclerosis. <i>Clinical Pharmacokinetics</i> , 2022, 61, 387-400.	1.6	7
1647	Spectrum of sublytic astrocytopathy in neuromyelitis optica. <i>Brain</i> , 2022, 145, 1379-1390.	3.7	18
1648	COVID-19 susceptibility and outcomes among patients with neuromyelitis optica spectrum disorder (NMOSD): A systematic review and meta-analysis. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 57, 103359.	0.9	18
1649	Neuromyelitis optica spectrum disorder: an overview. <i>Acta Neurobiologiae Experimentalis</i> , 2020, 80, 256-272.	0.4	4
1650	An Autopsy Confirmed Neuromyelitis Optica Spectrum Disorder with Extensive Brain White Matter Lesion and Optic Neuritis but Intact Spinal Cord, Clinically Mimicking a Secondary Progressive Multiple Sclerosis-like Course. <i>Internal Medicine</i> , 2022, 61, 1415-1422.	0.3	1
1652	Longitudinal treatment responsiveness on plasma neurofilament light chain and glial fibrillary acidic protein levels in neuromyelitis optica spectrum disorder. <i>Therapeutic Advances in Neurological Disorders</i> , 2021, 14, 175628642110549.	1.5	15
1653	Neuromyelitis optica spectrum disorders in the Arabian Gulf: challenges and growing experience. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2020, 6, 205521731985019.	0.5	1
1656	Multiple Sklerose und andere Autoimmunerkrankungen. , 2020, , 431-440.		0
1657	A review of chronic relapsing inflammatory optic neuropathy. <i>Apollo Medicine</i> , 2020, 17, 256.	0.0	1
1658	Strategies of Virtual Screening in Medicinal Chemistry. , 2020, , 194-225.		1
1659	Demyelinating disorders of the central nervous system. , 2020, , 6026-6042.		0
1660	Serum Aquaporin 4-Immunoglobulin G Titer and Neuromyelitis Optica Spectrum Disorder Activity and Severity: A Systematic Review and Meta-Analysis. <i>Frontiers in Neurology</i> , 2021, 12, 746959.	1.1	10
1661	Pruritus in neuromyelitis optica spectrum disorders and multiple sclerosis. <i>Journal of Clinical Neuroscience</i> , 2020, 79, 108-112.	0.8	3
1662	Efficacy and safety of rituximab in patients with refractory neuromyelitis optica spectrum disorders: A prospective observation in Iranian cases. <i>Caspian Journal of Internal Medicine</i> , 2020, 11, 155-162.	0.1	4
1663	Anti-aquaporin-4 IgG in Patients Presenting with Unilateral Optic Neuritis: A Cohort Study. <i>International Journal of Preventive Medicine</i> , 2012, 3, 612-5.	0.2	7
1664	Elevation of AQP4 and selective cytokines in experimental autoimmune encephalitis mice provides some potential biomarkers in optic neuritis and demyelinating diseases. <i>International Journal of Clinical and Experimental Pathology</i> , 2015, 8, 15749-58.	0.5	4



#	ARTICLE	IF	CITATIONS
1665	A descriptive study of prevalence, clinical features and other findings of neuromyelitis optica and neuromyelitis optica spectrum disorder in Khuzestan Province, Iran. Iranian Journal of Neurology, 2015, 14, 204-10.	0.5	17
1666	Devic's syndrome in aquaporin-4 antibody negative patient. What we need to know â€¦. GMS Ophthalmology Cases, 2014, 4, Doc09.	0.1	0
1667	T cells targeting neuromyelitis optica autoantigen aquaporin-4 cause paralysis and visual system injury. Journal of Nature and Science, 2017, 3, .	1.1	6
1668	Pathobiology, Diagnosis, and Current Biomarkers in Neuromyelitis Optica Spectrum Disorders. journal of applied laboratory medicine, The, 2022, 7, 305-310.	0.6	5
1669	Diagnosis and Management of Central Nervous System Demyelinating Disorders. Neurologic Clinics, 2022, 40, 113-131.	0.8	4
1670	Visual Evoked Potentials in Neuromyelitis Optica Spectrum Disorders. Journal of Central Nervous System Disease, 2021, 13, 117957352110573.	0.7	1
1671	Dysregulated B cell differentiation towards antibody-secreting cells in neuromyelitis optica spectrum disorder. Journal of Neuroinflammation, 2022, 19, 6.	3.1	12
1672	Comparative Study of Brain fMRI of Olfactory Stimulation in Neuromyelitis Optica Spectrum Disease and Multiple Sclerosis. Frontiers in Neuroscience, 2021, 15, 813157.	1.4	2
1673	Multidisciplinary Rehabilitation of a Patient With Neuromyelitis Optica. Function and Disability Journal, 2020, 3, 69-76.	0.2	0
1675	Antibodies to Neural Cell Surface Antigens. , 2022, , 135-166.		1
1676	Sociodemographic and Illness-Related Indicators to Predict the Status of Neuromyelitis Optica Spectrum Disorder (NMOSD) Five Years after Disease Onset. Journal of Clinical Medicine, 2022, 11, 734.	1.0	1
1677	Paraneoplastic Neuromyelitis Optica Spectrum Disorder Associated With Lung Adenocarcinoma: A Case Report. Frontiers in Medicine, 2021, 8, 743798.	1.2	4
1678	Social participation and quality of life among patients with neuromyelitis optica spectrum disorders: The mediating effects of depression. Multiple Sclerosis and Related Disorders, 2022, 57, 103445.	0.9	8
1679	Neuromyelitis Optica Spectrum Disorders and Glial Fibrillary Acidic Protein Autoimmunity. , 2022, , 315-341.		0
1680	Optic Neuritis: Hidden Manifestations and Mimickers. Open Journal of Ophthalmology, 2022, 12, 1-15.	0.1	0
1681	Serum molecular biomarkers in neuromyelitis optica and multiple sclerosis. Multiple Sclerosis and Related Disorders, 2022, 59, 103527.	0.9	3
1682	Anti-aquaporin-4 immunoglobulin G colorimetric detection by silver nanoparticles. Nanomedicine: Nanotechnology, Biology, and Medicine, 2022, 41, 102531.	1.7	2
1683	To treat or not to treat? A case of remote asynchronous bilateral optic neuritis with aquaporin-4 IgG seropositivity. Neuroimmunology Reports, 2022, 2, 100069.	0.2	0

#	ARTICLE	IF	CITATIONS
1684	IL-6 Revisited: From Rheumatoid Arthritis to CAR T Cell Therapy and COVID-19. Annual Review of Immunology, 2022, 40, 323-348.	9.5	50
1685	Incidence and risk factors for venous thromboembolism during an acute attack in patients with neuromyelitis optica spectrum disorders. Multiple Sclerosis and Related Disorders, 2022, 58, 103513.	0.9	2
1686	Lower motor neuron involvement in patients with neuromyelitis optica spectrum disorders. Multiple Sclerosis and Related Disorders, 2022, 59, 103544.	0.9	0
1687	CLINICAL CASE OF NEUROMYELITIS OPTICA SPECTRUM DISORDERS IN YOUNG WOMAN TREATED WITH RITUXIMAB. Wiadomości Lekarskie, 2022, 75, 132-137.	0.1	1
1688	Neuromyelitis Optica Spectrum Disorder Associated with Cryptogenic Organizing Pneumonia in a Young Patient. European Journal of Case Reports in Internal Medicine, 2022, 9, 003105.	0.2	0
1690	A Case of Neuromyelitis Optica: Puerto Rican Woman with an Increased Time Lag to Diagnosis and a High Response to Eculizumab Therapy. Case Reports in Neurological Medicine, 2022, 2022, 1-5.	0.3	0
1691	<sc>RGMa</sc> Signal in Macrophages Induces Neutrophil-Related Astrocytopathy in <sc>NMO</sc>. Annals of Neurology, 2022, 91, 532-547.	2.8	7
1692	Neuromyelitis Optica Spectrum Disorder in Central America and the Caribbean: A Multinational Clinical Characterization Study. Neurology International, 2022, 14, 284-293.	1.3	5
1693	Clinical and prognostic aspects of patients with the Neuromyelitis Optica Spectrum Disorder (NMOSD) from a cohort in Northeast Brazil. BMC Neurology, 2022, 22, 95.	0.8	4
1694	Monoclonal Antibody Therapies Beyond Complement for NMOSD and MOGAD. Neurotherapeutics, 2022, 19, 808-822.	2.1	14
1695	Neuromyelitis Optica Spectrum Disorders (NMOSD). Current Treatment Options in Neurology, 0, , 1.	0.7	1
1696	Immunopathology of Tumefactive Demyelinating Lesions-From Idiopathic to Drug-Related Cases. Frontiers in Neurology, 2022, 13, 868525.	1.1	9
1697	Multimodal magnetic resonance imaging quantification of gray matter alterations in relapsing-remitting multiple sclerosis and neuromyelitis optica spectrum disorder. Journal of Neuroscience Research, 2022, 100, 1395-1412.	1.3	3
1698	Towards imaging criteria that best differentiate MS from NMOSD and MOGAD: large multi-ethnic population and different clinical scenarios. Multiple Sclerosis and Related Disorders, 2022, 61, 103778.	0.9	5
1699	Experiences of social isolation among patients with neuromyelitis optica spectrum disorder in China: A qualitative study. Multiple Sclerosis and Related Disorders, 2022, 60, 103711.	0.9	1
1700	Opticneuromyelitis associated with melanoma. Case report. Consilium Medicum, 2021, 23, 884-890.	0.1	0
1701	Can Immune Tolerance Be Re-established in Neuromyelitis Optica?. Frontiers in Neurology, 2021, 12, 783304.	1.1	2
1702	Predominant Myofibrillar Pathology with Preserved Sarcolemmal Aquaporin 4 Immunoreactivity in a Patient with Neuromyelitis Optica-Associated HyperCKemia. Kosin Medical Journal, 2021, 36, 206-210.	0.1	0

#	ARTICLE	IF	CITATIONS
1703	Lymphocyte Subsets Are Associated with Disease Status in Neuromyelitis Optica Spectrum Disorders. <i>NeuroImmunoModulation</i> , 2022, 29, 296-305.	0.9	2
1704	Wernicke Encephalopathy as the First Presentation of Neuromyelitis Optica Spectrum Disorder With Horizontal Nerve Palsy. <i>Journal of Neuro-Ophthalmology</i> , 2023, 43, e293-e295.	0.4	1
1705	Quantitative Susceptibility Mapping-Derived Radiomic Features in Discriminating Multiple Sclerosis From Neuromyelitis Optica Spectrum Disorder. <i>Frontiers in Neuroscience</i> , 2021, 15, 765634.	1.4	3
1706	Prof. Ren ZHANG's experience in acupuncture for neuromyelitis optica spectrum disorders. <i>Journal of Acupuncture-moxibustion</i> , 2021, , .	0.1	1
1708	Fractional anisotropy helps to differentiate the optic nerve impairment between neuromyelitis optica spectrum disorders and multiple sclerosis. <i>European Radiology</i> , 2022, , 1.	2.3	3
1709	Relatively Early and Late-Onset Neuromyelitis Optica Spectrum Disorder in Central China: Clinical Characteristics and Prognostic Features. <i>Frontiers in Neurology</i> , 2022, 13, 859276.	1.1	2
1710	Pain Symptoms in Optic Neuritis. <i>Frontiers in Pain Research</i> , 2022, 3, 865032.	0.9	4
1722	Infection and neuromyelitis optica spectrum disorders. <i>Journal of Central South University (Medical)</i> Tj ETQq1 1 0.784314 rgBT /Overlo	0.1	0
1723	Influence Of Pregnancy On Neuromyelitis Optica From An Ophthalmological Point Of View. A Case Report. <i>Ceska A Slovenska Oftalmologie</i> , 2022, 78, 31-34.	0.1	0
1725	Human Umbilical Cord Mesenchymal Stem Cells to Treat Neuromyelitis Optica Spectrum Disorder (hUCMSC-NMOSD): A Study Protocol for a Prospective, Multicenter, Randomized, Placebo-Controlled Clinical Trial. <i>Frontiers in Neurology</i> , 2022, 13, 860083.	1.1	4
1726	Late onset neuromyelitis optica spectrum disorders (LONMOSD) from a nationwide Portuguese study: Anti-AQP4 positive, anti-MOG positive and seronegative subgroups. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 63, 103845.	0.9	3
1727	HLA-genotyping by Next-Generation-Sequencing reveals shared and unique HLA alleles in two patients with coexisting neuromyelitis optica spectrum disorder and thymectomized myasthenia gravis: immunological implications for mutual aetiopathogenesis?. <i>Multiple Sclerosis and Related Disorders</i> , 2022, , 103858.	0.9	2
1728	Seronegative neuromyelitis optica spectrum disorder with longitudinally extending transverse myelitis and optic neuritis: A case report. <i>Annals of Medicine and Surgery</i> , 2022, , 103757.	0.5	0
1729	Therapeutic Plasma Exchange in Neuromyelitis Optica Spectrum Disordersâ€”Experience from Tertiary Care Center in North India. <i>Neurology India</i> , 2022, 70, 710.	0.2	0
1730	Molecular biomarkers in multiple sclerosis. <i>Arhiv Za Farmaciju</i> , 2022, 72, 127-148.	0.2	0
1731	Immuno-pathogenesis of neuromyelitis optica and emerging therapies. <i>Seminars in Immunopathology</i> , 2022, 44, 599-610.	2.8	6
1733	Cerebrospinal fluid cystatin C levels in patients with anti-NMDAR encephalitis and other neurological diseases. <i>Journal of Neuroimmunology</i> , 2022, 369, 577900.	1.1	0
1735	Protocol for the treatment of patients with a spectrum of opiomyelitis-associated diseases using bone marrow stromal cells in the State Institution "Institute of Neurology, Psychiatry and Narcology of the National Academy of Medical Sciences of Ukraine". <i>Ukrains Kyi Visnyk Psykhonevrolohii</i> , 2022, , 75-79.	0.0	0

#	ARTICLE	IF	CITATIONS
1736	Transformer-Based Deep-Learning Algorithm for Discriminating Demyelinating Diseases of the Central Nervous System With Neuroimaging. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1
1737	Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD): A Review of Clinical and MRI Features, Diagnosis, and Management. <i>Frontiers in Neurology</i> , 0, 13, .	1.1	84
1738	LncRNA Xist may regulate Th17 cell differentiation through TDP43-IRF3 pathway in neuromyelitis optica spectrum disorders. <i>Medical Hypotheses</i> , 2022, 165, 110894.	0.8	0
1739	Disease Course and Outcomes in Patients With the Limited Form of Neuromyelitis Optica Spectrum Disorders and Negative AQP4-IgG Serology at Disease Onset: A Prospective Cohort Study. <i>Journal of</i>		

#	ARTICLE	IF	CITATIONS
1754	Expression of antimicrobial host defence peptides in the central nervous system during health and disease. , 2022, 1, .		5
1755	Neuromyelitis Optica Spectrum Disorder. <i>New England Journal of Medicine</i> , 2022, 387, 631-639.	13.9	40
1756	Eculizumab for acute relapse of neuromyelitis optica spectrum disorder: Case report. <i>Frontiers in Neurology</i> , 0, 13, .	1.1	6
1757	Relapsing antibody-negative patients with features of neuromyelitis optica spectrum disorders: Differences in N-acetylaspartate level in the cervical spinal cord indicate distinct underlying processes. <i>Multiple Sclerosis Journal</i> , 2022, 28, 2221-2230.	1.4	1
1758	Comparing evolvement of visual field defect in neuromyelitis optica spectrum disorder-optic neuritis and idiopathic optic neuritis: a prospective study. <i>BMC Ophthalmology</i> , 2022, 22, .	0.6	1
1759	Neuromyelitis Optica Spectrum Disorders. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2022, 28, 1131-1170.	0.4	6
1760	The genealogy, methodology, similarities and differences of immune reconstitution therapies for multiple sclerosis and neuromyelitis optica. <i>Autoimmunity Reviews</i> , 2022, 21, 103170.	2.5	1
1761	Risk factors associated with permanent disability in neuromyelitis optica spectrum disorders. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 68, 104114.	0.9	6
1762	Autologous hematopoietic stem cell transplantation in neuromyelitis optica spectrum disorder: A systematic review and meta-analysis. <i>Journal of Clinical Neuroscience</i> , 2022, 105, 37-44.	0.8	8
1763	Imaging characteristics of Sjögren's syndrome. <i>Clinical Imaging</i> , 2022, 92, 7-18.	0.8	1
1764	What's new in neuromyelitis optica spectrum disorder treatment?. <i>Taiwan Journal of Ophthalmology</i> , 2022, 12, 249.	0.3	3
1765	What's new in neuromyelitis optica spectrum disorder treatment?. <i>Taiwan Journal of Ophthalmology</i> , 2022, .	0.3	0
1766	Neuromyelitis Optica Spectrum Disorders in North Indian Population: Experience from a Tertiary Care Center. <i>Neurology India</i> , 2022, 70, 1500.	0.2	3
1767	Neurosarcoidosis presenting as longitudinally extensive myelitis: Diagnostic assessment, differential diagnosis, and therapeutic approach. <i>Translational Neuroscience</i> , 2022, 13, 191-197.	0.7	4
1768	Enlarged perivascular spaces, neuroinflammation and neurological dysfunction in NMO patients. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	8
1769	The Prevalence, Demographics, Clinical Features, Neuroimaging, and Inter-ethnic Differences of MOGAD in Malaysia with Global Perspectives. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 67, 104168.	0.9	5
1770	A meta-analysis on efficacy and safety of rituximab for neuromyelitis optica spectrum disorders. <i>Medicine (United States)</i> , 2022, 101, e30347.	0.4	1
1771	CXCL7 aggravates the pathological manifestations of neuromyelitis optica spectrum disorder by enhancing the inflammatory infiltration of neutrophils, macrophages and microglia. <i>Clinical Immunology</i> , 2022, 245, 109139.	1.4	3

#	ARTICLE	IF	CITATIONS
1772	Different visual evoked potentials in neuromyelitis optica spectrum disorder-related optic neuritis and idiopathic demyelinating optic neuritis: a prospective longitudinal analysis. <i>BMC Ophthalmology</i> , 2022, 22, .	0.6	1
1773	Effectiveness and Safety of Immunosuppressive Drug Therapy for Neuromyelitis Optica Spectrum Disorders: An Overview of Meta-analyses and Systematic Reviews. <i>Current Neuropharmacology</i> , 2022, 20, .	1.4	0
1774	Sustained Infiltration of Neutrophils Into the CNS Results in Increased Demyelination in a Viral-Induced Model of Multiple Sclerosis. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
1775	The patient journey with NMO: From initial diagnosis to chronic condition. <i>Frontiers in Neurology</i> , 0, 13, .	1.1	3
1776	AQP4-IgG-positive neuromyelitis optica spectrum disorder and temporally detected neoplasms: case report and systematic review. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 68, 104212.	0.9	3
1777	Incidence and Prevalence of Neuromyelitis Optica Spectrum Disorders in the Background of International Consensus Diagnostic Criteria – A Systematic Review. <i>Neurology India</i> , 2022, 70, 1771.	0.2	1
1778	Cuprizone feeding induces swollen astrocyte endfeet. <i>Pflugers Archiv European Journal of Physiology</i> , 2022, 474, 1275-1283.	1.3	2
1779	A novel aquaporin-4-associated optic neuritis rat model with severe pathological and functional manifestations. <i>Journal of Neuroinflammation</i> , 2022, 19, .	3.1	1
1780	Multiple Sclerosis Followed by Neuromyelitis Optica Spectrum Disorder. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2023, 10, e200037.	3.1	0
1781	Framework for Patient Experience Value Elements in Rare Disease: A Case Study Demonstrating the Applicability of Combined Qualitative and Quantitative Methods. <i>Pharmacoeconomics - Open</i> , 2023, 7, 217-228.	0.9	4
1782	Intravenous ofatumumab treatment of multiple sclerosis and related disorders: An observational study. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 68, 104246.	0.9	3
1783	Neuromyelitisoptica Spectrum Disease with Brown-SÄquard Syndrome as the Initial Presentation: A Case Report and Literature Review. <i>Advances in Clinical Medicine</i> , 2022, 12, 10052-10058.	0.0	1
1784	Autoimmune Myelitis and Myocarditis in a Patient With Anti-Aquaporin-4, Antinuclear, and Antiphospholipid Autoantibodies: The Neuromyelitis Optica-Systemic Lupus Erythematosus (NMO-SLE) Overlap Syndrome. <i>Cureus</i> , 2022, , .	0.2	0
1785	Association between B-cell depletion and attack risk in neuromyelitis optica spectrum disorder: An exploratory analysis from N-MOmentum, a double-blind, randomised, placebo-controlled, multicentre phase 2/3 trial. <i>EBioMedicine</i> , 2022, 86, 104321.	2.7	9
1786	Analysis of Neuromyelitis Optica Spectrum Disorder in an Indian Cohort using International Consensus Diagnostic Criteria. <i>Neurology India</i> , 2022, 70, 2416.	0.2	2
1787	Non-immune system comorbidity in neuromyelitis optica spectrum disorders. <i>Journal of Clinical Neuroscience</i> , 2023, 107, 16-22.	0.8	1
1788	Magnetic Resonance Imaging in Acute Optic Neuritis in Singapore. <i>Annals of the Academy of Medicine, Singapore</i> , 2009, 38, 821-826.	0.2	11
1789	Plasmapheresis for Neuromyelitis Optica: A Review from the Transfusion Medicine Specialist's Perspective. <i>European Medical Journal Neurology</i> , 0, , 95-101.	0.0	1

#	ARTICLE	IF	CITATIONS
1790	B Cells at the Cross-Roads of Autoimmune Diseases and Auto-Inflammatory Syndromes. <i>Cells</i> , 2022, 11, 4025.	1.8	4
1791	Behandlung der Neuromyelitis-optica-Spektrum-Erkrankung: Rückblick auf das Komplementsystem und andere Aspekte der Pathogenese. <i>Wiener Medizinische Wochenschrift</i> , 2024, 174, 4-15.	0.5	1
1792	Bloodâ€“Brain Barrier Disruption and Its Involvement in Neurodevelopmental and Neurodegenerative Disorders. <i>International Journal of Molecular Sciences</i> , 2022, 23, 15271.	1.8	10
1793	Age of onset correlates with clinical characteristics and prognostic outcomes in neuromyelitis optica spectrum disorder. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
1794	Consensus opinion on the management of patients with neuromyelitis optica spectrum diseases: issues of terminology and therapy. <i>Nevrologiya, Neiropsikhiatriya, Psikhosomatika</i> , 2022, 14, 139-148.	0.2	4
1795	The circadian rhythms regulated by Cx43-signaling in the pathogenesis of Neuromyelitis Optica. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	0
1797	Effects of physical therapy intervention in the management of neuromyelitis optica: a case report. <i>Bulletin of Faculty of Physical Therapy</i> , 2023, 28, .	0.2	0
1798	DÃ©vic-Syndrom (Neuromyelitis optica). <i>Springer Reference Medizin</i> , 2023, , 1-3.	0.0	0
1799	Differentially Expressed Erythrocyte Proteins in Neuromyelitis Optica Spectrum Disorders and Their Functional Annotation Using DAVID Bioinformatics Tool. <i>Neurochemical Journal</i> , 2022, 16, 465-471.	0.2	0
1800	Area postrema syndrome: Intractable hiccups and vomiting as a result of neuromyelitis Optica Spectrum disorder. <i>JRSM Open</i> , 2023, 14, 205427042311596.	0.2	1
1801	The role of the gut microbiota and fecal microbiota transplantation in neuroimmune diseases. <i>Frontiers in Neurology</i> , 0, 14, .	1.1	5
1802	ACT001 Relieves NMOSD Symptoms by Reducing Astrocyte Damage with an Autoimmune Antibody. <i>Molecules</i> , 2023, 28, 1412.	1.7	0
1804	A comparison of the efficacy of tocilizumab versus azathioprine for neuromyelitis optica spectrum disorder: A study protocol for systematic review and meta-analysis. <i>Medicine (United States)</i> , 2023, 102, e32748.	0.4	0
1805	Postinfectious aquaporin-4-positive neuromyelitis optica syndrome disorder and nephrotic syndrome. <i>APIK Journal of Internal Medicine</i> , 2023, .	0.1	0
1806	SAkuraBONSAI: Protocol design of a novel, prospective study to explore clinical, imaging, and biomarker outcomes in patients with AQP4-IgG-seropositive neuromyelitis optica spectrum disorder receiving open-label satralizumab. <i>Frontiers in Neurology</i> , 0, 14, .	1.1	0
1807	Comments on the article â€œConsensus opinion on the management of patients with neuromyelitis optica spectrum diseases: issues of terminology and therapyâ€“ <i>Nevrologiya, Neiropsikhiatriya, Psikhosomatika</i> , 2023, 15, 119-122.	0.2	1
1808	Understanding Treatment Decisions in Neuromyelitis Optica Spectrum Disorder: A Global Clinical Record Review with Patient Interviews. <i>Neurology and Therapy</i> , 2023, 12, 619-633.	1.4	3
1809	Characterization of Disease Severity and Stability in NMOSD: A Global Clinical Record Review with Patient Interviews. <i>Neurology and Therapy</i> , 2023, 12, 635-650.	1.4	3

#	ARTICLE	IF	CITATIONS
1810	Ravulizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder. <i>Annals of Neurology</i> , 2023, 93, 1053-1068.	2.8	29
1811	Different monoclonal antibodies and immunosuppressants administration in patients with neuromyelitis optica spectrum disorder: a Bayesian network meta-analysis. <i>Journal of Neurology</i> , 2023, 270, 2950-2963.	1.8	2
1812	A novel rare variant of CNPY3 from familial NMOSD impairs the TLR-mediated immune response. <i>Journal of Neuroimmunology</i> , 2023, 377, 578065.	1.1	1
1813	Neuromyelitis optica spectrum disorders: a review with a focus on children and adolescents. <i>Arquivos De Neuro-Psiquiatria</i> , 2023, 81, 201-211.	0.3	0
1814	Other demyelinating diseases. , 2013, , 443-450.		0
1815	Astrocyte-Derived Exosomes Contribute to Pathologies of Neuromyelitis Optica Spectrum Disorder in Rodent Model. <i>Annals of Neurology</i> , 2023, 94, 163-181.	2.8	4
1817	Targeting chemoattractant chemokine (C-C motif) ligand 2 derived from astrocytes is a promising therapeutic approach in the treatment of neuromyelitis optica spectrum disorders. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	4
1818	Efficacy and safety of monoclonal antibody therapy in patients with neuromyelitis optica spectrum disorder: A systematic review and network meta-analysis. <i>Frontiers in Neurology</i> , 0, 14, .	1.1	0
1819	Artificial intelligence in healthcare: a mastery. <i>Biotechnology and Genetic Engineering Reviews</i> , 0, , 1-50.	2.4	3
1820	THE ROLE OF MRI IN DIFFERENTIATING DEMYELINATING AND INFLAMMATORY (NOT INFECTIOUS) MYELOPATHIES. <i>Seminars in Ultrasound, CT and MRI</i> , 2023, , .	0.7	0
1821	Neuromyelitis Optica Spectrum Disorders: Clinical Perspectives, Molecular Mechanisms, and Treatments. <i>Applied Sciences (Switzerland)</i> , 2023, 13, 5029.	1.3	1
1822	Symptomatic trigeminal autonomic cephalalgias in neuromyelitis optica spectrum disorders. <i>Multiple Sclerosis and Related Disorders</i> , 2023, 74, 104722.	0.9	0
1836	Rare autoimmune and autoinflammatory neurologic disorders. , 2023, , 189-219.		0
1842	Machine Learning in Multiple Sclerosis. <i>Neuromethods</i> , 2023, , 899-919.	0.2	0
1851	Immune system. , 2023, , 127-140.		0
1853	Astrocytes in human central nervous system diseases: a frontier for new therapies. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	7.1	15
1859	Neuroinflammatorische und demyelinisierende Erkrankungen des Kindesalters. , 2023, , 145-173.		0
1867	Methyl-CpG-Binding Protein 2 Emerges as a Central Player in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders. <i>Cellular and Molecular Neurobiology</i> , 2023, 43, 4071-4101.	1.7	0



#	ARTICLE	IF	CITATIONS
1868	Neuromyelitis Optica Spectrum Disorders. , 2023, , .		0
1876	Astrocytes in Neuroinflammatory and Neurodegenerative Diseases. , 2023, , .		0
1877	Introduction to Neural Networks: Biological Neural Network. , 2024, , 1-18.		0
1879	Enlarged Perivascular Space and Index for Diffusivity Along the Perivascular Space as Emerging Neuroimaging Biomarkers of Neurological Diseases. Cellular and Molecular Neurobiology, 2024, 44, .	1.7	0
1886	An overview of neuromyelitis optica spectrum disorders. , 2024, , 35-66.		0